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Abstract 
 
The overall aim of this PhD was to improve our understanding, including the clinical 
potential, of neonatal Nav1.5 (nNav1.5) expression in human metastatic breast 
cancer. Mainly, the strongly metastatic MDA-MB-231 cells were used throughout 
the studies. The specific aims were threefold, as follows: 1) To test the effects of 
several types of voltage-gated sodium channel (VGSC) blocker on nNav1.5 mRNA 
and protein expression and metastatic cell behaviours (MCBs); (2) to determine the 
effects of hypoxia on the drug treatments and MCBs; and (3) to elucidate a possible 
association of carbonic anhydrase-9 (CA9) and nNav1.5 expression/activity. There 
are three main Results chapters. 
Results-1 demonstrates the effects of the drugs on MCBs of MDA-MB-231 
cells under normal oxygen level (normoxia). Two classes of blocker were used: a) 
Local anaesthetics (lidocaine and procaine) and (b) blockers of persistent current 
(INaP) (ranolazine and riluzole). In addition, a specific VGSC blocker, tetrodotoxin 
(TTX), was incorporated as a control. At concentrations not affecting the cells‘ 
viability or proliferative activity, 24 h treatment with all the drugs tested significantly 
reduced MCBs (lateral motility, transverse migration and Matrigel invasion). 
Concurrently, the treatments reduced nNav1.5 mRNA and protein levels. TTX had a 
similar effect. Overall, this chapter showed (i) that MCBs in MDA-MB-231 cells 
were enhanced by VGSC activity and (ii) that INaP played a significant role in the 
enhancement.  
Results-2 shows that viability and proliferative activity of MDA-MB-231 
cells were not affected by hypoxia (mostly 2 % oxygen applied for 24 h). However, 
hypoxia increased the cells‘ invasiveness and this was accompanied by upregulation 
of HIF-1α (protein), nNav1.5 (mRNA) and CA9 (both mRNA and protein). 
Treatment for 24 h with INaP blockers; ranolazine and riluzole under hypoxia reduced 
lateral motility, transverse migration and Matrigel invasion. At concentrations not 
affecting cell viability and proliferation, the effects of ranolazine and riluzole in 
suppressing MCBs were generally greater under hypoxia compared to normoxia. It 
was concluded (i) that hypoxia enhanced VGSC-mediated MCBs and (ii) that the 
enhancements were likely to be increase in INaP amplitude induced by hypoxia. 
Results-3 examined a possible functional link between hypoxia (HIF-1α and 
CA9) and VGSCs. Acetazolamide was used as a general inhibitor of CAs and siRNA 
was used to silence specifically CA9. Under hypoxia, treatment with acetazolamide 
for 24 h had no effect on invasion, and treatment with TTX was without effect on 
CA9 expression. In contrast, silencing CA9 using siRNA (siCA9) reduced CA9 and 
nNav1.5 expression and Matrigel invasion was also significantly inhibited. It was 
concluded (i) that CA9 played a role in cellular invasion and (ii) that nNav1.5 was 
down-stream to CA9 in the control of MCBs. 
The Thesis is concluded with a General Discussion and Conclusion chapter 
integrating the findings and highlighting their clinical potential.  
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Metastasis is the main cause of death from breast cancer (BCa), as in most other 
cancers. Consequently, much work has been done to understand the development and 
progression of metastatic disease. Recently, voltage-gated sodium channels (VGSCs) 
have been shown to be significantly and functionally upregulated in human 
metastatic BCa in vitro and in vivo (Roger et al. 2003; Roger et al. 2004; Fraser et al. 
2005; Brackenbury et al. 2007; Onkal & Djamgoz 2009). High expression levels of 
VGSC mRNA and protein have been found in the strongly metastatic MDA-MB-231 
cells and also in human primary BCa biopsy samples (Fraser et al. 2005). More than 
80 % of the overall VGSC mRNA expression in MDA-MB-231 cells was found to 
be contributed by the cardiac type, Nav1.5 (Fraser et al. 2005). However, 
importantly, partial sequencing of the gene showed that it was present predominantly 
in its embryonic/ ‗neonatal‘ splice form, nNav1.5 (Fraser et al. 2005). Supported by 
functional assays, nNav1.5 was suggested to be responsible for potentiating 
metastatic cell behaviours (MCBs) in BCa (Fraser et al. 2005; Chioni et al. 2005; 
Brackenbury et al. 2007; Palmer et al. 2008; Onkal et al. 2008; Pan & Djamgoz 
2008; Chioni et al. 2009; Chioni et al. 2010; Fraser et al. 2010). Accordingly, 
nNav1.5 could serve as a novel marker of metastatic phenotype as well as a 
therapeutic target for metastatic BCa (Onkal & Djamgoz 2009). 
In a normal cell, the level of intracellular Na
+
 depends on activities of sodium 
channels (including VGSCs) and Na
+
/K
+
 ATPase/pump; in turn, the trans-membrane 
Na
+
 concentration gradient controls intracellular Ca
2+
 and H
+
 concentration via 
Na
+
/Ca
2+
 and Na
+
/H
+
 exchangers (NCX and NHE), respectively (Hasenfuss & Maier 
2006; Vaughan-Jones et al. 2006). In MDA-MB-231 cells, overexpression/activity of 
nNav1.5 protein expressed in plasma membrane may disrupt intracellular ion 
homeostasis. Increased Na
+
 concentration in malignant breast tissue has indeed been 
 23 
reported (Cameron et al. 1980; Oukerwerk et al. 2007). Whole-cell patch clamp 
recordings from MDA-MB-231 cells have revealed a fast transient voltage-activated 
inward current attributable to nNav1.5 (Roger et al. 2003; Fraser et al. 2005; Chioni 
et al. 2005; Brackenbury et al. 2007; Onkal et al. 2008; Chioni et al. 2009; Onkal & 
Djamgoz 2009). In addition, there could be a small persistent current (INaP) 
component due to the slow inactivation of the transient current (Roger et al. 2003; 
Onkal et al. 2008; Onkal & Djamgoz 2009). The latter could contribute further to the 
disruption of the intracellular ionic balance. Although there is no direct evidence of 
high Na
+
 promoting MCBs in BCa but in other pathological condition such as serious 
arrhythmias, contractile dysfunction and angina, overload intracellular Na
+
 due to 
VGSC dysfunction has been shown to be a significant cause (Roden 2009). 
Therefore, manipulating the transient and/or INaP, using drugs or a specific antibody 
to restore the ionic balance would be beneficial. 
Hypoxia is an important factor in the progression of solid cancers, including 
BCa. The hypoxia transcriptional factor, HIF-1α has been reported to be involved in 
many aspects of cancer development/progression including metastasis. There are 
some reports on effects of hypoxia on individual MCBs. For example, hypoxia via 
HIF-1α was shown to promote the upregulation of genes involved in pH regulation 
under hypoxia e.g carbonic anhydase-9 (CA9), carbonic anhydrase-12 (CA12) and 
NHE to achieve acidosis (Wykoff et al. 2001; Cardone et al. 2007; Swietach et al. 
2007; Brisson et al. 2010). In turn, this would enhance (i) cancer invasion via 
secretion of the matrix metalloproteinases (MMPs) and urokinase plasminogen 
activator (uPA) (Pugh & Ratcliffe 2003) and (ii) angiogenesis via release of pro-
angiogenic growth factors such as the vascular endothelial growth factor (VEGF) 
(Fukumura et al. 2001; Jain 2002; Choi et al. 2003; Kyzas et al. 2005; Zhang et al. 
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2010). Furthermore, hypoxia has been shown to modulate several types of ion 
channels, including VGSC, in neurons and other cell types (Hammarstrom & Gage 
1998; Hammarstrom & Gage 2002; Fearon & Brown 2004; Zhou et al. 2006; Wang 
et al. 2007). In particular, hypoxia has been shown to increase the amplitude of INaP 
(Hammarstrom & Gage 1998; Hammarstrom & Gage 2002; Weiss & Saint 2010; 
Saint 2010). Such an increase would mean prolonged influx of Na
+
 into the 
cytoplasm that would further disturb the ionic balance. The phenomenon of hypoxia-
induced increase in INaP has been widely demonstrated to occur during cardiac 
ischemia and blocking it could be effective in protecting the heart from ischemia in 
animal models as well as in human clinical trials (Williams et al. 2007; Létienne et 
al. 2009; Maier 2009; Vacher et al. 2009; Weiss et al. 2010). One of the aims of the 
present study was to investigate the role of hypoxia and its relation to VGSC-
mediated MCBs, so as to have a better understanding of BCa metastasis. 
 
1.1 Breast cancer 
Worldwide, BCa is the most common cancer of females, constituting about one 
million cases each year in the world (McPherson et al. 2000; Cronin et al. 2010). In  
the United Kingdom alone, BCa accounted for 32 % of new cancer cases and 
~10,000 of female mortality in 2004 (Westlake & Cooper 2008). It is well known 
that the female sex hormone, estrogen is linked to the disease; the risk of getting BCa 
also depends on age, heredity, lifestyle, ethnicity, exposure to radiation, etc. 
(Moulder & Hortobagyi 2008). Ultimately, the development of BCa is due to an 
interaction between genetic (as well as epigenetic) predisposition and environmental 
factors. Like any other cancers, BCa involves alterations in expression of oncogenes 
(e.g HER-2, c-myc) and tumour suppressor genes (e.g BRCA, p53, PTEN, VHL). It 
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is reported that people with mutations in one of the BRCA genes (BRCA1 or 
BRCA2) would have 40 – 80 % chance of developing BCa (Fackenthal & Olopade 
2007).  
BCa is heterogeneous, being biologically and molecularly different amongst 
patients. This creates a significant problem in personalizing therapy for BCa patients. 
At present, treatment for BCa takes into account size, location, stage, hormone 
sensitivity (e.g estrogen receptor positive or negative (ER+/-) or progesterone 
receptor positive or negative (PR+/-) and status of human epidermal receptor-2 
(HER-2) expression (Peppercorn et al. 2008; Moulder & Hortobagyi 2008; Saghir et 
al. 2011). As part of their cancer treatment, majority of women with BCa undergo 
surgery; the standard type of breast surgery is lumpectomy or mastectomy. In 
addition, some women will receive adjuvant (additional) treatment to suppress any 
residual cancer, spread or recurrence. Types of adjuvant therapies include 
chemotherapy (e.g doxorubin and cyclophosphamide), radiation therapy, hormone 
therapy (e.g tamoxifen and anastrozole) and targeted therapies (e.g 
traszumab/Herceptin) (Moulder & Hortobagyi 2008; Saghir et al. 2011). 
Nevertheless, many of the therapeutic interventions work for limited time only, so it 
is essential to develop novel treatment strategies.  
 
1.2 Metastasis 
The major problem in BCa management is metastasis. Despite being one of the most 
investigated cancer types, the mechanisms of BCa metastasis are still not completely 
understood. The process by which BCa cells interact with their microenvironment, 
alter their invasive potential and ultimately metastasize both regionally and distantly 
have been intensely investigated (Rofstad 2000; Paszek et al. 2005; Rinker-Schaeffer 
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et al. 2006; Steeg 2006; Bacac & Stamenkovic 2008; Stock & Schwab 2009). It is 
reported that for patients at the age of less than 50 with primary BCa without 
apparent lymph node metastasis, approximately 25 % would develop distant 
metastases within 5 years (Nuyten & van de Vijver 2007). When lymph node 
metastasis is present at primary diagnosis, approximately 50 % of cases would 
ultimately develop distant metastases (Nuyten & van de Vijver 2007). There are 
three ways for cancer cells to spread in the body: (i) through invasion of the 
surrounding tissue, (ii) invasion through lymphatics and (iii) through blood 
circulation. In most cases, BCa spreads through the circulation. Metastatic BCa tends 
to spread to lungs, pleura (the lining of the lungs), liver, brain and most commonly to 
bones especially vertebrae and long bones of the arms, legs and ribs (Plunkett et al. 
2000). As in other cancers, the process of BCa metastasis involves (1) dissemination 
of cancer cells from primary cancer and detachment from the extracellular matrix 
(ECM), (2) local invasion of the surrounding tissue and basement membrane and (3) 
extravasation of the surviving cancer cells and intravasation - re-attachment to a new 
sites. Additionally, tumour growth and metastases at distant sites depend on the 
ability of the surviving cancer cells to induce their own blood supply through 
angiogenesis/vascularization (Eccles & Welch 2007; Shibue & Weinberg 2011; 
Chaffer & Weinberg 2011). 
 
1.2.1 Mechanisms of metastasis 
Metastasis is a sequential multistep process that ultimately leads to the cancer's 
outgrowth in a different organ from which it had originated. Several escape 
mechanisms have been suggested in cancer cell dissemination but most involves 
‗mesenchymal movement‘ (Yang & Weinberg 2008; Shibue & Weinberg 2011; 
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Chaffer & Weinberg 2011). It is suggested that with the help of genetic instability 
and microenvironmental factors, e.g hypoxia, at least some cancer cells can be 
transformed to an invasive phenotype (Sullivan & Graham 2007; Chaffer & 
Weinberg 2011). Once transformed, cancer cells become elongated (fibroblast-like) 
and attain the properties of a mesenchymal cell, known as ―epithelial-mesencymal-
transition‖ (EMT). During EMT, cancer cells undergo (1) loss of cell-cell and cell-
ECM adhesion by inactivation of cell adhesion molecules such as E-cadherins 
(Bulkhom et al. 1998; Guarino et al. 2007; Chao et al. 2010) and (2) upregulation of 
genes controlling cell motility e.g activation of RhoGTPases (Yilmaz et al. 2010). 
These changes promote cancer cell dissemination from the primary tumour and 
movement towards circulating system. Another important property of EMT is the 
ability of cancer cells to secrete or to manipulate multiple cell types (e.g stromal 
cells) to secrete proteases e.g MMP or uPA to invade the surrounding tissue. This is 
important for cancer cells to digest through the ECM barrier. Increase expressions of 
several types of MMP (e.g MMP-3, MMP-7 and MMP-9) have been associated with 
distant metastases of BCa (Hughes et al. 2007).  
Once freed and successfully beyond the ECM barrier, cancer cells may 
ultimately enter the circulation. It is estimated that each day in a BCa patient, several 
millions of cancer cells per gram of primary tumour can be shed (Butler & Gullino 
1975). However, such cells can remain in circulation for some time before possible 
extravasation. Circulating cancer cells (CTCs) have been found in ≥ 70 % of patients 
with distant metastases (Iakovlev et al. 2008). It was reported that the presence of 
CTCs in BCa patients‘ peripheral blood (> 5 CTCs in 7.5 ml of blood) would be 
associated with shortened survival times (Hayes et al. 2006). 
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In ‗extrasavation‘, surviving CTCs will escape from the vessels and enter 
secondary sites. When CTCs are ready to escape, they must re-establish the adhesive 
connection initially to lodge at the endothelial lining of the vessel, followed again by 
degradation of the endothelial walls by proteolytic enzymes. Then, the cells have to 
migrate through tissue to reach the target sites. Thus, the metastatic process involves 
dynamic behaviour of cancer cells. Following extravasation, metastising CTCs 
undergo reverse MET (Hugo et al. 2007; Yang & Weinberg 2008; Shibue & 
Weinberg 2011; Chaffer & Weinberg 2011). It was suggested that CTCs 
transcriptionally re-express the adhesion molecules (e.g E-cadherin) that were ‗shut 
down‘ during intravasation (Christofori 2003; Chao et al. 2010). At the secondary 
sites, before developing into macroscopic metastases, individual cancer cells can lay 
dormant for periods of months or even years.  
Expression of VGSCs have been reported to be up-regulated in BCa and 
suggested to be a potentiating factor in metastasis (Roger et al. 2003; Fraser et al. 
2005; Brackenbury et al. 2007; Onkal & Djamgoz 2009). Accordingly, functional 
VGSC expression in BCa could be a novel prognostic marker for the ability of 
cancer to develop into metastatic disease. Several earlier studies have suggested that 
rapidly proliferating and transformed cells have electrically depolarized cell 
membranes compared to normal cells (Roger et al. 2003). Subsequently, functional 
VGSC up-regulation was first reported for the invasive phenotype of rat prostate 
cancer (PCa) (Grimes et al. 1995). In both cases, VGSC mRNA and protein 
expression has also been seen in vivo (Fraser et al. 2005; Brackenbury et al. 2007). 
Accordingly, it is suggested that the VGSC up-regulation would potentiate the 
transformation of cancer cells to become invasive, hence favouring the initial step of 
metastasis. Indeed, using MDA-MB-231 cells as model cell line of invasive BCa and 
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treatment with specific VGSC blocker, tetrodotoxin (TTX) or siRNA, functional 
VGSC (nNav1.5) expression has been linked to reduced adhesion and increased 
motility and invasion (Fraser et al. 2005; Chioni et al. 2005; Brackenbury et al. 2007; 
Palmer et al. 2008; Onkal et al. 2008; Pan & Djamgoz 2008; Chioni et al. 2009; 
Gillet et al. 2009; Gao et al. 2009; Onkal & Djamgoz 2009; Chioni et al. 2010; Fraser 
et al. 2010; Brisson et al. 2010) (Figure 1.1). 
 
1.2.1.1 Adhesion of cancer cells 
In general, in normal cells, adhesion molecules play an important role in holding 
cells together or mediating attachment to ECM. In cancer, these cell adhesion 
molecules (CAMs) are not prominent and consequently, cellular adhesion is 
generally reduced. However, the adhesiveness of cancer cell is likely to depend on 
the stage of cancer progression. For example, in early metastasis, reduced 
adhesiveness would allow cancer cells to disseminate from the primary tumour. 
Thus, at the beginning of metastasis, transcriptional expression of cell-cell adhesion 
molecules (e.g E-cadherin) was found to be switched off. In primary carcinoma cells 
including BCa, it was shown that E-cadherin activity was lacking or completely lost 
during progression towards an aggressive phenotype (Cleton-Jansen 2002; Fujita 
et al. 2003; Yang et al. 2004; Moody et al., 2005; Onder et al. 2008). Therefore, E-
cadherin has been defined as an ‗invasion suppressor protein‘ (Berx et al. 1995; 
Knudsen & Wheelock 2005). Subsequently, when the microenvironment is suitable 
for cancer cells to settle at a suitable secondary site, cancer cells will need an 
opposite mechanism to re-attach and grow. There have been reports on E-cadherin 
restoration during the transition of mesenchymal to epithelial (MET) of BCa (Chao 
et al. 2010). Furthermore, at a new site, another ECM adhesion molecule, integrins  
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Figure 1.1 Stages of cancer metastasis with corresponding involvement of 
VGSCs 
 
During metastasis, cancer cells interact with their microenvironment, alter their 
invasive potential and spread to a new distant site. Lack of adhesiveness due to loss 
expression of cell-adhesion molecules helps cancer cells to move and disseminate 
from the primary tumour. Acidosis and increase expression/activity of proteases 
facilitate cancer cells to digest ECM and intravasate into the lymphatic or blood 
circulation system. The cells remain in circulation until extravasation and settling at a 
secondary tumour site. VGSCs were suggested to play an important role in 
potentiating processes integral to metastasis that includes during the detachment of 
the cells from the primary tumour, invasion through the ECM, migration, 
proliferation, angiogenesis and the microenvironment activation as indicated by the 
arrows. Modified from Bacac & Stamenkovic (2008) and Onkal & Djamgoz (2009). 
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has also been shown to be up-regulated (McSherry et al. 2007). Integrins are 
transmembrane glycoproteins that act as receptors for ECM components. Opposite to 
E-cadherin, in addition to their role in cell-ECM adhesion, integrins are involved in 
signaling and regulation of growth factor expression that generally promotes 
metastasis (McSherry et al. 2007). For example, it was shown that elevated 
expression of α6β4 integrin in BCa cells activates the expression of ErbB2 receptor 
that correlate significantly with reduced patient survival (Friedrichs et al. 1995).  
Up-regulation of VGSC functional expression in human BCa was suggested 
to correlate with reduced adhesiveness of the strong metastatic, MDA-MB-231 cells, 
compared with the weakly/non metastatic MCF-7 cells (Palmer et al. 2007). VGSC 
auxiliary β-subunit family has been shown earlier to have the immunoglobulin 
domain that could enable functioning as a CAM (Brackenbury et al. 2008). 
Subsequently, β1-subunit has been found to play an important role in cancer cell 
adhesion (Chioni et al. 2009). Elevated β1-subunit expression has been shown in the 
more adherent, MCF-7 cells. Accordingly, Chioni et al. (2006) showed that silencing 
β1-subunit expression by siRNA reduced adhesion of MCF-7 cells and increased 
migration, suggesting that β1-subunit could indeed be important in controlling 
migration of BCa via adhesive interactions. 
 
1.2.1.2 Motility and migration of cancer cells 
Cell motility plays a crucial role in several types of cellular biology, such as 
embryonic development, wound healing, immune responses and importantly for 
cancer invasion and metastasis. In metastasis, motility enables the cells to 
disseminate away from the primary tumour. There is a broad spectrum of motility 
mechanism suggested for cancer cell metastasis. It is known that dynamic assembly 
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and disassembly of actin filaments are required for cells to move and change shape. 
Morphologically, cancer cells can be classified into those that are predominantly 
elongated or rounded (or a mixture of both). Cancer cells have a tendency to switch 
between elongated and rounded modes according to their microenvironment and this 
‗plasticity‘ allows them to move away from the primary tumour (Wolf et al. 2003; 
Sahai & Marshall 2003). It has become apparent that integrins can mediate cytosolic 
signaling that can have a dramatic impact on cell shape and motility, as well as 
adhesion, proliferation and survival. For example, during the initiation of migration, 
integrin starts to cluster at the focal adhesions along the leading edge of the cancer 
cells (White & Muller 2007). During this process, members of the Rho family of 
small GTP-binding proteins are activated and contribute to the integrin-mediated 
changes in cell shape and polarity (Kiosses et al. 2001; Hyness 2002).  
The involvement of VGSC in the morphological development of metastatic 
cell type has brought in the association of VGSC with cellular motility. TTX has 
been shown to suppress the morphological development of highly metastatic PCa, 
Mat-LyLu (Fraser et al. 1999). Consequently, TTX reduced both lateral motility and 
transverse migration of metastatic cells in PCa (Fraser et al. 2003), BCa (Fraser et al. 
2005; Roger et al. 2003) and mesothelioma (Fulgenzy et al. 2006). Galvanotaxis, a 
directional motility in a direct-current electric field was also found to be controlled 
by VGSC activity in BCa and PCa (Djamgoz et al. 2001; Fraser et al. 2005).  
 
1.2.1.3 Invasiveness of cancer cells 
Invasion is the overall process by which cancer cells get to occupy new tissue sites 
usually via secreting an enzyme that would degrade the surrounding ECM. Various 
degradative enzymes have been proposed, including cathepsin, uPA, MMPs, 
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glycosidases and heparanases. Increased MMP activity has been detected and shown 
to correlate positively with invasion and metastatic potential of BCa and in a wide 
range of other cancers, including those of ovary, lung, prostate and pancreas. 
Additionally, acidic extracellular pH (pHe) of cancer microenvironment also 
potentiates invasion. Overexpression of acid extruders such as Na
+
/H
+
 exchanger 
(NHE) and monocarboxylate transporters (MCT) help to contribute to acidosis of 
pHe (Stock & Schwab 2009; Brahimi-Horn et al. 2011). Acidosis facilitates the 
release or increase activity of proteolytic enzymes and degradation of ECM to 
promote invasion (Egeblad & Erb 2002; Liaudet-Coopman et al. 2006; Mohamed & 
Sloane 2006; Gatenby et al. 2006). For example, acidosis indirectly promotes the 
release of cathepsin B from the stromal cells to promote invasion of BCa and 
melanoma cells (Rohzin et al. 1994). Furthermore, increased expression of the acid-
base regulator CA9 in the cancer microenvironment that would further acidify in 
vitro pHe has also been shown to contribute to acidosis-dependent invasion of gastric 
cancer and BCa (Chen et al. 2005; Li et al. 2009).  
A recent finding suggested that functional expression of the VGSC subtype, 
Nav1.5 potentiated the invasive behavior of human BCa cell line MDA-MB-231 by 
increasing the secretion of MMP-9 (Gao et al. 2009). Moreover, Nav1.5 was also 
shown to enhance the invasiveness of MDA-MB-231 cells by favouring the pH-
dependent activity of cysteine cathepsins (Gillet et al. 2009). Subsequently, Nav1.5 
was demonstrated to increase the activity of Na
+
/H
+
 exchanger-1 (NHE1) to achieve 
acidosis in these cells thus favouring invasiveness (Brisson et al. 2010). Interestingly, 
recent evidence from colon cancer demonstrated that Nav1.5 plays an important role 
as a key regulator of a gene transcriptional network that controls colon cancer 
invasion (House et al. 2010). 
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Figure 1.2 Functional structure of VGSC 
 
The α-subunit (main box) can be associated with one, two or more of β-subunits. 
However, all important conserved motifs are contained within the α-subunit. The α-
subunit consists of four homologous domains. The ion-conducting pore is formed by 
transmembrane segments 5 and 6 (S5 and S6) of each homologous domain (green). 
The S4 domain (yellow) contains positive charges every third amino acid that sense 
transmembrane potential. Multiple sites on the intracellular surface of the α-subunit 
are important for inactivation (blue circles) with the intracellular segment connecting 
homologous domains III and IV, forming the inactivation gate. α-β ScTx represents 
binding sites for scorpion neurotoxin. Identified phosphorylation sites for protein 
kinase A are depicted as red circles and for protein kinase C as red diamonds. 
Modified from Yu & Catterall et al. (2005). 
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1.3 Voltage-gated sodium channels 
Taking all the evidences together, VGSCs have been shown to be associated with 
several including early stages of cancer metastasis. Therefore, it is important to 
understand the VGSC structure, electrophysiology, pharmacology and the factors 
that could regulate its activity and expression. Such information is essential for 
evaluating the potential of VGSCs as a target to restrain metastasis. 
VGSCs are transmembrane protein complexes with a single pore-forming, 
heavily glycosylated α-subunit (VGSCα) of approximately 220-260 kDa, often 
‗physically‘ associated with one or more auxiliary β-subunit (VGSC-β) of 33-36 kDa 
(Figure 1.2) (Catterall et al. 2005; Yu & Catterall 2003; Brackenbury et al. 2008). 
The ‗classic‘ role of VGSC is to mediate cell regenerative membrane depolarization 
and conduction of electrical signaling (action potentials) in traditionally ‗excitable‘ 
cells such as nerves, neuroendocrine, skeletal and heart muscle cells (Hille 1992; 
Catterall 2000). However, recent discoveries have shown that VGSCs are also 
expressed in traditionally ‗non-excitable‘ cells such as glia, fibroblasts, osteoblasts, 
endothelia, lymphocytes and recently, in metastatic cancer cells where their 
functional role is not fully understood (Diss et al. 2004: Catterall et al. 2005). 
Furthermore, both α- and β-subunits may have additional dynamic interactive roles 
together with other effector proteins, anchoring proteins and regulatory proteins to 
form a signaling complex depending on cell/tissue type, developmental stage and 
pathophysiology (Brackenbury et al. 2008; Catterall 2010). As regards cancer, both 
α- and β-subunits have been associated with metastatic potential in many types of 
cancer. The α-subunit is shown to be up-regulated in highly metastatic cancer types 
in line with increased invasive behaviours e.g motility, migration and invasion 
(Fraser et al. 2005; Grimes et al. 1995; Onganer & Djamgoz 2005). Conversely, β-
 36 
subunits, particularly β1, which has been structurally proven to be cell-adhesion-
molecule like is shown to be highly expressed in weakly metastatic BCa types in line 
with their strong adhesiveness (Chioni et al. 2006; Brackenbury et al. 2008). 
 
1.3.1 VGSC-α subunits 
VGSC-α is the main subunit that forms the functional channel pore. In mammals, all 
VGSC-α isoforms that have been defined and functionally expressed are >50 % 
identical in amino acid sequence in transmembrane and extracellular domains 
(Catterall et al. 2005). There are nine different VGSCα genes (Nav1.1-Nav1.9) and a 
tenth member (Nax) has been recognized as a related gene (Catterall et al. 2005). The 
VGSC-α‘s are generated by gene duplication and are composed of highly conserved 
four repeat domains (DI-DIV), each domain containing six α-helical transmembrane 
segments (S1-S6) (Figure 1.2). The main functional elements including the ion-
conducting pore are contained in the α-subunit. The pore-forming region contains the 
selectivity filter formed by a circular motif of highly conserved Asp, Glu, Lys and 
Ala residues called the ―DEKA‖ locus (Terlau et al. 1991; Heinemann et al. 1992). 
DEKA locus plays an important role in selecting the ions/agents that can go through 
the pore. It also separates the outer pore (which can be targeted by TTX, saxotoxin, 
and conotoxins) from the inner pore, which is targeted by local anaesthetics (LAs) 
and other small cationic drugs (Zhorov & Tikhonov 2004). The voltage sensor is 
located in S4, containing a positively-charged acid amino at every third position. 
Another important portion of the channel is the IFM (Ile-Phe-Met) motif found in the 
intracellular loop between DIII and DIV. This area is flanked by hinge regions and 
collectively forms the fast inactivation gate. This region is able to ‗flip up‘ and 
occlude the inner mouth of the pore, regulating the classic fast inactivation of the  
 37 
channel (England 2008).  
Despite these common features, however, each isoform owns a specialized 
‗physiological signature‘ (amino acid sequence) in regions associated with channel 
modulation (Diss et al. 2004; Catterall et al. 2005). Different isoforms tend to have a 
differential tissue-specific expression pattern, although multiple isoforms of VGSC 
expression can occur in single cells (Diss et al. 2004; Ou et al. 2005). For example, 
Nav1.1-1.3 and Nav1.6-1.9 are expressed in neurons (Burbidge et al. 2002), Nav1.4 
and Nav1.5 in skeletal muscle and heart (Goldin 2001) and Nav1.6 and Nav1.7 in 
glial cells (Ou et al. 2005). Little is known in the mechanism underlying the tissue 
specificity of VGSC expression. However, previously, a silencing transcription 
factor (REST) was shown to control the expression of Nav1.2. The function of REST 
is to silence or inactivating Nav1.2 promoter gene to block its expression in non-
neuronal cells (Chong et al. 1995).  
It was suggested that the multiplicity of expression of VGSC-α‘s in given 
tissues is important for further ‗fine-tuning‘ of overall tissue-specific channel 
functioning (Diss et al. 2004). Although the different VGSC-α‘s have basically 
similar structural and functional properties, they differ in their pharmacological 
sensitivity, affinity to VGSC-βs and electrophysiological characteristic, especially 
kinetics (Catterall et al. 2005; Diss et al. 2004; Brackenbury et al. 2008; Catterall 
2010). An important property that divides VGSC is their sensitivity to TTX. TTX–
sensitive (TTX-S) VGSCs (Nav1.1 – 1.4, Nav1.6 and Nav1.7) are blocked by TTX 
in nM range, whilst TTX–resistant (TTX-R) VGSCs (Nav1.5, Nav1.8 and Nav1.9) 
are blocked by TTX in µM range (Catterall et al. 2005; Yu & Catterall 2003). 
Diversity of genes can be generated by transcriptional, pre-transcriptional and 
post-transcriptional regulation, including mRNA splicing (Diss et al. 2004; Catterall 
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et al. 2005). Various transcriptional and translational processes can give rise to 
further diversity in VGSC-α‘s. One important mechanism for generating structural 
and functional diversity of VGSC-α is alternative splicing (Beam 1999; Diss et al. 
2004). Alternative splicing can occur in two ways: (1) by deletion or insertion of a 
sequence, creating long and short isoforms or (2) by choice of one of mutually 
exclusive sequences and creating a partially different isoforms (Minorov et al. 1999). 
To date, five major sites for alternative splicing of VGSC-α‘s have been identified: 
DI:S3 (developmentally regulated, giving adult and neonatal isoforms), interdomain 
1-2 (ID1-2), interdomain 2-3 (ID2-3), D3 and D4:S3 (Diss et al. 2004; Ou et al. 
2005). The developmentally regulated splicing of VGSCα genes involves two 
alternate exons in DI:S3 resulting in two possible transcripts: DI:S3 5‘-exon 
(‗neonatal‘) and DI:S3 3‘-exon (‗adult‘) (Diss et al. 2004). DI:S3 5‘-exon was 
designated ‗neonatal‘ because it was expressed in early embryonic development and 
was rapidly replaced by the ‗adult‘ isoform soon after birth. Splicing at this position 
was first described for Nav1.2 and Nav1.3 in rat brain (Sarao et al. 1991; Gustafson 
et al. 1993). At present, the mechanism controlling the splicing of VGSC genes is not 
known but could include membrane potential, growth factor and phosphorylation 
(Diss et al. 2004). In highly metastatic BCa, it was the developmentally regulated, 
‗neonatal‘ splice form nNav1.5 that was highly expressed (Figure 1.3). 
 
1.3.1.1 Developmentally regulated Nav1.5: ‘neonatal’ Nav1.5 
Three functional VGSCs were identified to be expressed in highly metastatic BCa, 
MDA-MB-231 cells: Nav1.5 (tetrodotoxin resistant), Nav1.6 and Nav1.7 (both 
tetrodotoxin sensitive). The cumulative level of all VGSCs expression was >100-fold 
higher in MDA-MB-231 compared with the weakly metastatic MCF-7 cells. This 
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higher expression level was primarily due to Nav1.5 (∼1,800-fold greater expression 
in MDA-MB-231 cells), which constituted ∼82% of the total VGSCs mRNA 
expression in these cells (Fraser et al. 2005). Subsequently, partial sequencing of 
Nav1.5 demonstrated that it is predominantly present in a developmentally regulated 
form, ‗neonatal‘ Nav1.5 (nNav1.5). Importantly, nNav1.5 differs from the ‗adult‘ 3′-
form (aNav1.5) at 31 out of 92 nucleotides, resulting in 7 amino acid changes in 
D1:S3 and the S3/D4 linker. The stretch of the 7 amino acid differences between 
aNav1.5 and nNav1.5 was exploited to produce a polyclonal antibody that selectively 
recognized nNav1.5, namely NESOpAb. NESOpAb was generated by immunizing 
rabbits against a synthetic peptide with an amino acid sequence contained within the 
extracellular D1:S3 of nNav1.5/VSENIKLGNLSALRC-NH2. Subsequently, the 
specificity of NESOpAb for the nNav1.5 was validated on cell lines transfected with 
either neonatal or ‗adult‘ Nav1.5 expression plasmids, using Western blotting, 
immunocytochemistry and electrophysiology (Fraser et al. 2005; Chioni et al. 2005).  
Accordingly, from Western blot and immunocytochemistry, using 
NESOpAb, it was confirmed that nNav1.5 is more highly expressed in the strongly 
metastatic MDA-MB-231 cells compared to weakly metastatic MCF-7 cells. Whilst 
in vivo, strong immunohistochemincal staining with NESOpAb was detected only in 
human BCa tissues, but not in normal breast tissue. These results complemented 
Mrna expression correlation of nNav1.5 expression in primary tumours and lymph 
node metastases (Fraser et al. 2005). Furthermore, in preliminary studies, NESOpAb 
was employed to demonstrate by immunohistochemistry that nNav1.5 protein is not 
expressed in a range of human tissues (post-mortem or biopsy), including skeletal 
muscle, oesophagus, small intestine, colon, stomach, bladder and prostate (R. 
Fahrioglu, H. Kaya and M.B.A. Djamgoz, unpublished observations) (Onkal & 
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Figure 1.3 Molecular differences between ‘neonatal’ and ‘adult’ Nav1.5 
 
(A) Schematic diagram of the SCN5A gene encoding Nav1.5 showing the relative 
positions of the 5' (‗neonatal‘: shaded) and 3' ('adult': black) exon 6. (B) Deduced 
amino acid sequences of Nav1.5 exon 6 alternatives, with 7 amino acids changed are 
underlined. (C) Location of the splicing is the S3 and S4 regions of domain (D1) of 
the protein, including the extracellular S3–4 linker (shaded area). The sequence 
differences between the two isoforms (black circles/white lettering) are located 
mainly in the C-terminal end of D1:S3 and the S3/S4 linker region of the channel, 
close to the four positively charged residues of the voltage-sensing S4. Small arrow 
indicates the ―charge-reversing‖ amino acid change (negative aspartate in ‗adult‘ to 
positive lysine in ‗neonatal‘ exon 6). Modified from Onkal et al. (2008). 
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Djamgoz 2009). All of these support the specificity of NESOpAb against nNav1.5. 
Consistent with the electrophysiology, NESOpAb suppressed in vitro migration and 
invasion of metastatic breast cancer cells. This also confirmed the specific 
involvement of nNav1.5 in breast cancer invasiveness, as shown independently by 
the siRNA experiments (Fraser et al. 2005; Chioni et al. 2005; Brackenbury et al. 
2007). 
 
1.3.2 VGSC-β subunits 
VGSC-βs are single transmembrane domain proteins (Figure 1.4). In vertebrates, 
there are four different VGSC-β subunit genes (SCN1B – SCN4B). These shares a 
similar structure, comprising one N-terminal extracellular immunoglobulin domain 
(IgG loop) which is homologous to the Ig superfamily of CAMs, one transmembrane 
segment and a small intracellular domain (Brackenbury & Isom 2008). Like the α-
subunit, the post-transcriptional process such as alternative splicing can give rise to 
several types of VGSC-β transcripts variant reported especially for SCN1B (Dibb-
Haj et al. 1995; Kazen-Gillespie et al. 2000; Qin et al. 2003; Fein et al. 2007; 
Watanabe et al. 2008). Species-specific alternative splicing has been reported for β1-
subunit. In zebra fish, alternative splicing within exon 5 results in two splice variants 
scnb1_tv1 and scnb1_tv2 (Fein et al. 2007); in rat, intron 5 retention results in splice 
variant β1.2 with 3‘ untranslated region (Dib-Hajj et al. 1995) whilst intron 3 
retention results in splice variant β1A (Kazen-Gillespie et al. 2000). Interestingly, 
β1A was expressed dominantly in embryonic rat brain while none was found in adult 
brain (Kazen-Gillespie et al. 2000). Finally in human, intron 3 retention resulted in 
splice variant β1B that shares >33 % sequence identity with rats, β1A (Qin et al. 
2003 & Watanabe et al. 2008). However, recent evidence has now shown that β1A is  
 42 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structural features of VGSC β-subunits 
 
All β-subunits are composed of a large N-terminal extracellular immunoglobulin 
loop that contained several glycosylation sites (ψ), one transmembrane segment and 
an intracellular C-terminal. The β1 and β3 subunits (A) are bound at a much weaker 
bond whilst β2 and β4 subunits (B) are reported to bind to the channel covalently via 
disulfide bond. In β1/β3, there is one tyrosine phosphorylalation site was suggested. 
Modified from Brackenbury et al. (2008). 
 
 
 
 
 
 
 
 
 
A                                                              B 
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similar to and known as β1B (Brackenbury et al. 2008). 
VGSC-β subunits have been suggested to modulate α-subunits expression and 
function (Isom 2001; Meadows & Isom 2005; Catterall et al. 2005). VGSC-β can 
affect VGSC functioning via multiple mechanisms, including modification of 
voltage-dependent gating, activation and inactivation. β-subunits can also increase 
the amplitude of VGSC currents by (i) modulating the intracellular trafficking of 
VGSC-α protein (thereby incorporating more VGSC into plasma membrane) and (ii) 
increasing their cell surface stability via association with cytoskeletal molecules such 
as ankyrin. However, VGSC-β can also function independently from the α-subunits, 
for example in interaction with CAMs and ECM (for example, tenascin-C and 
tenascin-R) to induce cellular repulsion and cytoskeleton, cell migration and neurite 
outgrowth (Catterall et al. 2005; Diss et al. 2007; Brackenbury et al. 2008). In fact, it 
has been proposed that the functions of VGSC-β that are independent from VGSC-α 
may be more important than their role in modulating the channel activity. In 
particular, all β-subunits are substrates for sequential cleavage by the β-site amyloid 
precursor protein-cleavage enzyme 1 (BACE1) and γ-secretase (Wong et al. 2005). 
Such cleavage of β-subunits generates intracellular domains (ICDs) that were 
suggested to play a functional role as transcriptional factors in the signaling 
mechanisms mediating adhesion, neurite extension and migration (Brackenbury et al. 
2008).  
In cancer, the β-subunits especially β1, β2 and β4 are shown to be expressed 
in human BCa and PCa (Chioni et al. 2006; Diss et al. 2007; Chioni et al. 2009). In 
contrast, β3 has not been detected in either cell line. It is reported that β3 contained 
two response element domains for the cancer suppressor gene, p53 and it is 
suggested that the presence of β3 would promote p53-dependent apoptosis (Adachi et 
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al. 2004). Accordingly, the absence of β3 in cancer cells would be consistent with 
oncogenesis (Chioni et al. 2006; Chioni et al. 2009). In BCa and PCa, VGSCβ‘s are 
proposed to control adhesion (Isom 2002; Brackenbury et al. 2008). β1, β2 and β4 
were found in both weakly and strong metastatic, MCF-7 and MDA-MB-231 cells, 
respectively. β1-subunit was found to be the most abundant subtype in both cell 
lines; however, the mRNA expression was 40-fold higher in MCF-7 cells. A similar 
observation was obtained from PCa where β1 mRNA was found to be abundant in 
the weakly metastatic rat cell lines, AT-2 compared to the strongly metastatic, Mat-
LyLu (Diss et al. 2008). This observation suggested that the reduced expression of 
β1 may enhance the metastatic potential of cancer cells (Brackenbury & Isom 2008).  
Thus, silencing of β1 in MCF-7 cells reduced the adhesion and increased migration 
significantly (Chioni et al. 2006; Brackenbury et al. 2008; Chioni et al. 2009). 
Moreover, down-regulation of β1 in MCF-7 cells caused an increased expression of 
nNav1.5 mRNA and protein, suggesting that β1 may also play a role in regulating the 
expression of the α-subunit (Chioni et al. 2006; Chioni et al. 2009). 
 
1.3.3 Pharmacological properties of VGSCs 
There are at least six distinct receptor sites for neurotoxins and one receptor site for 
LAs and related drugs in VGSC (Catterall 1980; Cestele & Catterall 2000; England 
& de Groot 2009) (Figure 1.5). The selectivity filters (DEKA locus) located at the 
pore region plays an important role in selecting the agents that bind to the receptors 
sites. Drugs like LAs, anti-arrhythmics, anti-convulsants usually have smaller 
molecular weights than those of toxins (TTX, saxitoxin and conotoxin) and are lipid-
soluble that enable them to easily penetrate deep into the channel and bind to an 
inner site (Denac et al. 2000). In particular, most LA agents are weak bases, i.e they 
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exist in both uncharged and charged forms. For LAs (e.g lidocaine), the uncharged 
form accounts for approximately 50 % of the drug and this can readily cross the 
hydrophobic membranes and block VGSC intracellularly at the inner domain 
segment DIV:S6 (Hille 1977; Clancy et al. 2007). This inner domain has affinity for 
small molecules and shares overlapping site for LAs, anticonvulsants and anti-
arrhythmic; it has become known as the LA binding site (Ragsdale et al. 1994; 
Fozzard et al. 2005).  
It is not clear how the binding of different agents at a given site could induce 
different effects on channel gating and kinetics. Importantly, in pharmacological 
targeting of VGSCs, it is crucial to understand how the binding of different agents to 
their target sites could alter the disease state. For example, for epilepsy, 
anticonvulsant drugs were shown to strengthen or restore prolonged inactivation of 
Nav1.1 and this proved particularly helpful in protecting most sufferers from having 
frequent attacks (Hemming et al. 2008). 
 
1.3.4 VGSC current components: Transient and persistent currents 
The inward current generated by VGSC can be divided into two main components: 
transient and persistent (INaP) (Hammarstrom & Gage 2002; Song et al. 2004). The 
transient (msec) current represents the brief rapid opening of the channel pore once it 
is activated, allowing a fast transient influx of Na
+
. Under normal conditions, 
however even after fast inactivation, the influx of Na
+
 may continue, giving rise to 
INaP, typically less than 1 - 2 % of the transient current (Hammarstrom & Gage 2002; 
Saint 2006; Saint 2008).  
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Figure 1.5 Location of the neurotoxin and other VGSC modulator binding sites 
within VGSCs 
 
There are at least six binding sites for neurotoxin and other drugs located in VGSCs. 
The binding site for tetrodotoxin (TTX) is at (1), batrachotoxin at (2), α-scorpion 
toxin at (3), β-scorpion toxin at (4), brevetoxin at (5) and local anaesthetics and other 
small-molecule drugs is at ―LA‖. Modified from England & de Groot (2009). 
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1.3.4.1 Persistent current: INaP 
INaP is defined as steady, TTX-sensitive sodium current at voltages in the range of 
−60 to −40 mV (Taddese & Bean 2002). In general, INaP has similar properties to INaT 
except that the inactivation component of INaP is missing or greatly slowed. Hence, at 
potentials more positive than resting potential, the transient current inactivates but 
INaP does not. However, the origin of persistent sodium current has still been unclear. 
In rat ventricular cells INaP has a V50 for activation about 20mV more negative than 
INaT (V50 of -52 and -34mV) (Saint et al. 1992). INaP in cardiac cells has the same 
ionic selectivity as INaT and the single channels have the same conductance, mean 
open time and reversal potential as the transient channel (Gintant et al. 1984). INaP is 
not a ‗window‘ current since it can be recorded at very positive membrane potentials 
(Saint et al. 1992). INaP should also not be confused with the background or ‗leak‘ 
sodium current, which is TTX insensitive and not voltage dependent (Spindler et al. 
1998). INaP usually has a magnitude of about 1% of the transient component but the 
range of size depends on type of cells and animals (Saint et al. 1992). 
INaP component lacks inactivation or this is greatly reduced. Accordingly, at 
potentials of more positive than resting potential, the transient current inactivates 
whilst INaP does not. However, INaP deactivates very rapidly on repolarization and has 
slightly different activation properties to the transient component at the macroscopic 
level (Saint et al. 1992). INaP is believed to play an important role in boosting 
excitatory synaptic inputs, acceleration of firing rates and promotion of oscillatory 
neuronal activities (Liu et al. 2004) and to contribute to the shaping and duration of 
action potentials and their trains (Fearon & Brown 2004). The origin of INaP has 
remained controversial. Some studies support the notion that it is mediated by an 
unidentified sodium channel isoform distinct from the conventional VGSC, whereas 
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others suggested that INaP reflects a non-inactivating gating mode of conventional 
VGSCs (Liu et al. 2004). More recently, it was suggested that the range of INaP 
amplitudes produced by the VGSC complex could be defined by the complement 
with β-subunits (Aman et al. 2009). In particular, co-expressing neuronal Nav1.1 
with β4 caused a three-fold increase in INaP amplitude (Aman et al. 2009). Although 
the size of INaP is small, its persistence when the channel is activated would permit a 
significant rise in Na
+
. Importantly, INaP is also known to be increased by a number 
of conditions such as hypoxia (Figure 1.6A) (Ju et al. 1996; Fearon & Brown 2004), 
ischemic metabolites (amphiphiles) (Undrovinas et al. 1992), oxygen free radicals 
(Ward & Giles 1997; Song et al. 2006), post-myocardial infarction (Huang et al. 
2005; Weiss & Saint 2010) and mutation (Liao et al. 2010; Huang et al. 2011; 
Shinlapawittayatorn et al. 2011). Under such ‗abnormal‘ conditions, enhanced INaP 
would lead to further Na
+
 overload (Fraser et al. 2006; Saint 2008; Saint 2009). Such 
overloading and its impact upon of Na
+
/Ca
2+
 exchange is an underlying cause of 
conditions  as such the Long-QT syndrome (Clancy et al. 2002) and Brugada 
syndrome (Brugada et al. 2005). These syndromes are linked to mutations of VGSC 
(especially Nav1.5) and clinically can cause arrhythmias that can lead to sudden 
death. For example, in Long QT syndrome type 3 (LQT3), mutation in the SCN5A 
gene in which the cysteine is substituted for a highly conserved tyrosine (Y1767C) 
located near the cytoplasmic entrance of the Nav1.5 channel pore, also has been 
reported to have a raised in INaP (Huang et al. 2011).  
As for the VGSC in BCa, particularly MDA-MB-231 cells, the resting 
membrane potential for these cells is -18.9 +/- 2.1 mV in external bath solution. 
However, at this voltage we would not expect the channel to be active (i.e. it would 
be inactivated). However, in vitro experiments using TTX, NESOpAb and siRNA 
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directed against nNAv1.5 indicates that it is active (Fraser et al. 2005; Chioni et al. 
2005; Brackenbury et al. 2007). Thus it is suggested that there are mechanisms (e.g. 
ligand-gated ion channels, hormones, growth factors) that cause the membrane 
potential to fluctuate hence cause channel to activate. Since there may be INaP 
component following the activation of VGSC, there may be prolonged Na
+
 influx. 
However, at present, we do not know how this mechanism may affect INaP. Indeed, 
it been has shown that the MDA-MB-231 cells are electrically excitable (Onkal, R, 
personal communication). Besides they can be electrically-evoked, whether the cells 
have spontaneous action potentials are not known. However, recent data have shown 
that nNav1.5 has much slower activation and inactivation kinetics and recovers from 
inactivation more slowly than the ‗adult‘ form (Figure 1.6B) (Onkal et al. 2008). 
Thus, it is possible that similar to the condition mentioned above, the INaP in BCa is 
enhanced and could lead to Na
+
 overload, in line with reports showing that Na
+
 
concentration is higher in BCa (Cameron et al. 1980; Oukerwerk et al. 2007). 
Therefore, it is possible that inhibition of INaP selectively could correct intracellular 
Na
+
 and Ca
2+
 homeostasis and could be a novel target therapy for BCa. Indeed, there 
have been drugs that have proven to have preferential blocks of INaP, for example, 
ranolazine and riluzole (Saint 2008; Saint 2009). Both drugs have been shown to 
selectively inhibit INaP of the cardiac of VGSC (Nav1.5) during the myocardial 
ischemia (Antzelevitch et al. 2004; Wu et al. 2004; Hale et al. 2006; Song et al. 
2006; Weiss et al. 2009; Weiss & Saint 2009). Additionally, both drugs are already 
clinically used in treating diseases related to excitability, such as angina, LQT 3 
syndrome and amyotrophic lateral sclerosis (ALS) (Vadnais & Wenger 2010; 
Gordon 2011). 
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Figure 1.6 Electrophysiological properties of VGSC currents 
 
(A) Electrophysiological component of VGSC comprises of transient and INaP. The 
amplitude of INaP is very small that is less than 1-2 % of the transient current 
however it could be increased under hypoxia. Example shows, exposure to ~3-4 min 
of hypoxia caused a very large increase in the amplitude of INaP in HEK293 cells 
expressing the human cardiac α-subunit of VGSC. Modified from Hammarstrom & 
Gage (2002). (B) Electrophysiological recordings from the ‗adult‘ and ‗neonatal‘ 
Nav1.5 overexpressed in EBNA cells. The nNav1.5 has a slower inactivation 
compared to adult type that could contribute to larger INaP. Modified from Onkal et 
al. (2008).  
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1.4 Involvement of VGSC in cancer progression: Cellular excitability (CELEX) 
hypothesis of metastasis 
The first description of abnormal (‗epigenetic‘) expression of VGSC in cancer was 
made in rat and human PCa (Grimes et al. 1995; Laniado et al. 1997; Bennett et al. 
2004). Subsequently, VGSC have been shown to be widely expressed in a range of 
cancer cells: BCa (Fraser et al. 2005; Chioni et al. 2005; Brackenbury et al. 2007; 
Palmer et al. 2008; Onkal et al. 2008; Pan & Djamgoz 2008; Chioni et al. 2009; 
Gillet et al. 2009; Gao et al. 2009; Onkal & Djamgoz 2009; Chioni et al. 2010; Fraser 
et al. 2010; Brisson et al. 2010), lung cancer, including small-cell (Pancrazio et al. 
1989; Blandino et al. 1995; Onganer & Djamgoz 2005; Onganer et al. 2005), non-
small-cell (Roger et al. 2007) and mesothelioma (Fulgenzi et al. 2006), cervical 
cancer (Shen et al. 1996; Diaz et al. 2007), neuroblastoma (Ou et al. 2005), 
melanoma (Allen et al. 1997), ovarian cancer (Gao et al. 2010) and colon cancer 
(House et al. 2010). Importantly, VGSC mRNA and protein were reported to be 
expressed specifically in the invasive (‗metastatic‘) variants of BCa, PCa and small-
cell lung cancer (SCLC) in vitro and in vivo (Fraser et al. 2005; Grimes et al. 1995; 
Onganer et al. 2005). Recent evident from colon cancer demonstrated that Nav1.5 
plays an important role as a key regulator of a gene transcriptional network that 
controls invasion (House et al. 2010). In BCa, the pre-dominant VGSC, nNav1.5 was 
~1800-fold higher at mRNA level in strongly metastatic MDA-MB-231 cells 
compared to the weakly metastatic MCF-7 cells (Fraser et al. 2005). Similar 
observations were made for PCa, where the pre-dominant VGSC, Nav1.7, mRNA 
was ~1000-fold higher in the strongly metastatic rat Mat-LyLu and human PC-3 
cancer cell lines compared to the weakly metastatic rat AT-2 and human LNCaP cell 
lines (Diss et al. 2001). Furthermore, the fast inward current produced by VGSC 
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activity in the strongly metastatic cell lines was inhibited by TTX and this correlated 
with an inhibitory effect on cellular behaviours processes integral to metastasis, e.g 
lateral motility, transverse migration and invasion (Grimes et al. 1995; Onganer & 
Djamgoz 2005; Fraser et al. 2005; Brackenbury et al. 2007). 
Whole-cell patch clamp recording from normal breast epithelial cells and 
several types of human BCa cells showed (1) that only strongly metastatic, MDA-
MB-231 cells expressed a fast inward current and (2) that outward current density 
and resting membrane potential decreased with metastatic potential (Figure 1.7) 
(Marino et al. 1994; Fraser et al. 2005). A similar situation was observed in human 
and rat PCa (Smith et al. 1998). The fast inward, current in BCa was mainly, 
attributed from the activity of VGSC. In accordance with these patch clamp 
observations, CELEX hypothesis was proposed by Djamgoz & Isbilen (2006). This 
stated that the aggressiveness/hyperactivity of metastatic cancer cells was driven by 
increased activity/expression of VGSC and concurrent downregulation/loss of 
outward current due mainly to voltage-gated potassium channels (VGPC). 
Accordingly, metastatic cancer cells demonstrate a ‗neuronal‘ phenotype (Liotta & 
Clair 2000; Onganer et al. 2005; Hagel & Stavrou 2007; Brackenbury et al. 2008) 
and are potentially electrically ‗excitable‘ (Hoang et al. 2007). 
 
1.4.1 ‘Neonatal’ Nav1.5 activity potentiates metastatic cell behaviours in BCa 
In the strongly metastatic MDA-MB-231 BCa cell line, three types of VGSC were 
found to be expressed: Nav1.5, Nav1.7 and Nav1.6 (Fraser et al. 2005). However, 
~80 % of the overall expression was contributed to Nav1.5. Importantly, RT-PCR 
and sequencing of the DI:S3/S4 showed that Nav1.5 was present pre-dominantly in 
its neonatal splice form, nNav1.5. nNav1.5 mRNA and protein were also found in  
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Figure 1.7 Voltage-activated membrane currents in human breast epithelial 
cells of different metastatic potential 
 
Whole-patch clamp recordings from a variety of human breast epithelial cells from 
the normal to highly metastatic cell lines. The metastatic potential increases from left 
to right. (A) MCF-10A (normal human breast epithelial cells, (B) MCF-7, (C) MDA-
MB-468 and (D) MDA-MB-231. Only the strongly metastatic, MDA-MB-231 
generates a fast inward current. Please note that the outward current amplitude is 
reduced with metastatic potential. Modified from Fraser et al. (2005). 
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human breast biopsies and correlated with lymph node metastasis (Fraser et al.2005). 
Partial DNA sequencing revealed that nNav1.5 exon differs from the ‗adult‘ exon at 
31 of its 92 nucleotides resulting in seven amino acid differences (Figure 1.3) 
(Chioni et al. 2005). A similar observation was made for PCa, where the ‗neonatal‘ 
splice form of Nav1.7 (nNav1.7) was found to be pre-dominant in the strongly 
metastatic rat and human cell lines (Onkal & Djamgoz 2009). These findings support 
the notion that embryonic genes that are silent after a tissue/organ reaches its mature 
stage are re-expressed in cancer cells as ―oncofetal‖ genes (Monk & Holding 2001; 
Ben Porath et al. 2008). Indeed, it has been noted that physiological invasive and 
migratory process integral to neuronal pathfinding in the embryo may be a 
comparable, deregulated form in pathophysiological cancer cells invasion (Liotta et 
al. 1991). There is another interesting example of how re-expression of a ‗neonatal‘ 
gene isoform could cause pathological state. For example, in an experimental rat 
epilepsy model, a convulsive agent, kainate was injected intraperitoneally, resulting 
in limbic seizures. After the kainate injection, the levels of mRNA encoding Nav1.2 
and Nav1.3 subunits increase substantially in hippocampus (but not in neocortex 
tissue). Importantly, this overall increase was accompanied by a shift from adult to 
neonatal isoforms of these mRNAs. Both the absolute increase in VGSC mRNA - 
provided that it was followed by translation to functional channels - and the 
increased presence of ‗neonatal‘ forms might cause an increase in excitability 
(Gastaldi et al. 1997).  
As already noted, ‗neonatal‘ forms of VGSC (Nav1.5 and Nav1.7) are 
expressed in the highly metastatic BCa and PCa. A complementary result was 
obtained on BCa, by Onkal et al. (2008); in similar embryonic ion channels 
generally, nNav1.5 was found to have much slower activation and inactivation 
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kinetics allowing greater Na
+
 influx. As a consequence, the enhanced Na
+
 entry 
might be responsible for the increased intracellular Na
+
 observed in malignant breast 
tissue (Cameron et al. 1980; Oukerwerk et al. 2007). Nevertheless, it is still unclear 
how VGSC activity/Na
+
 concentration can regulate BCa metastasis. Apart from 
initiating and propagating membrane action potentials, VGSC activity could at least 
partially contribute to cellular ionic homeostasis via Na
+
/Ca
2+
 and Na
+
/H
+
 
exchangers (Le Guennec et al. 2007; Brisson et al. 2010). VGSC together with 
Na
+
/Ca
2+ 
and Na
+
/H
+
 exchangers can play a vital role in regulating intracellular Ca
2+
 
and H
+
 concentrations (Hiraoka 2006). Indeed, imbalanced cellular ionic homeostasis 
has been reported in various human diseases, as in heart, kidney failure and brain 
seizures (Saint 2008; Saint 2009). 
 
1.5 Regulation of VGSC expression/activity in cancer  
Regulation of VGSC expression has been studied in PCa. In human and rat PCa cell 
lines, Nav1.7 expression/activity was found to be regulated by growth factors, 
including nerve growth factor (NGF) and epidermal growth factor (EGF) (Ding et al. 
2008; Brackenbury & Djamgoz 2007; Onganer & Djamgoz 2005). Another factor 
that was reported to regulate the expression of VGSC in PCa is intracellular Na
+
 
concentration (Brackenbury & Djamgoz 2006). Furthermore, functional availability 
of VGSC in PCa was suggested to be potentiated by activity-dependent elevation of 
[Na
+
]i via protein kinase A (PKA) by a positive feedback autoregulation mechanism. 
Accordingly, Na
+
 influx-activated PKA would stimulate VGSC transcription and/or 
trafficking of protein to plasma membrane thus maintaining elevated VGSC activity. 
PKA was also shown to play an important role in activity-dependent positive 
feedback of the functional expression of nNav1.5 in BCa; and in turn, this would 
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enhance the cells' metastatic potential (Chioni et al. 2010). It was also shown that the 
local biochemical constitution especially insulin controlled the VGSC 
expression/activity and its coupling to the metastatic machinery of MDA-MB-231 
cells (Pan & Djamgoz 2008). Moreover, ‗auxiliary‘ β1 may also play a role in 
regulating the expression of the nNav1.5 where down-regulation of β1 in MCF-7 
caused an increased expression of nNav1.5 mRNA and protein (Chioni et al. 2009). 
Another key regulator for VGSC is hypoxia. Hypoxia was first discovered to 
regulate ion channels when K
+
 conductance was found to be inhibited in the rabbit 
carotid body (Lopez-Barneo 1988). Recent findings showed that hypoxia could 
increase the amplitude of INaP component (Hammarstrom & Gage 1998; 
Hammarstrom & Gage 2002; Fearon & Brown 2004). Since hypoxia is so closely 
related to growth of solid cancers, including BCa, further understanding of effects of 
hypoxia on VGSC-dependent MCBs could lay foundation for novel therapies of 
metastatic disease. 
 
1.6 Hypoxia and cancer progression  
Cell responses to hypoxia are controlled mainly by transcription factors, hypoxia-
inducible factors (HIFs). HIFs is a heterodimeric transcriptional factor consisting of 
one of three types of α-subunit (HIF-1-3α) and another constitutive β-subunit (HIF-
β). HIF-1α is ubiquitously expressed, whereas HIF-2α is expressed only in 
endothelial cells and in kidney, heart, lungs and small intestine
 
(Lopez-Lazaro 2006; 
Gordon et al. 2007). HIF-1α and HIF-2α function as transcriptional activators of 
oxygen-regulated target genes but the role of HIF-3α, rather newly described, is 
unclear (Gordon et al. 2007; Dang et al. 2008).  
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Under normoxic condition, HIF-α is regulated mainly by prolyl hydroxylase 
(PHD) and factor inhibiting HIF-1 (FIH) (Pouyssegur et al. 2006; Lisy & Peet 2008). 
PHD hydroxylates a prolyl residue in the amino- and the carboxy-terminal oxygen-
dependent degradation domains (NODDD and CODDD, respectively) (Mole & 
Ratcliffe 2007). FIH hydroxylates an asparaginyl residue in the carboxy-terminal 
activation domain (CAD) which blocks p300 co-activator recruitment (Schofield & 
Ratcliffe 2004). Hydroxylation of HIF-α promotes von Hippel-Lindau (VHL) 
tumour-suppressor protein binding to HIF-α, thus targeting it for proteosomal 
degradation (Brahimi-Horn et al. 2007) (Figure 1.8).  
However, under hypoxia, PHD and FIH activities gradually decrease. Thus, 
HIF-α stabilizes and heterodimerizes with the constitutively expressed HIF-β. HIF-β 
is an aryl hydro-carbon receptor nuclear translocator (ARNT). Activated HIF-α/β 
binds DNA at hypoxia response element (HRE) of a responsive gene, leading to 
enhanced transcriptional activation. Such target genes include those involved in 
intercellular pH regulation, glucose transport, glycolysis and vasculogenesis, together 
allowing for cellular adaptation to hypoxia (Dang et al. 2008).  
Although HIF-1α expression is tightly controlled by O2, it can also be 
regulated by an O2-independent mechanism. For example, loss of tumour suppressor 
gene e.g VHL, PTEN and mutation of succinate dehydrogenase and fumarate 
hydratase have been shown to induce stabilization of HIF-1α (Maxwell et al. 1999; 
Katherine et al. 2000; Selak et al. 2005; King et al. 2006; Lu & Kang 2010). 
Furthermore, reactive oxygen species (ROSs) e.g H2O2 also have been reported to 
stabilize HIF-1α expression through its blocking effect of PHD (Page et al. 2008; 
Patten et al. 2010). Consistently, H2O2 was shown to be responsible for stabilization 
of HIF-1α mRNA and protein expression in several types of cells e.g PASMCs  
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Figure 1.8 Regulation of HIF-α by hydroxylation through prolyl hydroxylation 
and asparaginyl hydroxylation pathways 
 
In the presence of oxygen, active hypoxia-inducible factor (HIF) hydroxylases — 
that is, prolyl hydroxylase domains (PHDs) and factor inhibiting HIF (FIH) — 
downregulate and inactivate HIF subunits. PHDs hydroxylate a prolyl residue in the 
amino- and the carboxy-terminal oxygen-dependent degradation domains (NODDD 
and CODDD, respectively), which promotes von-Hippel–Lindau-tumour-suppressor 
(pVHL)-dependent proteolysis and results in the destruction of HIF subunits. FIH, on 
the other hand, hydroxylates an asparaginyl residue in the carboxy-terminal 
activation domain (CAD), which blocks p300 co-activator recruitment and results in 
the inactivation of HIF-subunit transcriptional activity. In hypoxia, HIF hydroxylases 
are inactive and these processes are suppressed, which allows the formation of a 
transcriptionally active complex. Modified from Schofield & Ratcliffe (2004). 
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(Bonello et al. 2007) and murine embryonic cells lacking cytochrome c (Simon 
2006). 
It has been estimated that > 50 % of solid cancers contain hypoxic regions 
(Rankin & Giaccia 2008). Cancer hypoxia is increasingly being recognized as an 
important micro-environmental factor in promoting cancer aggressiveness and 
metastasis (Brahimi-Horn & Chiche 2007). As for BCa, approximately 25 – 40 % of 
invasive BCa have been shown to be hypoxic due to ‗uncontrolled‘ growth of 
vasculature (Gruber et al. 2004; Vleugel et al. 2005; Trastour et al. 2005). Thus, HIF-
1α expression is commonly found in BCa as well as other solid cancers. A large 
number of genes are known to be regulated by HIF-1α in promoting cancer 
invasiveness, including those promoting angiogenesis, (e.g VEGF, IL-8, angiogenin, 
FGF, and PDGF) and erythropoietin, glycolytic enzymes and inducible nitric oxide 
synthase (iNOS) (Melillo et al. 1995; Ebert et al. 1996; Forsythe et al. 1996; 
Semenza 2002). In fact, it has been suggested that acquisition of a metastatic 
phenotype is the result of a stepwise selection process driven by hypoxia (Sullivan & 
Graham 2007). Many reports have shown that hypoxia can play a role at every stage 
of metastasis from the initial dissemination of cancer cells from the primary tumour 
to the final stage of secondary proliferation (Cairns et al. 2011).  
Hypoxia has been shown to trigger the transition of immotile epithelial cells 
to motile mesenchymal cells in EMT. Studies have shown that inhibition of HIF-1α 
and HIF-2α by RNA interference caused restoration of E-cadherin expression as well 
as increased cell-cell adhesion and transepithelial resistance in renal cell carcinoma 
(Krishnamachary et al. 2006; Esteban et al. 2006). This process is important during 
the escape mechanism from the primary tumour via functional loss of E-cadherin 
which is a hallmark of EMT (reviewed by Sullivan & Graham 2007; Yang & 
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Weinberg 2008; Cannito et al. 2008). Hypoxia has been demonstrated to enhance cell 
motility through hypoxia-induced hepatocyte growth factor (HGF)-MET receptor 
signaling. The resulting cell migration towards blood or lymphatic vessels is a 
strategy used by cancer cells to escape from hypoxia to more oxygen- and nutrient- 
rich environments (Ide et al. 2006; Hara et al. 2006). Hypoxia also has been shown to 
facilitate cellular invasion via acidosis increasing the activity of proteolytic enzymes 
e.g cathepsin, MMPs, uPA and cathepsins (Graham et al. 1999; Maity & Solomon 
2000; Yoon et al. 2006). At a final stage of metastasis, at a secondary site where 
cancer cells will need to re-proliferate and grow, extensive studies have shown that 
hypoxia facilitates cancer cells to create new vascular networks that include 
angiogenesis and lymphangiogenesis via expression of VEGF in many types of 
cancer (Schoppman et al. 2006). 
 
1.6.1 Effect of hypoxia on VGSC expression/activity  
The concept of O2-sensitive ion channels was first shown when K
+
 channels currents 
in rabbit carotid body were reversibly inhibited by hypoxia (Lopez-Barneo et al. 
1988). Later, hypoxia has been shown to modulate several other types of ion 
channels that include Ca
2+
 channels and VGSC in neurons and other cell types. 
Effect of hypoxia on VGSC current conductance is still very new. In contrast to K
+
 
channels, hypoxia has been shown to increase activation and inactivation of VGSC 
current. For example, overnight exposure to hypoxia (4 % O2) increased activation 
and inactivation of TTX-resistant VGSC currents in DRG neurons (Ton et al. 2010). 
Importantly, hypoxia also increased INaP. For example, hypoxia has been shown to 
cause an increase in INaP amplitude of rat CA1 neurons (Hammarstrom & Gage 
1998), HEK293 cells expressing Nav1.5 (Hammarstrom & Gage 2002; Fearon & 
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Brown 2004) and guinea pig ventricular myocytes (Zhou et al. 2006; Wang et al. 
2007). In turn, such enhanced INaP could result in disruption of intracellular Na
+
 
and/or Ca
2+
 homeostasis. Indeed, increased INaP has now been implicated as one of 
the culprits in the cascade of events leading to cellular Na
+
 and/or Ca
2+
 overload and 
cellular damage during pulmonary hypertension and cardiac ischemia (Del Negro et 
al. 2005; Miles et al. 2005; Harvey et al. 2006; Theiss et al. 2007; Lamanauskas & 
Nistri 2008; Weiss 2009; Weiss & Saint 2009).  
To date, there is no report linking INaP of cancer cells, hypoxia and metastasis. 
As discussed earlier (Section 1.4), intracellular Na
+
/Ca
2+
 overload might play a role 
in the acquisition of invasive capability of cancer cells and therefore, inhibiting INaP 
could be a therapeutic strategy for BCa metastasis. Additionally, hypoxia also could 
regulate the expression of ion channels. For example, prolonged hypoxia has been 
shown to reduce the expression of K
+
 channels in PASMC (Platoshyn et al. 2000). 
Whilst, many have reported prolonged hypoxia increase neuronal excitability 
through increase expression and activity of VGSC (Xia et al. 2000; Zhang et al. 
2001; Zhao et al. 2004; Zhao et al. 2005). It would be interesting therefore to 
investigate the possible role of hypoxia in VGSC-dependent MCBs of BCa cells.  
 
1.6.2 H2O2 and cancer hypoxia 
Szatrowski & Nathan (1991) demonstrated that in many type of hypoxic cancer cells, 
H2O2 was produced excessively. Consequently, increasing data have suggested that 
increasing cellular concentration of H2O2 can result in the acquired capabilities of 
cancer cells i.e H2O2 caused DNA damage, mutations and genetic instability in many 
types of cells (Park et al. 2005; Hunt et al. 1998; Jackson et al. 2000; Pericone et al. 
2002; Henle et al. 1997; Imlay et al. 1988). Furthermore, several have shown that 
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treating cancer cells with H2O2-detoxifying enzymes reversed all those cancerous 
capabilities (Nelson et al. 2003; Nishikawa et al. 2004; Polytarchou et al. 2005). 
Importantly, H2O2 has been shown to activate and stabilize HIF-1α protein through 
the inactivation of PHD (Page et al. 2008).
 
Thus, H2O2 together with hypoxia can 
trigger the hallmarks of cancer (Lopez-Lazaro 2007). With regards to VGSC, similar 
to hypoxia, H2O2 has been demonstrated can increase INaP (Ward & Giles 1997; Song 
et al. 2006). Subsequently, H2O2 can mimic hypoxia. 
 
1.6.3 Regulation of pH in normal and cancer cell  
Aerobic and anaerobic ‗respiration‘ of cells generates CO2 and lactic acid. 
Intracellular accumulation of these substances could induce acidosis. Acidosis of the 
intracellular pH (pHi) has been shown to affect cell function, growth and division 
(Roos & Boron 1981) and could even induce apoptosis (McConkey et al. 1996). 
Therefore, intercellular regulation of acid/base is important in maintaining pHi near 
neutral ~7.2 and extracellular pH (pHe) ~7.5 (Swietach et al. 2007). In maintaining 
normal pHi and pHe, normal cells have multiple membrane transport mechanisms. 
There is at least five H
+
 - equivalent transporters; 1) Na
+
/H
+
 exchanger (NHE); (2) 
Na
+
/HCO3
−
 - cotransporter (NBC) that mediates acid-extrusion while; (3) Cl
−
/HCO3
−
 
exchanger (CBE) and (4) Cl
−
/OH
−
 exchanger (CHE) which mediates acid-loading; 
(5) a lactate – H+ cotransport (monocarboxylate transporter, MCT) that can operate 
in either efflux or influx mode (Vaughan-Jones et al. 2009) (Figure 1.9). 
It has been reported that in heart, smooth muscle, skeletal muscle and 
neurons, pHi is sensitive to pHe. For example, H
+
 efflux by both NHE and NBC is 
inhibited by reduce of pHe and is stimulated by reduce of pHi. Similarly, H
+ 
influx on 
CBE and CHE is stimulated by reduce of pHe and is inhibited by a fall of pHi 
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(Vaughan-Jones 1986; Vaughan-Jones & Wu 1990; Sun et al. 1996; Ch‘en & 
Vaughan-Jones 2001). 
When pHi is acidified, HCO3
- 
will be transported in to the cell by NBC. The 
importance of HCO3
-
 is to act as a buffer molecule to neutralize H
+
 intracellularly 
(Vaughan-Jones & Spitzer 2002). In general, HCO3
-
 is a product of CO2 hydration. 
CA is a zinc-containing enzyme that catalyzes the reversible reaction between CO2 
hydration and HCO3
-
 dehydration:  
 
H2O + CO2                        H
+
 + HCO3
-
 
 
Thus, HCO3
-  
transport has been reported to be commonly coupled with CA (Robey 
et al. 2009; Vaughan-Jones 2006). Indeed, many HCO3
- 
transporters have been 
reported to have binding site for CA (Vaughan-Jones 2006). Thus, the catalytic 
reaction by CA provides an efficient production and transportation of HCO3
-
. There 
are at least 12 - 16 different isoforms of CA (Gilmour 2010). Some CA isoforms are 
expressed intracellular e.g CA1, 2, 3 and 7 while some are confined to extracellular 
surface e.g CA4, 9, 12, 14 and 15 (Swietach et al. 2007). Two isoforms, CA9 and 
CA12 have been shown to be controlled by HIF-1α (Chiche et al. 2009).  
Solid cancers, including BCa, are believed to be hypoxic due to excessive 
growth and up-regulate HIF-1α. HIF-1α is mainly responsible in the development of 
glycolytic phenotype and increased metabolism, characteristic of cancer cells. 
Increased CO2 and lactic acid production in cancer cells mean that there is ‗extra 
work‘ for cancer cells to effectively remove acid to maintain pHi ~7.1. High 
expression of NHE and H
+
-ATPase has been reported in several types of cancers 
including BCa and these efficiently extrude acid out of the cells (Lagadic-Grossman  
CA9 
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Figure 1.9 Schematic ilustration of five generic types of H
+
-equivalent transport 
protein identified functionally in the mammalian ventricular myocyte 
 
Na
+
/H
+
 exchanger (NHE) and Na
+
/HCO3
−
 cotransporter (NBC) mediate acid-
extrusion while Cl−/HCO3
−
 exchanger (CBE) and Cl
−
/OH
−
 exchanger (CHE) 
mediate acid-loading. A lactate/H
+
 cotransport (monocarboxylate transporter, MCT) 
operates in either efflux or influx mode, depending on circumstances. Under 
normoxic, non-exercise conditions lactate concentrations are low so that 
sarcolemmal MCT is largely inactive. During hypoxia, however, when lactate levels 
are high, its influence on pHi becomes significant. Modified from Vaughan-Jones et 
al. (2009). 
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et al. 2004; Cardone et al. 2005; Harguindey et al. 2005). Consequently, due to active 
acid-extrusion process, pHe of cancer cells is acidic. Hypoxic cancer correlates 
positively with levels of acidosis in the extracellular environment; thus, pHe of 
cancer cells is in the range of 6.0 - 6.9, whereas the pHe of normal tissues is 
significantly more alkaline, 7.0 - 7.2 (Brahimi-Horn & Pouysségur 2006). 
Furthermore, other than the active acid-extruding process, CA, especially the 
membrane-bound CA9 and CA12 which could be induced by HIF-1α, has been 
shown to increase in cancer cells (Ivanov et al. 2001; Chiche et al. 2009). Increased 
expression and activity of CA9 and CA12 has been suggested to ‗trap‘ H+ in the 
extracellular environment. Accordingly, to help maintaining pHi ~ 7.1, to ensure 
cancer cell survival, increased expression and activity of CA9 and CA12 lead to 
increased HCO3
-
 production to recycle back into the cells to neutralize H
+
 (Swietach 
et al. 2008; Chiche et al. 2009; Swietach et al. 2010). Thus, HCO3
-
 cotransport has 
been shown to increase in colon cancer, T84 cells in its pH regulation (Ramirez et al. 
2000). The ‗byproduct‘ of CA catalytic activity, H+ will remain in the extracellular 
where they will potentiate extracellular acidification (Swietach et al 2007; Svastova 
et al. 2004; Stock & Schwab 2009). Additionally, poor microvascular structure 
surrounding cancer cells increases the diffusion distances that poorly facilitate the 
wash-out of the excessive waste products e.g H
+
, CO2 further contributing to acidosis 
(Figure 1.10). 
 
1.6.3.1 Acidosis facilitates cancer invasion 
It has been demonstrated that cancer cells have pHi similar to normal cells but acidic 
pHe around 6.0 – 6.9 (Gillies et al. 2002). The latter has been reported to be a 
consequences of increased acid-extruding process by increased activity of the acid 
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exchangers/transporters and moreover by increase expression/activity of surface 
membrane CA. In advanced cancer, acidic pHe would enhance metastasis via 
increased invasive potential. Acidic pHe has been demonstrated (1) to facilitate 
tumour acid extrusion and (2) increase the release and activity of pH-
dependent/driven proteases. For example, acidic pHe has been shown to increase the 
release and activity of proteases that include cathepsin-B, -D, -L, MMP-9 and MMP-
2 (Bourguignon et al. 2004; Kato et al. 2005; Mohamed & Sloane 2006; Harguindey 
et al. 2009).  
Extracellular acidification by NHE1 was demonstrated to be important for the 
cathepsin-B-dependent ECM proteolytic activity and invasion of BCa cells 
(Bourguignon et al. 2004). In addition, acidification of cancer pHe by surface 
membrane CA e.g CA9 and CA12 has also been implicated in cancer invasion 
(Wykoff et al. 2000). Both CAs have been associated with acidosis of several types 
of cancer (Chiche et al. 2009). However, CA9 has attracted more attention due to 
high evidences of CA9 expression in hypoxic tumor tissues but not in normal tissues. 
CA12 expression increased in tumour tissue whilst still being expressed in normal 
tissue (Ivanov et al. 2001). Furthermore, CA9 has a higher extracellular activity than 
CA12 (Whittington et al. 2001; Supuran et al. 2008; Pastorekova et al. 2008). 
Consequently, CA9 has been hugely accepted as a HIF-1α-activated gene/protein.  
Co-localization of CA9 and HIF-1α has been shown in BCa and in many 
other cancers including kidney (Liao et al. 1997), colorectal (Saarnio et al. 1998), 
lung / non-small cell (Vermylen et al. 1999; Giatromanolaki et al. 2001), cervical 
(Olive et al. 2001; Kim et al. 2005), bladder (Turner et al. 2002) and nasopharyngeal 
carcinomas (Hui et al. 2002). Expression of CA9 in these cancers has been associated 
with poor prognosis. Its role in cancer has been linked to increased  
 67 
 
 
 
Figure 1.10 Schematic illustration of role of surface carbonic anhydrase in 
normal cells and hypoxic cancer cells 
 
(A) In normal cells, CO2 produced by the mitochondria through the aerobic 
respiration pathway can be diffused easily through the plasma membrane. Whilst H
+
 
needs to be titrated by HCO3
−
 thus producing CO2 through cytosolic CA before 
diffuse out to the vessel. Aerobic respiration and the titration of intracellular H
+
 by 
HCO3
−
, both produce CO2, which must be vented out to prevent acidosis. The rate of 
CO2 removal can be accelerated by hydrating extracellular CO2 to H
+
 and HCO3
−
, 
which then diffuse in parallel with any remaining unhydrated CO2 to the nearest 
capillary (facilitated CO2 diffusion). This maintains a steep transmembrane CO2 
gradient for venting more of the gas. CO2 hydration is catalysed by extracellular-
facing carbonic anhydrase (CA). (B) However, in hypoxic cancer cells, HIF-1α 
increased the expression of CA9 at the plasma membrane accelerated CO2 hydration. 
Lack of vascularization, traps H
+
 at the extracellular environment thus brings 
acidosis. Modified from Vaughan-Jones et al. (2009).  
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expression/activity of degradative enzymes e.g cathepsin-B, MMP-2 and MMP-9 
(Rozhin et al. 1994; Swietach et al. 2007; Giatromanolaki et al. 2001). Such 
extracellular acidosis resulting from increased CA9 expression and activity has been 
shown to facilitate invasion of melanoma in vitro and promote its metastasis in vivo 
(Gatenby et al. 2004; Rosftad et al. 2006; Moellering et al. 2008). Also, CA9-siRNA 
transfected colorectal cancer cells showed a reduced level of active MMP-2 that 
associated with decreased ECM invasion (Sansone et al. 2009). 
In BCa, CA9 mRNA expression was found mainly in high-grade, steroid 
receptor negative cancer tissues (Span et al. 2003; Rakha et al. 2011). CA9 protein 
over-expression has also been associated with over-expression of HER-2 (Blackwell 
et al. 2004). A few studies have also reported CA9 protein expression in invasive 
type of BCa (Chia et al. 2001; Bartosova et al. 2002). Although CA9 expression has 
been suggested to be a potential prognostic marker for BCa, there is still insufficient 
data to understand how CA9 could contribute to increased BCa invasiveness.  
 Brisson et al. (2010) recently demonstrated that in MDA-MB-231 cells, 
Nav1.5 plays a role in increasing the activity of NHE1 to acidify pHe thus facilitating 
the activity of pH-dependent cathepsin to degrade ECM. This finding has opened a 
new understanding on how VGSC could contribute to BCa invasion. Therefore, it 
would be interesting to investigate a possible association of VGSC with CA9 in BCa. 
 
1.7 Strategies for suppressing metastatic cell behaviours of MDA-MB-231 cells 
using VGSC blockers  
The major barrier to the treatment of BCa is metastasis. Therefore, it is of crucial 
importance to understand the molecular mechanisms underlying the process of 
metastasis and to develop therapeutic strategies to reduce the spreading of cancer 
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cells from primary tumour. Every single step in the metastatic process can potentially 
be targeted by pharmacological agents and this may be therapeutically useful. 
Recently, important methodological advances have led to the designing of more 
appropriate pharmacological strategies to bring to a halt of specific steps in 
metastasis. Roger et al. (2004) proposed that modulating VGSC current can affect 
the invasiveness of metastatic BCa cells through changes of the channels‘ current 
amplitude. Therefore, targeting both the transient and INaP component of VGSC using 
VGSC blocker drugs could be a viable strategy for suppressing MCBs. In this regard, 
a number of points need to be considered: (1) many of VGSC blockers target the 
transient rather than INaP. Furthermore, (2) many blockers that have been reported to 
suppress the activity of VGSC are not subtype-selective and (3) some of VGSC that 
are expressed in cancer cells are also normally expressed in nerves, muscles and 
other tissues. Therefore, it is important to develop strategies that would selectively 
affect VGSC only in cancer cells and would block INaP component of VGSC without 
affecting the transient current especially in relation to cardiac function.  
There are several types of VGSC blockers: local anaesthetics (e.g lidocaine), 
anti-convulsants (e.g phenytoin) and anti-arrhythmics (e.g flecainide) (Roselli et al. 
2006). Indeed, some pharmacological blockers of VGSC e.g phenytoin suppressed 
MCBs e.g lateral motility at a non-toxic concentration of the strongly metastatic of 
PCa and BCa (Fraser et al. 2003; Fraser et al. 2005). Recently, a polyclonal antibody 
against nNav1.5, NESOpAb was developed (Fraser et al. 2005; Chioni et al. 2005; 
Brackenbury et al. 2007). NESOpAb not only blocked the VGSC current but also 
suppressed in vitro migration and invasion of metastatic breast cancer cells. This also 
confirmed the specific involvement of nNav1.5 in breast cancer invasiveness (Fraser 
et al. 2005; Chioni et al. 2005; Brackenbury et al. 2007). When NESOpAb was first 
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developed, tested and presented in Fraser et al. (2005), the polyclonal antibody was 
shown to work perfectly against nNav1.5 in both Western blot and 
immunocytochemistry. However, in the recent years, the antibody did not show 
similar results – NESOpAb only worked best in immunocytochemistry. Basically, 
for efficient interaction to occur between the antigen and the antibody, the epitope 
must be readily available for binding. If the target molecule is denatured, e.g through 
fixation, reduction, pH changes or during preparation for gel electrophoresis, the 
epitope may be altered and this may affect its ability to interact with an antibody. 
This explain why some antibodies are ineffective in Western blot but very good in 
immunohistochemistry because in the latter procedure, a complex antigenic site 
might be maintained in the tissue, whereas in the former procedure the process of 
sample preparation alters the protein conformation sufficiently to destroy the 
antigenic site and hence eliminate antibody binding. In this study, we believed that 
the modification of the Western blot procedure in the recent study had affected the 
target epitope thus altered the efficiency of NESOpAb for Western blot. 
Consequently, in this study, NESOpAb was only used in the immunocytochemistry. 
In order to test the effect of VGSC blockers on BCa MCBs, two VGSC 
blockers will be used in the present study: lidocaine and procaine. In addition, recent 
development in cardiac therapy have reported, a new anti-angina agent, ranolazine 
and neuroprotective agent, riluzole have been shown to selectively block INaP 
component over the transient current of VGSC. The inhibition of INaP by both drugs 
could be an advantage to investigate its effect on the metastatic behaviours of BCa 
cells.  
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1.7.1 Ranolazine 
Angina or angina pectoris is a condition of chest pain that is caused mainly by 
insufficient oxygen (resulting from a low coronary blood flow or increased oxygen 
demand) necessary to support oxidative metabolism in heart muscle. In this 
condition, there would be increased INaP, leading to excessive Na
+
 influx into cardiac 
cells and disruption of intracellular Ca
2+
 homeostasis (Saint 2008; Saint 2009). 
Pharmacologically, an accepted general strategy for treating angina is using drugs 
that could improve the myocardial oxygen balance through either increasing the 
coronary blood flow or decreasing the cardiac mechanical function (Hara et al. 1999; 
Pham & Mehta 2007). Indeed, several types of anti-angina drugs have already been 
approved e.g vasodilators and cardio-inhibitory drugs. More recently, a new class of 
anti-angina drug was introduced and approved for treatment of angina, namely 
ranolazine (Antzelevitch et al. 2004). Ranolazine is a piperazine derivative drug used 
for adjunctive therapy when angina is inefficiently controlled with other 
conventional agents (Siddiqui & Keam 2006). Different from other anti-angina 
drugs, the cardio-protective action of ranolazine was not due to improvement of the 
myocardial oxygen balance but thought to be due to stimulation of glucose oxidation 
and reduction of fatty acid oxidation through activation of pyruvate dehydrogenase 
(McCormack et al. 1996; Stanley et al. 2002).  
Many reports have shown that ranolazine displays a broad pharmacological 
profile on a number of targets and has complex electrophysiological effects on 
cardiac cells (Antzelevitch et al. 2004). However, Wang et al. (2008) have reported 
that ranolazine could also block the neuronal Nav1.7 and muscle Nav1.4. The most 
compelling mode of action of ranolazine is its selective inhibition of INaP (Figure 
1.11A) (Antzelevitch et al. 2004; Undrovinas et al. 2006; Fredj et al. 2006). Fredj et 
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al. (2006) showed in HEK 293 cells over-expressing Nav1.5 that ranolazine 
significantly blocked INaP with 10 times more potency than the transient current. In 
dog ventricular myocytes with chronic heart failure, ranolazine was reported to 
selectively inhibit INaP with 38 times higher relative to the transient (Undrovinas et 
al. 2006). Recently, Huang et al. (2010) demonstrated that ranolazine inhibited INaP 
of the mutant Nav1.1 (associated with Long QT syndrome type 3) with 16 times 
higher potency compared to transient current. Ranolazine was also reported to be a 
more effective blocker of INaP compared with other VGSC blockers such as lidocaine 
(Burashninov et al. 2007). Importantly, ranolazine was suggested to share the same 
binding site as the local anaesthetics of VGSC since a single mutation at LAs site 
altered ranolazine‘s binding affinity drastically (Fredj et al. 2006). 
To date, the action of ranolazine has not been investigated in VGSCs of 
cells/tissue other than the heart and neuronal cells. Since VGSC, especially nNav1.5 
was functionally up-regulated and found to potentiate MCBs in BCa, studying the 
effects of ranolazine on BCa cells could provide useful information regarding its 
therapeutic potential as an anti-metastatic drug. Additionally, since INaP would be 
enhanced under hypoxia, investigating the effects of ranolazine under this condition 
would expand our understanding the relation of VGSC and cancer hypoxia.  
 
1.7.2 Riluzole 
Riluzole is a neuroprotective and anticonvulsant drug used to treat amyotrophic 
lateral sclerosis (ALS) (Besimon et al. 1994; Lacomblez et al. 1996; Meininger et al. 
2000). A number of recent case studies have also indicated that riluzole may have 
clinical use in mood and anxiety disorders (Mathew et al 2005; Pittenger et al. 2008), 
refractory depression (Zarate et al 2004) and obsessive- compulsive disorder (Coric  
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Figure 1.11 Inhibition of VGSC persistent current by ranolazine and riluzole 
 
(A) 10 µM ranolazine (RAN) inhibits VGSC persistent current of left ventricular 
myocytes isolated from canine failing hearts. Modified from Undrovinas et al. 
(2006). (B) Riluzole at a concentration of 0.01, 0.03, 0.1, 0.3, 1.0, 3.0 and 10 µM 
(traces from bottom to top, respectively) inhibits persistent current induced by 
perfusing with N2 in rat myocites. The topmost trace was recorded in the presence of 
20 µM TTX (control). Modified from Weiss et al. (2010). 
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et al. 2005). The drug has also been suggested for treating spinal damage (Schwartz 
& Fehlings 2002) and brain injury (Wahl & Stutzmann 1999), Huntington‘s disease 
(Squitieri et al. 2008) and epilepsy (Farber et al. 2005). In treating all these 
conditions, riluzole has been reported to have several mechanisms of action 
including as a VGSC blocker (Song et al. 1997; Beltran-Parrazal & Charles 2003; 
Wang et al. 2008), voltage-gated calcium channels (VGCCs) blocker, glutamate/N-
methyl-D-aspartate (NMDA) receptor antagonist, and glutamate transporter activator 
(Belingham 2011).  
More recently, the action of riluzole has been attributed to its block of the INaP 
(Del Negro et al. 2005; Miles et al. 2005; Harvey et al. 2006; Theiss et al. 2007; 
Lamanauskas & Nistri 2008; Weiss 2009; Weiss & Saint 2009). Riluzole strongly 
reduced INaP at low, therapeutic (nanomolar) concentrations in rat cortical neurons 
(Urbani & Belluzzi 2000; Spadoni et al. 2002). Similar observation was also reported 
for NG108-15 neuronal cells and neuroendocrine cells in vivo where riluzole 
inhibited INaP preferentially over the transient current (Wu et al. 2009). Consistently, 
in rat myocytes, riluzole was shown to inhibit INaP more effectively than TTX (Weiss 
et al. 2010) (Figure 1.11B). 
In relation to cancer, Namkoong et al. (2007) showed that treatment of 
GRM1-positive human melanoma cells with riluzole reduced the release of 
glutamate, suppressed cell growth and induced apoptosis. Furthermore, riluzole was 
shown to be effective in suppression of cancer growth in a xenograft model (Yip et 
al. 2009). Recently, the National Cancer Institute of USA is conducting a clinical 
trial for riluzole in treating melanoma patients with stage III or IV. Interestingly, the 
trial is now expanded to BCa cancer patients. Riluzole caused dose-dependent 
growth-inhibition of all PC3, DU145, LNCaP and MDA-PCA-2B PCa cells (Abdul 
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& Hoosein 2002). Interestingly, in melanoma and PCa, VGSC has been reported to 
be over-expressed and to potentiate MCBs (Allen et al. 1997; Fraser et al. 1999; 
Fraser et al. 2003; Roger et al. 2003). In the present study, we aimed to investigate 
the effect of riluzole on the MCBs of BCa under both under normoxic and hypoxic 
conditions. 
 
1.7.3 Local anaesthetics: Lidocaine and procaine 
Local anaesthetics (LAs) have been used widely to characterize the pharmacology of 
VGSC in many different species and tissues. In fact, there is a binding site dedicated 
to LAs in VGSC that is situated at the inner domain segment of domain IV segment 
S6 (Clancy et al. 2007). As VGSC blockers, LAs are well-established and safe for 
use against neuropathic pain and as an anti-arrhythmic drug. Effects of LAs on 
cancer cells have not been studied, although, LAs are used frequently in almost all 
cancer-related procedures e.g chemotherapy, immunotherapy, radiation and 
importantly surgery. Interestingly, there are reports suggesting that application of 
local anesthesia to patients during surgery reduced the risk of recurrence or 
metastasis four-fold during a 2.5 to 4-year follow-up period from BCa, consistent 
with the proposed role of VGSC activity in cancer progression (Exadaktylos et al. 
2006). Subsequently, extensive in vitro and in vivo data on effects of LAs on cancer 
were published (Santamaria et al. 2010). In particular, Siddiqui et al. (2005) 
demonstrated that propofol based conjugates (propofol-DHA or propofol-EPA) 
conjugates significantly inhibit cell adhesion (15–30 %) and migration (about 50 %) 
and induced apoptosis (about 40 %) in BCa cells. In another report, BCa axillary 
recurrence was significantly reduced after sentinel lymph node biopsy was carried 
out under local anaesthesia (Groetelaers et al. 2008). In this present study, two LAs 
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that will be tested as potential anti-metastatic agents in the present study are 
lidocaine and procaine.  
Lidocaine is a local anaesthetic of amide type that is commonly used to 
control pain (e.g during surgical procedures) as well as an anti-arrhythmic drug. In 
pain control, as a VGSC blocker, the main mechanism of action is inhibiting the ion 
(Na
+
) flow necessary for the conduction of impulses in the pain sensation pathways. 
In relation to cancer, lidocaine was shown to reduce the endocytic membrane activity 
(a process integral to metastasis) of the small-cell lung cancer cell lines in a dose-
dependent manner (Onganer & Djamgoz 2005). Lidocaine was also shown to have 
anti-proliferative in cancer cells; Sakaguchi et al. (2006) suggested that the inhibition 
of EGF-stimulated EGFR activity was one of the mechanisms of the anti-
proliferative effect of lidocaine on oral adenosquamous carcinoma cell line, CAL27 
cells. Furthermore, lidocaine was shown to induce apoptosis in a concentration-
dependent manner and with higher concentrations inducing necrotic cell death in 
human neuroblastoma cells (Werderhausen et al. 2009).  
Different from lidocaine, procaine is an ester type local anaesthetic drug 
primarily used to reduce the intramuscular pain from penicillin injection. It is also 
commonly being used as a local anaesthetic in dentistry. Similar to lidocaine, in 
relation to cancer, procaine induced apoptosis in a concentration-dependent manner 
and with higher concentrations caused necrotic cell death in human neuroblastoma 
cells (Werderhausen et al. 2009). In relation to BCa, procaine was shown to have 
DNA-demethylating and growth-inhibitory effects over MCF-7 cell lines via mitotic 
arrest (Villar-Garea et al. 2003). 
Most importantly, a number of studies involving lidocaine and procaine 
report increased anti-cancer activity of several major conventional chemotherapy 
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drugs (as well as radiotherapy) such as cisplatin, mytomycin C, peplomycin, 
bleomycin and doxorubin (Chlebowski et al. 1982; Mizuno & Ishida 1982; Block et 
al. 1983; Viale et al. 1998). Based on these reports and the known effect of lidocaine 
and procaine on VGSC, in this study, these agents were adopted for testing as 
potential anti-metastatic agents. 
 
1.8 Aims and scope of the present study 
This PhD project is divided into 3 main parts. Part 1 (chapter 3) investigates the 
possible effects of several VGSC blockers (lidocaine, procaine ranolazine and 
riluzole) on MCBs (lateral motility, transverse migration and Matrigel invasion) of 
the highly metastatic human BCa cell line, MDA-MB-231. Part 2 (chapter 4) 
complement Part 1 by undertaking complementary studies on the cells following 
exposure to hypoxia using INaP blockers, ranolazine and riluzole. Part 3 (chapter 5) 
investigates a possible relation, between VGSC (nNav1.5) and CA9 
expression/activity on MCBs. The overall aim was to build a therapeutic strategy for 
selectively suppressing the VGSC-dependent metastatic potential of BCa. 
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Chapter 2 
 
MATERIALS AND METHODS 
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This thesis utilized a variety of techniques and procedures, which are described in 
this chapter. 
 
2.1 Cell culture 
2.1.1 Cell lines and growth conditions  
The human breast cancer (BCa) cell line, MDA-MB-231 was used throughout the 
studies. MCF-7 cell line was used only in the experiments involving riluzole. Both 
are epithelial mammary gland cancer cells, derived from metastatic pleural effusions 
(adenocarcinomas) (Cailleau et al. 1974; Cailleau et al. 1978). MDA-MB-231 cells 
are strongly metastatic whilst MCF-7 cells are weakly/non-metastatic (Cailleau et al. 
1974; Cailleau et al. 1978). Voltage-gated sodium channels (VGSC) are functionally 
expressed in MDA-MB-231 cells and VGSC activity potentiates metastatic cell 
behaviours (Roger et al. 2003; Fraser et al. 2005; Chioni et al. 2005; Brackenbury et 
al. 2007; Onkal & Djamgoz, 2009; Gao et al. 2009; Gillet et al. 2009; Brisson et al. 
2010). This makes MDA-MB-231 cells a good model for studying the specific 
subcellular mechanisms linking VGSC activity to invasiveness (Fraser et al. 2005). 
Morphologically, MDA-MB-231 cells are elongated and tend to grow separately 
from each other (Figure 2.1A). On the other hand, MCF-7 cells are ‗rounded‘, grow 
in clumps and do not express any functional VGSC (Figure 2.1B).  
The cells were cultured in 10 cm or 35 mm Falcon plastic dishes (Beckton 
Dickinson) and maintained in Dulbecco‘s Minimum Essential Medium (DMEM) 
(Gibco) supplemented with 4 mmol/L L-glutamine (Gibco) and 5 % of fetal bovine 
serum (FBS) (Gibco). Cultured cells were maintained in a humidified incubator 
(Heraeus) at 37 
o
C, 100 % relative humidity and 5 % CO2 (Fraser et al. 2005). The 
growth medium was replaced every 2 days until the cells reached ~80 % confluence 
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Figure 2.1 Typical images of human breast cancer MDA-MB-231 and MCF-7 
cells 
 
Images were taken after plating 5 x 10
3
 cells/ml and maintaining them for 24 h in 
normal incubator at 37 
o
C. (A) The strongly metastatic cell line, MDA-MB-231 cells 
tend to have an elongated shape and grow as single cells. (B) The weakly/non-
metastatic MCF-7 cells tend to grow in clumps and have more round shapes. Scale 
bar 100 µm (both panels). 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
50 µm 
 
50 µm 
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where upon they could be used in experiments or stored as frozen stock. 
 
2.1.2 Passaging 
When the cells reached near-confluence (~80 %), they were passaged. Briefly, 
Trypsin was used to passage MCF-7 cells but not MDA-MB-231 cells, since the 
latter were easily detached from the dish and could be lost in the process. For 
trypsinization of MCF-7 cells, the medium was removed and 3 ml of Trypsin 
(Sigma) were added into 10 cm dish. The dish was placed in the incubator for about 
3 minutes and then an equal volume of growth medium was added. The cells were 
removed from the dish by pipetting and collected in a 15 ml Falcon tube. The cell 
suspension was centrifuged for 3 minutes at ~70 g to form a cell pellet. The trypsin 
solution was removed and fresh growth medium was added to re-suspend the pellet. 
Prior to experiments, cells were counted using a haemacytometer; cell number was 
calculated according to the following equation:  
          
                 Equation 2.1 
 
Where, n = number of cells in one section of the haemacytometer. 
   
Then, the required number of cells could be seeded into a new 10 cm or 35 mm 
tissue culture dish and re-incubated. Cells were always allowed to ‗settle‘ for 24 h 
before any experimental treatment started. For passaging MDA-MB-231 cells, 
medium of the near-confluence dish was changed with 5 ml of fresh medium. The 
cells were removed mechanically by pipetting and collected in a 15 ml Falcon tube. 
The cell suspension was directly counted using a haemacytometer prior to 
(n1 + n2 + n3 + n4) / 4 = x cells/ml 
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experimentation. In all experiments, the passage number for every cell line used was 
< 20. 
 
2.1.3 Freezing and thawing of cell stocks 
A ‗confluent‘ dish of cells was trypsinized with 3 ml of Trypsin (Sigma). An equal 
volume of normal medium (containing 5 % FBS) was then added to each dish to 
‗neutralize‘ the Trypsin. The cell suspension was collected into a 15 ml Falcon tube 
and centrifuged for 2 minutes at ~70 g. The cell pellet was re-suspended in a freezing 
medium containing 10 % dimethyl sulfoxide (DMSO) and 20 % FBS and transferred 
to a freezing vial. The stock vial containing the cell pellet was kept at –80 oC until 
use. 
 To defrost frozen cells, a stock vial was placed in the incubator for 2 -3 
minutes. One ml of growth medium was then pipetted into the vial and the contents 
were transferred to a new 10 cm dish. Five ml of normal growth medium were added. 
The dish was placed in the incubator (37 
o
C) and the medium was changed after 24 h 
to remove any residual DMSO from the medium. 
 
2.2 Pharmacology 
2.2.1 Drugs  
All pharmacological agents used in this study were dissolved in the appropriate 
solvents and then diluted with growth medium (Table 2.1). Ranolazine, riluzole, 
lidocaine and procaine were obtained from Sigma-Aldrich (USA) whilst tetrodotoxin 
(TTX) was obtained from Alomone (Israel). Hydrogen peroxide (H2O2) was obtained 
from Analar (Germany). Riluzole and lidocaine were dissolved in DMSO whilst 
TTX, ranolazine, procaine and H2O2 were prepared in normal DMEM growth  
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Table 2.1 Pharmacological agents used in the experiments 
 
 
Agents SC WC Solvent Supplier 
 
TTX 
Ranolazine 
Riluzole 
Lidocaine 
Procaine 
H2O2 
DMSO 
 
3132 µM 
10 mM 
66.6 mM 
10 mM 
10 mM 
10 mM 
100 % 
 
10 µM 
1, 10 and 100 µM 
1, 10 and 100 µM 
1, 10 and 100 µM 
1, 10 and 100 µM 
1, 10 and 100 µM 
0.01 – 0.1 % (v/v) 
 
Growth medium 
Growth medium 
DMSO 
DMSO 
Growth medium 
Growth medium  
- 
 
Alomone 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
Sigma 
 
Each stock concentration (SC) was prepared in its appropriate solvent. For given 
treatment, the working concentration (WC) of each drug was prepared fresh in 
growth medium (5 % FBS and 4 mmol/L L-glutamine). Control treatments with 
equimolar DMSO were used for riluzole and ranolazine.  
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medium containing 5 % FBS. The stock concentration of ranolazine, lidocaine and 
procaine stock solutions was 10 mM. TTX was prepared as a stock solution of 3132 
µM and riluzole as a stock solution was 66.6 mM. All stock solutions were kept at -
20 
o
C until use. For every experiment, the working concentration of the required drug 
was freshly prepared by diluting appropriately in normal growth medium. 
 
2.2.2 Treatment regimes 
2.2.2.1 Normoxia 
All treatments were started after incubating the cells in normal growth medium and 
‗settling‘ overnight (24 h) in the normal incubator at 37 oC, 100 % relative humidity 
and 5 % CO2. Treatments started the following day. For experiments lasting for 
longer than 24 h, the treatment medium was changed with fresh solution of the same 
every 24 h. For each treatment, a control experiment of untreated cells was set up in 
parallel. 
 
2.2.2.2 Hypoxia 
Similar to normoxia, all treatments under hypoxia were started after incubating the 
cells in normal growth medium overnight (24 h) under normal incubator conditions 
(37 
o
C, 100 % relative humidity and 5% CO2). Treatments started the following day 
in a hypoxia incubator (MicroGalaxy). Again, for experiments lasting for longer than 
24 h, the treatment medium was changed with fresh solution of the same every 24 h. 
The conditions in the hypoxic atmosphere were as follows: 37 
o
C, 100 % relative 
humidity, 5% CO2 and 2% O2 (replacement with nitrogen).  
In order to ensure correct sensitivity of the O2 sensor of the hypoxia chamber, 
the sensor was referred to atmospheric air once a month. If necessary and at the end 
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of the sensor‘s working life, it was replaced according to manufacture‘s protocol 
(MicroGalaxy). In some initial experiments, ‗chemical hypoxia‘ was used by treating 
the cells with H2O2 (50 µM) in the normal incubator. In another experiment of testing 
the effects of H2O2 on SCAMA, the concentration of H2O2 used were in the range of 
0.1 – 100 µM. Again, control and treated cells were studied in parallel.  
 
2.3 Molecular biology  
2.3.1 Total RNA extraction 
Total RNA was extracted directly from a confluent dish of cells using the ‗Trizol 
method‘ according to the protocol provided by the manufacturer (Calbiochem). 
Briefly, the medium was removed and immediately, 1 ml of Trizol (Calbiochem) was 
added directly to the culture dish. Then, the Trizol solution with the cells was 
transferred to a 1.5 ml tube. The mixture was passed through a 26 G needle and 2 ml 
syringe. After homogenization was complete, 0.2 ml of chloroform was added and 
the mixture was shaken vigorously and then allowed to settle at room temperature 
(~25 
o
C) for 5 minutes. The mixture was then centrifuged at 10,000 g at 4 
o
C for 15 
minutes to separate the phenol and chloroform phases. The chloroform phase was 
removed carefully to a new tube, 0.5 µl of isopropyl-alcohol was added and the 
mixture vortexed. After 1 h of settling at -20 
o
C, the mixture was centrifuged again at 
12,000 g at 4 
o
C for 15 minutes to obtain a pellet. The isopropyl-alcohol was 
removed carefully and 1 ml of 70 % ethanol was added to ‗wash‘ the RNA pellet. 
The tube was centrifuged at 7,500 g at 4
o
C for 5 minutes to separate the ethanol and 
the RNA pellet. Finally, the pellet was air-dried for 10 - 20 minutes before adding 20 
- 50 µl of elution buffer or RNAse/DNAse-free water. The concentration of the total 
RNA was determined by a NanoDrop instrument (Thermo Scientific) (Figure 2.2A); 
 86 
RNA integrity was assessed by electrophoresis on a 1 % agarose gel. One μg of RNA 
(from given sample) was mixed with 1 μl of loading buffer (6x; Promega, Madison, 
USA) and loaded onto a 1 % agarose gel containing 0.8 μg/ml SYBER Safe 
(Invitrogen) in a 1x Triz-Borate-EDTA buffer (TBE). The gel was run for 30 - 45 
minutes at 90 V. For good-quality RNA, the 28S band was much brighter than the 
18S rRNA band when visualised under ultraviolet (UV) radiation with an image 
analyzer (Uvidoc/Uvitec) (Figure 2.2B). The purified total RNA was used 
immediately for cDNA synthesis or stored at -80 
o
C until needed. 
 
2.3.2 cDNA synthesis  
Briefly, 1 µg of total RNA was added to 2.5 µl random-hexamer [R6pd(N6)] (100 
ng/µl) (GE Health Care). The total volume of the mixture was made up to 11 µl with 
RNAse/DNAse-free water and placed in a 70 
o
C ‗water bath‘ for 10 minutes to 
separate the RNA into a single strand. Then, immediately, the mixture was placed on 
ice. To every 8 µl of the mixture, were added the following: 2 µl of dithiothreitol 
(DTT) (0.1 M) (Invitrogen), 4 µl of 5X Superscript II first strand buffer (Invitrogen), 
1 µl of dNTP mix (10 mM) (GE Health Care) and 1 µl of porcine RNA guard (24.5 
U) (Qiagen). After standing for 2 minutes at room temperature (~25 
o
C), 1 µl of 
Superscript II RT Enzyme (200 U) (Invitrogen) was added to the reaction mix and 
allowed to settle again for 10 minutes at room temperature. For each RNA sample, a 
control without reverse transcriptase (―-RT‖) was also prepared to test for any 
genomic contamination. The tube was placed on a heating block at 42 
o
C for 90 
minutes. Finally, the mixture was placed in a 70 
oC ‗water bath‘ for 15 minutes to 
halt the reaction. The cDNA was stored at -20 
o
C until use. 
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Figure 2.2 Assessment of the quantity and quality of total RNA 
 
RNA was extracted from MDA-MB-231 cells. (A) Quantity was measured using a 
NanoDrop instrument. RNA absorption peaks at 260 nm. The ratio of this to 
absorption at 230 nm (solvent contamination) [―260/230 ratio‖] and 280 nm (DNA 
contamination) [―260/280 ratio‖] are a measure of ‗purity‘. For a good RNA, both 
ratios should be around 2. (A) The quality of total RNA extracted using the TRizol 
method was assessed by running on 1 % agarose gel. For high-quality, the 28S 
ribosomal RNA bands should have at least twice the intensity of the 18S RNA band. 
The ―5S‖ band represents 5S ribosomal RNA (5S Rrna). Each lane represents total 
RNA from three different samples.   
28S 
18S 
5S 
A 
 
 
 
 
 
 
 
B 
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2.3.3 Real-time PCR 
The ‗master mix‘ of the PCR reaction contained the following: 1 µl of reverse and 1 
µl of forward primer (each at a working concentration of 0.5 µM), 10 µl of 
QuantiTect SYBR Green PCR mix (Qiagen) (1X working concentration) and 3 µl of 
RNAse/DNAse-free water. The master mix was added to 5 µl of cDNA making the 
total volume of the PCR mix, 20 µl. Triplicate reactions on each sample cDNA was 
carried out simultaneously for both the target gene and the housekeeping gene (β-
actin). Each set of reactions also included a standard calibration curve for each target 
gene: nNav1.5, VGSC-β1, CA9 and β-actin. The standards were generated using five 
serial dilutions of a cDNA template. A linear regression line was produced by 
plotting the logarithm of cDNA concentration (X-axis) against the corresponding 
threshold cycle (Ct) (Y-axis). The quality of the standard curve can be judged from 
the slope and the correlation of determination (R
2
), near 1 (Figures 2.3). The 
indifference of ΔCt values with cDNA concentration for the different target genes 
was also produced (Figure 2.4). The ΔCt was calculated using equation as follow:  
 
Equation 2.2 
 
For this, the quality of the standard curve can be judged from the slope and the 
correlation of determination (R
2
), near 0 (Figures 2.4). Both slope of the line can be 
used to determine the efficiency of target amplification. Blank reactions, with sterile 
distilled water instead of cDNA were performed as a ‗negative‘ control for any cross-
contamination. The standard cycle protocol for PCRs was as follows: 95 
o
C for 15 
minutes to activate the Taq, 30 seconds at 95 
o
C for the first step, 30 seconds at 60 
o
C 
for annealing (depending on the melting temperature (Tm) of the primers) and,  
ΔCt = Ct value target – Ct value control 
 89 
 
 
 
 
 
 
  
 
 
 
Figure 2.3 Linearity of Ct value dependence on cDNA concentration for the 
different target genes 
 
The standard curves were generated using five serial dilutions of a cDNA template 
(1, 0.25, 0.0625, 0.015 and 0.004 ng). (A) nNav1.5, (B) VGSC-β1, (C) CA9 and (D) 
β-actin. Data are presented as mean ± SEM (n = 3) and were fit using semi-
logarithmic regression (correlation coefficients = 0.82 – 0.96). 
 
 
 
 
nNav1.5
R2 = 0.8654
25
26
27
28
29
30
31
0.001 0.01 0.1 1
cDNA dilutions
C
t 
v
a
lu
e
CA9
R2 = 0.8163
25
26
27
0.001 0.01 0.1 1
cDNA dilutions
C
t 
v
a
lu
e
VGSC-β1
R2 = 0.9564
25
26
27
28
29
30
31
0.001 0.01 0.1 1
cDNA dilutions
C
t 
v
a
lu
e
β-actin
R2 = 0.8662
0
5
10
15
20
0.001 0.01 0.1 1
cDNA dilutions
C
t 
v
a
lu
e
C                                                                      D 
A                                                                       B 
 90 
 
 
 
Figure 2.4 Indifference of ΔCt values with cDNA concentration for the different 
target genes 
 
Values of ΔCt were calculated using equation 2.2 (with β-actin as the normalizing 
control gene). The standard curves were generated with the best fit horizontal 
logarithmic from the serial dilutions of a cDNA template (1, 0.25, 0.0625, 0.015 and 
0.004 ng). (A) nNav1.5, (B) VGSC-β1 and (C) CA9. Data are presented as mean ± 
SEM (n = 3) and were fit using semi-logarithmic regression (correlation coefficients 
= 0.01 – 0.13). 
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Figure 2.5 Typical melting curves for the different target genes in real-time 
PCR reactions 
 
The singularity of the PCR product from each primer pair was verified by the sharp 
peak in the final melting curve obtained by heating from 65 
o
C to 95 
o
C in 0.3
o
C 
steps. (A) nNav1.5, (B) VGSC-β1, (C) CA9 and (D) β-actin.  
 
C                                                                        D 
A                                                                        B 
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Figure 2.6 Typical gel images of target genes 
 
5 µl of real-time PCR product was mixed with 1 µl of 6x loading dye in each lane. A 
1 Kbp (5 µl) DNA ladder was used as a marker (M). Gels wereloaded in parallel. 1% 
agarose gel was prepared and run for 1 h at 100 V. Band sizes: (A) nNav1.5 – 101 
bp, (B) VGSC-β1 – 379 bp, (C) CA9 – 105 bp and (D) β-actin - 356 bp. All samples 
were from MDA-MB-231 cells. 
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Table 2.2 Sequences of the primer pairs used for conventional or real-time PCR  
 
 
Gene 
 
Primer sequence 
Amplicon size (bp) 
(NCBI Ref No). 
 
nNav1.5 
 
 
5‘ - CTGCACGCGTTCACTTTCCT - 3‘ (F) 
5‘ - GACAAATTGCCTAGTTTTATATTT - 3‘ (R)  
 
 
101  
(AB158470.2) 
 
VGSC-
β1 
 
 
5‘- AGAAGGGCACTGAGGAGT - 3‘ (F) 
5‘- GCAGCGATCTTCTTGTAGCA - 3‘ (R) 
 
 
379  
(NM_001037.4) 
 
CA9 
 
5‘- GACGCCTGGCCGTGTTG - 3‘ (F) 
5‘- CTGAGCCTTCCTCAGCGACGA - 3‘ (R) 
 
 
105 
(NM_001216.2) 
 
β-actin 
 
 
5‘ - ATGGATGATGATATCGCC - 3‘ (F) 
5‘ - ATCTTCTCGCGGTTGGCCTT - 3‘ (R) 
 
 
356 
(NM_001101.3) 
 
The working concentration for each primer in PCR reaction was 10 µM. For each 
primer pair, the forward (F) and reverse (R) primers and the size of amplicon are 
given. The reference numbers of the genes were obtained from National Center for 
Biotechnology Information (NCBI).  
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finally, 30 seconds at 72 
o
C for elongation. The reactions were carried out for 35 – 44 
cycles using Opticon Monitor 2 (MJ Research, USA). The melting curve for the 
primers was set between 65 – 95 oC with 0.3oC steps to verify the singularity of the 
PCR products (Figure 2.5). Finally, the quality of the PCR product was assessed by 
electrophoresis on a 1 % agarose gel (Figure 2.6). Five  μl of PCR product (from 
given sample) was mixed with 1 μl of loading buffer (6x; Promega, Madison, USA) 
and set up  on a 1 % agarose gel. The latter contained 0.8 μg/ml SYBER Safe 
(Invitrogen) in a 1x Triz-Borate-EDTA buffer (TBE). The gel was run for 30 - 45 
minutes at 90 V. The sequences for the primers used (MWG Biotech) are given in 
Table 2.2. Figure 2.5 shows typical melting curves for the primers / target genes. The 
PCR product bands were visualized with image analyzer (Uvidoc/Uvitec). 
 
2.3.4 Small interfering RNA  
This technique was used for silencing CA9 expression in MDA-MB-231 cells. The 
stock solution (100 µM) of the siRNA for CA9 (Eurofin-MWG) was resuspended 
and stored at -20 
o
C. Cells (70 - 80 % confluent in 35 mm culture dish) were 
transfected for 18 h with the siRNA (10 µM) using Oligofectamine according to the 
manufacturer‘s instructions (Invitrogen, UK). Target (siCA9) and non-target/control 
(siControl) transfections were performed in parallel. The sequences of the siRNAs 
were as follows: 
 
siCA9: 5‘ – CAG UGC CUA UGA GCA GUU G- 3‘ 
siControl: 5‘ – AGG UAG UGU AAU CGC – 3‘ 
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Briefly, aliquots of 250 µl Optimem (Invitrogen, UK) were placed in separate 1.5 ml 
tubes (A and B). Five µl of 10 µM siRNA were added into tube A and mixed. In tube 
B, 5 µl Oligofectamine 2000 were added and mixed. The tubes were stood at room 
temperature for 5 minutes and then the contents of tube B were transferred to tube A, 
and mixed with a pipette 3 times. The tube with the overall mixture was stood for 
further 20 minutes at room temperature. Later, the siRNA mixture was added to the 
cells. The cells were incubated overnight in the normal incubator (37 
o
C). The next 
day, normal growth medium (2 ml) was added to the cells. The transfected cells were 
used for mRNA, protein analyses and functional tests after a total of 48 h ‗silencing‘. 
In each experiment, transfected cells were compared to several controls: 1) untreated; 
2) mock-treated (only oligofectamin without the siRNA); and 3) siControl-treated 
cells.  
 
2.3.5 Real-time PCR data analysis 
The number of threshold amplification cycle (CT) was determined for each reaction 
using Opticon software (2.02).  The 2
-ΔΔCT
 method (Livak and Schmittgen, 2001) 
was used to analyze the relative level of gene expression (―Y‖) in each sample by 
using the following equation: 
      
                Equation 2.3 
 
The expression of the target gene in each sample was normalized relative to the 
corresponding sample-matched expression level of the housekeeping gene (β-actin). 
Each experiment was carried out at least 3 times and data were expressed as mean ± 
standard error. Differences in expression levels between different samples were 
Y = 2 – {[mean ΔCt (test)
] – [mean ΔC
t (control)
]} 
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analyzed statistically with two-tailed, un-paired Student‘s t-test using SigmaStat 
software (version 2.0). 
 
2.4 Studies of protein expression 
2.4.1 Immunocytochemistry 
One sterile cover slip (13 mm) was put into each well of a 24-well culture plate. 500 
µl of poly-L-lysine (Sigma-Aldrich) solution (0.25 mg/ml) was added into each well 
and incubated for 30 minutes in the normal incubator (37 
o
C). Then, 3 x 10
4
 cells in 
500 µl of growth medium were seeded into each well and incubated for 24 h. The 
next day, the media were changed with appropriate drug solution and incubated 
continued for a further 24 h.  
The following solutions were prepared fresh in 1 X PBS and kept refrigerated 
until use: 1) a fixative solution of 4 % paraformaldehyde (PFA) (Sigma) in 1X PBS; 
(2) 5 % BSA (Sigma) in 1X PBS; and (3) 0.1 % saponin (Sigma) in 1X PBS. After 
the treatment period, the medium in each well was poured out and the cells were 
washed with 500 µl cold PBS. Immediately afterwards, 500 µl of cold fixative (4 % 
PFA) was added and left for 15 minutes at room temperature to fix the cells. 50 µl of 
concovalin A (ConA) (Sigma) solution (1:10 dilution in 1 % PBS) was put on top of 
a clean platform in an immunocytochemistry chamber. The cover slips were 
transferred onto the platform with the cells-surface contacting the ConA solution. 
The chamber was covered with aluminum foil and left on a rocker for 45 minutes at 
room temperature. Then, the cover slips were transferred back to the 24-well plate 
and washed with 500 µl of PBS for 20 minutes (4x5 times). 500 µl of 0.1 % saponin 
was added and incubated continued for 4 minutes on the rocker. The permeablizing 
solution (0.1 % saponin) was poured out and cells were washed with 500 µl PBS for 
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20 minutes (4x5 times). Finally, 500 µl of cold 5 % BSA was added into each well 
and treatment continued for a further 1 h at room temperature.  
During the final phase of the pre-treatment, the primary antibody was 
prepared in 5 % BSA (1:200 dilution for NESOpAb). 50 µl of antibody solution was 
put on top of a clean platform onto which the cover slip was placed with the cell-
surface bathed in the antibody solution. The chamber was ‗shaken‘ for 1 h at room 
temperature on a rocker. After 1 h, the cover slips were transferred back to the 24-
well plate and washed with 500 µl of PBS for 5 minutes (the washing was repeated 
for 5 times x 5 minutes). The secondary antibody was prepared in 5 % BSA (1: 250 
dilution for Alexaflour-568). 50 µl of the secondary antibody solution was put on top 
of a clean platform and the cover slip was placed on this with the cell-surface down, 
as before. The chamber was covered with aluminium foil and left on the rocker for 1 
h at room temperature. Then, the cover slips were transferred back to the 24-well 
plate and the cells were washed with 500 µl of PBS for 5 minutes (the washing was 
repeated for 5 times x 5 minutes). Finally, the cover slip was mounted in 
fluorescence preserving medium (Dako) on a glass slide and kept at 4 
o
C covered 
with aluminum foil until needed for microscopy. 
Two control experiments were prepared for the immunocytochemistry (ICC): 
1) Antibody control - to test for possible cross-reactivity of the secondary antibody; 
and (2) BSA control - to test for possible signal from BSA causing cross-reactivity to 
any given antibody. For (1), in each repeat, one cover slip was treated only with the 
secondary antibody. Similarly, for (2), one cover slip was treated only with BSA. 
These confirmed the specificity of the immunocytochemical reactions. 
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2.4.1.1 Confocal microscopy and image analysis 
Immunocytochemical fluorescence was detected with a Leica confocal laser scanner 
(TCS-NT with an Ar/Kr laser; Leica Microsystems, Milton Keynes, UK). FITC and 
Alexa568 were excited with the 488 and 568 nm laser lines, respectively. Cells were 
viewed in a Leica DM IRBE microscope under an oil immersion x100 objective. The 
images (512 x 512 pixels) were obtained simultaneously from two channels a 
confocal pinhole of 183.91 um (Airy 1). The images were captured by arranging the 
Z-position in the centre of the cells and an average of 6 single scans were taken. 
Densitometric quantification of total VGSC protein expression in treated and non-
treated cells was performed with the Leica confocal software LCS Lite (version 
2.00). The subcellular distribution of nNav1.5 protein was determined by ‗cross-
sectional‘ analysis with a straight line drawn across the cytoplasm avoiding the 
nucleus (Figure 2.8) (Okuse et al. 2002; Shah et al. 2004; Brackenbury & Djamgoz 
2006). ICC signal intensity in plasma membrane (set to cover 1.5 µm inward from 
the edge of ConA staining), was compared with cytoplasmic signal intensity within 
the central 30 % of the line profile. In general, a minimum of 20 cells (randomly 
chosen) from three independent experiments were analysed and the statistical 
significance was tested using non-parametric Mann-Whitney test from SigmaStat 
software (version 2.0), since the data were not normally distributed.  
 
2.4.2 Western blotting 
2.4.2.1 Total protein extraction 
Protein was extracted from 80 - 100 % confluent culture dishes. The lysis solution (1 
ml) contained: 1 x RIPA Lysis Buffer (Millipore), phosphatase inhibitors including 
10 µl PMSF (200 mM in ethanol), 10 µl aprotinin, 1 µl leupeptin, 1 µl NaF (1 M)  
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Figure 2.8 Typical confocal images and digital analysis of MDA-MB-231cells 
 
The cells were fixed and permeabilized and stained for nNav1.5. (A) A confocal 
image of merged signal from concovalin A (ConA), a plasma membrane marker 
(green) and NESOpAb (red). Colored lines indicate cross-sections used for analysis 
of subcellular distribution of immunoreactivity. Scale bar represents 30 µm. (B) 
Typical profile of signal intensity from ConA and NESOpAb produced by Leica 
confocal software LCS Lite (version 2.00). The vertical dashed lines and horizontal 
arrow indicates the 30 % cytoplasmic region used for intracellular signal intensity. 
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and 1 µl pepstatin. Medium was drained and cells were washed with cold PBS. Lysis 
solution was added and cells were scrapped off after 10 minutes on ice. The cell 
suspension was transferred to a 1.5 ml tube and was homogenized in several passes 
using a syringe and 26 G needle. The homogenate was placed on ice on a rocker for 
30 minutes and then centrifuged at 4 
o
C at 13,000 g for 30 minutes. The supernatant 
was removed. An 10 µl aliquot of  the supernatant and 90 µl of deionized water were 
added to x5- diluted Bradford Reagents and its yield (protein content) was 
determined using a spectrophotometer with reference to a standard calibration curve, 
as described in section 2.4.2.3  (Figure 2.9).  
 
2.4.2.2 Preparation of nuclear protein  
Cells (about 1 x 10
7
) were plated in 10 cm culture dish and incubated normally for 24 
h. The cells were were washed once with 1x iced-cold PBS. The extraction process 
comprised two solutions: ―buffer A‖ to lyse the cells to expose the nuclei and ―buffer 
B‖ to lyse the nuclei. Buffer A contained 10 mM HEPES (pH 7.9), 10 mM KCl and 
0.1 mM EDTA. For 1 ml of buffer A, 1 µl each of protease inhibitors (leupeptin, 
aprotinin, pepstatin, PMSF and DTT) and 40 µl of 10 % Triton-X were added. A 
volume (200 – 500 µl) of buffer A was added directly to the dish and left for 10 
minutes at room temperature before the cells were scraped and transferred into a new 
1.5 ml tube. The tube was centrifuged at 13, 000 g for 3 minutes at 4 
o
C. The 
supernatant was discarded and the pellet was saved. Buffer B contained 10 mM 
HEPES (pH 7.9), 10 mM NaCl, 0.1 mM EDTA and 10 % glycerol. For every 1 ml of 
buffer B, 1 µl each of protease inhibitors (leupeptin, aprotinin, pepstatin, PMSF and 
DTT) were added. A volume (100 – 150 µl) of buffer B was added to the pellet and 
re-suspended using a p100 pipette. The suspension was shaken vigorously on ice for 
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2 h and then centrifuged at 13, 000 g for 5 minutes. Finally, the suspension 
representing the nuclear protein fraction was assessed for protein content as in 
section 2.4.2.3 using Bio-Rad reagents. Lamin A/C (nuclear envelope protein) was 
used as a loading control in the Western blots. Previous work showed this procedure 
to produce nuclear protein with an estimated yield of 0.6 – 1 % (Carey et al. 2009).  
 
2.4.2.3 Quantification of protein  
A dye-binding assay, based on the differential colour change of a dye in response to 
various concentrations of protein, was used according to manufacturer‘s guidelines 
(Bio-Rad Protein Assay), to determine the concentration of protein to be loaded for 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Bovine serum albumin 
(BSA) diluted in lysis buffer was used as a protein standard to construct a standard 
calibration curve (Figure 2.9). Several dilutions of the protein standard in the range 
1.25 to 2.0 mg/ml were prepared. An aliquot of 20 l lysis buffer was used as the 
reagent blank. The dye reagent (Bradford Reagent) was diluted (1 in 4 v/v distilled 
deionized water). In order to obtain the yields in 20 l of total protein samples, 1 ml 
of diluted dye reagent was added and mixed several times by gentle inversion of the 
test tube. After a period of 5 minutes to 1 hour, the OD595 (with the reagent ‗blank‘ 
subtracted) was measured, using a spectrophotometer (CECIL, CE 1020) and 
referred to the linear part of the standard curve (Figure 2.9).  
 
2.4.2.4 SDS-PAGE 
A protein lysate of 80 µg (20 – 100 µl) was mixed with an appropriate volume of 6x 
SDS-sample buffer and heated at 95 
o
C in a ‗water bath‘ for 10 minutes. The running 
gel (6 - 8 %) contained: 9.36 ml of acrylamide (30 %), 13.1 ml of 1 M Tris (pH 8.8),  
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Figure 2.9 Typical protein concentration calibration curve 
 
Protein standards were prepared according to the instructions of the BSA – Bradford 
(Bio-Rad) kit. Several concentrations of BSA (20 – 136 µg) were prepared to 
generate a standard curve. Lysis buffer solution was used as a blank. The straight line 
was obtained by linear regression, extended to the origin (dashed portion). The curve 
was used to calculate protein concentration of a total protein for Western blot.  
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Table 2.3 Antibodies used for Western blot and immunocytochemistry 
 
Primary 
antibodies 
 
Supplier 
 
Species 
 
WC (WB) 
 
WC (ICC) 
MW 
(kDa) 
 
NESOpAb 
 
In house 
 
Rabbit 
 
- 
 
1 : 250 
 
- 
 
HIF-1α  
 
 
Novus 
Biologicals 
 
Mouse 
 
1 : 1000 
 
 
- 
 
 
120 
 
 
CA9 
 
Santa Cruz 
 
Rabbit 
 
1 : 200 
 
- 
 
58 
 
Anti-α-actinin 
 
Sigma-Aldrich 
 
Mouse 
 
1 : 200 
 
- 
 
100 
 
Lamin A/C 
 
Santa Cruz 
 
Mouse 
 
1.33 : 1000 
 
- 
 
67 
      
Secondary 
antibodies 
     
 
Goat anti-
rabbit HRP 
 
Sigma-Aldrich 
 
 
Goat 
 
1 : 10000 
 
 
- 
 
 
- 
 
 
Goat anti-
mouse HRP 
 
DakoCytomation 
 
 
Goat 
 
 
1 : 2000 
 
- 
 
- 
 
Anti-rabbit 
Alexaflour568 
 
Invitrogen 
(Molecular 
probes) 
 
Goat 
 
 
- 
 
1 : 100 
 
- 
 
WC (WB) – working concentration for Western blot; WC (ICC) – working 
concentration for immunocytochemistry; and MW (kDa) – molecular weight of 
protein band in kilo Dalton.  
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175 µl of SDS (20 %), 130 µl ammonium persulphate (10 %) and 30 µl of TEMED. 
The mixture was topped up with 12.29 ml deionized water. The mixture was loaded 
into the gel cast and left to polymerize for 45 minutes. The stacking gel (5 %) 
contained: 1.8 ml of acrylamide (30 %), 1.25 ml of 1 M Tris (pH 6.8), 50 µl of SDS 
(20 %), 50 µl of ammonium persulphate (10 %) and 20 µl of TEMED. The mixture 
was topped up with 7 ml of pure water. After the gel polymerized, 80 µg of protein 
was loaded into each well and the gel was run at 170 V for 3 h. Later, the gel was 
were transferred to a nitrocellulose membrane by running the ‗sandwich gel‘ for 20 h 
at 21 V in a cold room (4 
o
C). The membrane was ‗blocked‘ with 5 % milk/PBS 
Tween 20 (0.1 %) for 1 h and 30 minutes in 2 % BSA/PBS Tween 20 (0.1 %) on a 
rocker at a room temperature. After washing several times (3 x 15 minutes) with 1X 
PBS Tween 20 (0.2 %), the primary antibody was added (Table 2.3). The membrane 
was incubated in the primary antibody overnight. The membrane was re-washed (3 x 
15 minutes) with 1x PBS Tween 20 (0.2 %). As a loading control for the amount of 
protein loaded on the gels, anti-actinin or anti-actin antibodies were used in the 
Western blots (Table 2.3). Then, the HRP-conjugated secondary antibody (Table 2.3) 
was added and incubated for 1 h at room temperature. The membrane was re-washed 
(3 x 15 minutes) with 1X PBS Tween 20 (0.2 %). Finally, ECL Reagent was added 
onto the membrane and exposed to a film. The protein band intensity was quantified 
relative to actin or actinin using ImageJ. 
 
2.4.2.5 Blot stripping 
This process was carried out when the same blot was used to immunostain with a 
different primary antibody. Stripping involved incubation of blot in a stripping buffer 
containing 2 % SDS and 62.5 mM Tris-HCl pH 7.4 - 8.0 for 30 minutes at 65 
o
C. 
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Then, the blot was blocked again with 5% milk/PBS Tween 20 (0.1 %) for 1 h and 
30 minutes in 2 % BSA/PBS Tween 20 (0.1 %) on a rocker at room temperature. The 
primary antibody and subsequently the HRP-conjugated secondary antibody were 
added as described in section 2.4.2.4. 
 
2.5 Functional assays 
2.5.1 Toxicity and cell viability assays 
Cellular viability was assessed using the trypan blue exclusion assay. Cells were 
seeded into a 35 mm dish at an initial cells density of 3 x 10
4
 cells/dish and allowed 
to settle for 24 h. One ml of medium with a given concentration of drug was added to 
each treatment dish and left for 24 h. The medium was removed carefully and 1 ml of 
trypan blue solution (200 µl trypan blue and 800 µl of medium) was added into each 
dish and left for 10 minutes in the incubator (37 
o
C). Then, the trypan blue solution 
was removed and replaced with 1 ml of fresh medium. Dead cells (blue-coloured) 
and living cells (clear) were counted in at least 30 fields view (randomly chosen). 
Cellular viability was calculated using the following formula: 
 
                       Equation 2.4 
 
Nv = number of viable cells, and 
Nt = total number of cells in a given field of view 
 
2.5.2 Proliferation assay 
Proliferation was measured using an assay based upon colorimetric quantification of 
yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)  
Cell viability (%) = (Nv/Nt) x 100 
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Figure 2.10 Typical calibration curve for cell number 
 
The standard curve was obtained by measuring the optical densities (at 570 nm) of a 
set of different numbers of MDA-MB-231 cells (0.75x10
5
, 1.5x10
5
, 3x10
5
, 6x10
5
, 
12x10
5
 and 24x10
5
) cells labeled with MTT. Data are presented as mean ± SEM (n = 
3). Cell numbers in experimental tests were calculated using the linear equation 
generated from the standard curve. 
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reduced to purple formazan in living cells (Grimes et al. 1995). First, cells were 
plated in a 24-well plate at a density of 3 x 10
4
 cells/well and allowed to settle for 
24h prior to any treatment. Three wells were used set up for each treatment and 
medium was re-freshed every 24 h. Following the treatment period (24 - 48 h), 
medium was removed and 150 µl of MTT (at 5mg/ml in growth medium) and 600 µl 
of fresh medium were added into each well and the plate incubated at 37 
o
C for 3 h. 
Then, the MTT solution was removed carefully, 890 µl of DMSO and 110 µl glycine 
buffers were added to each well. After 15 minutes, absorbance was measured at 570 
nm using a spectrophotometer. Cell number was calculated from a standard curve 
covering the range 3 – 48 x 104 cells (Figure 2.10). For each treatment, three wells 
were used per experiment and these were repeated at least three times. 
 
2.5.3 Lateral motility assay 
Lateral motility was assessed using a monolayer wound assay (Fraser et al. 2003). 
Cells were plated in 35 mm dishes at an initial density of 5 x 10
5
 cells/dish and 
allowed to settle for 24 h prior to any treatment. Three wounds were made per dish 
using a sterile p200 pipette tip (Figure 2.11A). The cells were washed 3 times with 
fresh serum-free DMEM to remove any floating cells. One ml of medium with a 
given concentration of drug was then added to each dish. Wound widths were 
determined immediately (0 h) by measuring the widths of the wounds at the 45 fixed 
points per dish using a graticule on an inverted microscope. The same sites were re-
measured after 24 and 48 h, with a change of medium at 24 h. Lateral motility (%) of 
the cells was quantified as the ―motility index‖ (MoI), defined as follows:  
 
    Equation 2.5 MoI = 1 – (Wt/W0) 
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Figure 2.11 Schematic representation of lateral motility assay 
 
(A) A 35 mm dish was marked with 3 horizontal and 15 vertical lines. Each inter-
section was considered as one measuring point for motility giving a total of 45 
values. (B) The assays were carried out for 24 h and visualized for wound widths 
(dashed lines). Red lines represent the borders of the wounds. The two field of view 
(taken at 0 and 24 h) show clearly that the cells moved laterally during the assay 
period. 
 
 
 
 
 
 
 
 
 
0 h 24 h 
A 
B 
  
 109 
where Wt is the width of the wound at time ‗t‘ (24 or 48 h) and W0 is the width of the 
wound at 0 h. For each treatment, two dishes were used per experiment and these 
were repeated at least three times. Digital images of the wounds were also taken 
using a digital camera (Nikon) (Figure 2.11B).  
 
2.5.4 Transverse migration assay 
This assay was performed as described previously (Grimes et al. 1995; Fraser et al. 
2005) with some modifications. Briefly, cells (2 x 10
5
) were plated onto 8 µm-pore 
Transverse migration filters in 24-well companion-plates according to instructions of 
the manufacturer (Falcon). Cells were incubated with a drug or left untreated as a 
control. A chemotactic gradient was applied by including 1 % FBS (in the 
inserts/upper chamber - ‗cell-side‘) and 10 % FBS (in the well/lower chamber). 
Chemotactic migration was allowed to continue for 24 h. At the end of each assay, 
non-migrated cells were removed from the upper surface of the insert using two 
different swabs. The migrated cells on the other side were stained with crystal violet 
and counted using ImageJ (Figure 2.12).  
 
2.5.5 Matrigel invasion assay 
Invasion assays were carried out in a 24 well-companion plate with an insert (pore 
size 8 µm) coated with Matrigel (BD). A day prior to the experiment, 50 µl of 1.25 
µg/ml of Matrigel (in growth medium, DMEM) was coated on the insert and let to 
solidify at 37 
o
C in an incubator overnight. Two hours before starting the experiment, 
500 ml of medium without FBS was added onto the inserts and placed in normal 
incubator (37 
o
C) for hydrating. For the experiment, 750 µl of 10 % FBS growth 
medium with or without the agent to be tested was added to given wells. Cells were  
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Figure 2.12 Schematic representations of transverse migration and Matrigel
 
invasion assays 
 
(A) Components of transverse migration (without Matrigel) and Matrigel invasion 
chambers. Cells were plated in the upper part of the inserted chambers. Cell numbers 
were 2 x 10
5
 cells (transverse migration) and 15 x 10
4
 cells (Matrigel invasion). For 
both assays, the pore size of the inserts used was 8 µm. The assays were carried out 
for 24 h and inserts were stained with crystal violet before visualizing with digital 
camera. (B) Typical views of migrated/invaded cells. The two fields of view (taken 
after 24 h) were from Matrigel assays and show clearly that cell invasion was 
suppressed after treatment with TTX (10 µM). 
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collected, counted and 15 x 10
4
 cells  were re-suspended in 250 µl of 1 % FBS 
growth medium containing the drug to be tested and added onto the insert (upper 
chamber) (Figure 2.12A). The invasion plate was incubated in an incubator (normal 
or hypoxic) for 24 h. Then, the insert was removed and the upper-part of the insert 
was swabbed using a ‗cotton-bud‘ to removed cells that had not invaded. Invaded 
cells were stained with crystal violet according to section 2.5.5.1 and counting using 
ImageJ (Figure 2.12B). 
 
2.5.5.1 Crystal violet staining 
Crystal violet staining was used to facilitate the cell counting in the transverse 
migration and Matrigel invasion assays. Following the treatment period, the upper 
part of the insert was swabbed using a ‗cotton-bud‘ to remove cells that had not 
migrated/invaded. Inserts were fixed by adding ice cold 100 % methanol directly 
onto the cells and incubated on ice for 15 minutes. The methanol was removed and 
0.5 g/ml crystal violet in 0.25 % methanol was added immediately. The cells were 
stained with crystal violet for 15 minutes at room temperature. Later, the inserts were 
washed with distilled water. The insert was then let to dry for 1 h in the dark before 
images of cells were taken for counting. 
 
2.6 Data analysis 
All quantitative data are presented in the text as means ± standard error of the mean 
(SEM). Normality test was carried out before statistical significance was determined 
with two-tail, un-paired Student‘s t-test using SigmaStat software (version 2.0). 
Differences were considered significant for P < 0.05 (*) or highly significant for P < 
0.01 (**) or P < 0.001 (***).  
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Chapter 3 
 
EFFECTS OF PHARMACOLOGICAL BLOCKERS OF VGSCs ON 
METASTATIC CELL BEHAVIOURS: STUDIES ON NORMOXIC MDA-MB-
213 CELLS 
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3.1 Introduction 
 
At least six distinct
 
receptor sites for neurotoxins and one receptor site for local
 
anaesthetics and related drugs have been identified on the voltage-gated sodium 
channel α-subunit (VGSCα) protein (Catterall 1998; Cestele & Catterall 2000; 
Catterall et al. 2007). Consequently, agents that bind to these sites could result in a 
range of cellular effects, depending on concentration and the binding site(s) involved. 
For example, tetrodotoxin (TTX) binds to receptor site 1 and causes pore blockade, 
thereby inhibiting channel conductance and Na
+
 influx (Catterall 1998; Cestele & 
Catterall 2000; Catterall et al. 2007). The effects of blocking other sites were 
discussed in Chapter 1 (Section 1.3.3). 
Increasing evidence is suggesting that VGSCs play an important role in 
potentiating the metastatic cascade in several types of human cancer. According to 
Roger et al. (2003), modulating (down-regulating) the physiological properties of 
VGSCs (especially the conductance) using pore blockers would suppress the 
invasive capacity of breast cancer (BCa) cells. In the case of human prostate cancer 
(PCa), also, Bennett et al. (2004) concluded that functional VGSC expression was 
―necessary and sufficient‖ for increasing cellular invasiveness. Consistent with this, 
TTX was shown to suppress a variety of in vitro cell behaviours associated with 
metastasis, including lateral motility, endocytic/secretory membrane activity, 
adhesion and transverse migration of BCa and PCa (Grimes et al. 1995; Fraser et al. 
2003; Bennet et al. 2004; Fraser et al. 2005; Brackenbury et al. 2007). Recently, 
House et al. (2010) also concluded that the VGSC gene ―SCN5A is a key regulator of 
a gene transcriptional network that controls colon cancer invasion‖. In the case of 
human BCa, the VGSC subtype responsible for the reported pro-metastatic effects is 
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the neonatal splice variant of Nav1.5 (nNav1.5) (Fraser et al. 2005; Chioni et al. 
2005; Brackenbury et al. 2007; Onkal & Djamgoz 2009).  
Inhibition of VGSC activity is also the primary mechanism of action of many 
antiepileptic agents and local anaesthetics. Such drugs, therefore, may be useful for 
suppressing the progression of cancer cells expressing functional VGSCs. Indeed, 
there is some evidence that several antiepileptic drugs and anaesthetics suppress 
metastatic cell behaviours (MCBs). For example, lidocaine was shown to inhibit the 
endocytic membrane activity of human small-cell lung cancer cells (Onganer & 
Djamgoz 2005) and phenytoin was reported to inhibit cellular migration and lateral 
motility of PCa (Sikes et al. 2003; Fraser et al. 2003). Interestingly, it has also been 
noted that application of local anaesthesia to BCa patients during surgery reduced the 
risk of recurrence or metastasis during a follow-up period, consistent with the 
proposed role of VGSC activity in cancer progression (Exadaktylos et al. 2006).  
In the present study, two distinct strategies were adopted to further assess the 
potential of VGSC (nNav1.5) targeting in suppressing BCa cell invasiveness in vitro. 
First, we aimed to test pharmacological agents which were reported earlier to 
have some preference for blocking embryonic VGSCs. Such, agents were lidocaine 
and procaine which were shown previously to block VGSCs in rat neurons more 
effectively in embryo than adult (e.g Ribeiro & Costa 2003). 
Second, irrespective of the subtype of VGSC expressed, the role of the 
persistent component of VGSC current (INaP) was investigated. The advantages of 
this strategy were (i) that blocking persistent versus transient current would not be 
lethal (Saint 2006; Saint 2008; Saint 2009) and (ii) that safe drugs with this mode of 
action are already in clinical use. Such drugs include ranolazine for angina 
(Antzelevitch et al. 2004; Undrovinas et al. 2006; Fredj et al. 2006) and riluzole for 
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amyotropic lateral sclerosis (ALS) (Lamanauskas & Nistri 2008; Weiss & Saint 
2010; Weiss et al. 2010).  
The effects of these two kinds of VGSC blockers on the following MCBs 
were determined: Lateral motility, transverse migration and Matrigel invasion. These 
assays were supplemented by assessments of cell viability and proliferation. In 
addition, the possible effects of the drugs on nNav1.5 mRNA and VGSC protein 
levels were studied. 
 
3.2 Aims and scope 
 
The main aim of the present study was to determine the effects of (i) lidocaine and 
procaine and (ii) ranolazine and riluzole on the metastatic behaviours of MDA-MB-
231 cells. Some experiments were also carried out on weakly/non-metastatic MCF-7 
cells for comparison. The specific aims were as follows: 
1. To quantify the effects of the drugs in functional assays: cell viability, cell 
number (‗proliferation‘), lateral motility, transverse migration and Matrigel 
invasion; 
2. To evaluate the mRNA expression levels of nNav1.5 and VGSC-β1 after 
treatment with the drugs; and 
3. To determine the subcellular (re)distribution of VGSC (nNav1.5) protein 
after treatment with the drugs. 
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3.3 Results 
3.3.1 Control experiments 
Since lidocaine and riluzole were dissolved in DMSO, a concentration-dependent 
control experiment with the solvent was conducted to investigate its possible effect 
on cellular morphology, toxicity, growth and MCB (lateral motility) that could 
interfere with any of the drug effects over 24 h. Real-time PCR was also conducted 
to investigate the possible effect of DMSO on the mRNA expression levels of 
nNav1.5 and VGSC-β1. Up to the highest concentration used (0.1 %), DMSO had no 
effect on cellular viability or cell number (n = 4; P > 0.05; Figures 3.1A and 3.1B). 
DMSO (up to 0.05 %) also had no effect on cell morphology (Figures 3.5B) or the 
cells‘ lateral motility (n = 4; P > 0.05; Figure 3.1C). Following treatment with 
DMSO (up to 0.05 %), there was no effect on nNav1.5 mRNA expression level (n = 
3; P > 0.05; Figure 3.2A). However, DMSO did have some effect on VGSC-β1 
mRNA expression, which was reduced significantly to 77 ± 2.7 % (relative to control 
level) at the highest concentration (0.05 %) used (n = 3; P < 0.05; Figure 3.2B). 
 
3.3.2 Effects of TTX on metastatic cell behaviours and nNav1.5 and VGSC-β1 
mRNA expression  
The specific inhibitor of VGSCs, TTX, was used on MDA-MB-231 cells to 
investigate the role of channel activity on MCBs (i.e lateral motility, transverse 
migration and Matrigel invasion). Previously, it was shown that the dominant VGSC 
subtype expressed in these cells is the TTX-sensitive nNav1.5. It has also been 
shown that 10 µM TTX would block almost 80 % of the VGSCs activity in MDA-
MB-231 cells (Fraser et al. 2005). Accordingly, 10 µM TTX was used throughout the 
present study to assess the role of VGSC activity in (i) potentiation of MCBs and (ii)  
  
 117 
 
 
 
 
 
 
 
 
Figure 3.1 Lack of effects of DMSO on cell number and cell viability  
 
(A) DMSO did not have much effect on cell number after 24 – 48 h treatment. (B) 
DMSO did not affect cell viability after 24 h treatment and (C) DMSO did not affect 
lateral motility of MDA-MB-231 cells. Data were collected from n = 4 independent 
experiment for each condition, presented as means ± SEM and were compared to 
Control using unpaired Student t-test. (x) indicates non-significance (P > 0.05). 
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Figure 3.2 Effects of DMSO on nNav1.5 and VGSC-β1 mRNA expression levels  
 
nNav1.5 and VGSC-β1 mRNA expression level was normalized to Control as in 
percentage. (A) DMSO did not affect nNav1.5 mRNA expression level. Data were 
collected from n = 3 independent experiment for each condition, presented as means 
± SEM and were compared to Control using unpaired Student t-test. (x) indicates not 
significant (P > 0.05). However, (B) VGSC-β1 mRNA expression level was reduced 
at highest concentration of DMSO, 0.05 % tested. Data were collected from n = 3 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (*) indicates significant level at P 
< 0.05 and (x) indicates non-significance (P > 0.05). 
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autoregulation of its expression. After 24 h treatment with 10 µM TTX, compared 
with controls, lateral motility was reduced by ~ 29 % to 71 ± 5.6 % (n = 4; P < 0.01; 
Figure 3.3A), transverse migration was reduced by ~ 20 % to 80 ± 0.2 % (n = 4; P < 
0.01; Figure 3.3B) and Matrigel invasion was reduced by ~ 31 % to 49.0 ± 2.2 % (n 
= 3; P < 0.05; Figures 3.3C).  
Similar treatment with 10 µM TTX reduced nNav1.5 mRNA expression level 
significantly by ~ 48 % to 53 ± 3 % compared to control (n = 4; P < 0.05; Figure 
3.4A). However, there was no effect of 10 µM TTX on VGSC-β1 mRNA expression 
(Figure 3.4B).  
 
3.3.3 Studies using lidocaine and procaine 
As noted earlier, lidocaine and procaine were used since it has been reported 
previously that they may block embryonic VGSCs relatively more effectively, 
compared with adult channels (Ribeiro & Costa 2003). 
 
3.3.3.1 Lack of effect of lidocaine and procaine on cell morphology, viability and 
cell number 
Images of MDA-MB-231 cells were taken after 24 h of treatment with the drugs. 
Initial observations showed no apparent change in cellular morphology for lidocaine 
and procaine (100 µM each), as well as TTX (10 µM) and DMSO at the highest 
concentration (0.05 %) used (Figure 3.5A - E). Trypan blue exclusion assays and 
MTT assays were carried out to investigate the possible effects of lidocaine and 
procaine treatments on cell viability and cell number. There was no effect on cellular 
viability after 48 h treatment with lidocaine (1 - 100 µM) or procaine (1 - 100 µM), 
viability remaining between 98 – 100 % of controls (n = 4; P > 0.05;  Figure 3.6A  
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Figure 3.3 Effects 10 µM TTX on lateral motility, transverse migration and 
Matrigel invasion 
 
10 µM TTX was used in all functional assays. (A) After 24 h, 10 µM TTX 
suppressed lateral motility. (B) Transverse migration was quantified by normalizing 
number of migrated cell to Control. Transverse migration was suppressed by 10 µM 
TTX. Data were collected from n = 4 independent experiment for each condition, 
presented as means ± SEM and were compared to Control using unpaired Student t-
test. (**) indicates significant level at P < 0.01. (C) Matrigel invasion was quantified 
by normalizing number of invading cell to Control. Matrigel invasion was 
suppressed by 10 µM TTX. Data were collected from n = 3 independent experiment 
for each condition, presented as means ± SEM and were compared to Control using 
unpaired Student t-test. (*) indicates significant level at P < 0.05. 
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Figure 3.4 Effects 10 µM TTX on nNav1.5 and VGSC-β1 mRNA expression 
levels  
 
nNav1.5 and VGSC-β1 mRNA expression level was normalized to Control as in 
percentage. (A) nNav1.5 expression level was reduced after 24 h treatment with 10 
µM TTX. (B) 10 µM TTX did not affect VGSC-β1 mRNA expression level. Data 
were collected from n = 3 independent experiment for each condition, presented as 
means ± SEM and were compared to Control using unpaired Student t-test. (*) 
indicates significant level at P < 0.05 and (x) indicates non-significance (P > 0.05). 
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Figure 3.5 Lidocaine and procaine did not change cell morphology  
 
MDA-MB-231 cells were treated with the drugs (100 µM each) for 24 h before 
image was taken. Typical image of (A) Control, (B) DMSO at highest concentration 
used, 0.05 %, (C) TTX 10 µM, (D) lidocaine 100 µM and (E) procaine 100 µM. 0.05 
% DMSO did not affect cell morphology after 24 h treatment. 100 µM Lidocaine and 
procaine also did not affect cell morphology of MDA-MB-231 cells. Scale bar for 
panel on the left is 30 µm and for panel on the right is 100 µm. 
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and B). Finally, treatments with lidocaine and procaine also did not affect cell 
number (‗proliferation‘) (n = 4; P > 0.05; Figure 3.6C and D). 
 
3.3.3.2 Effects of lidocaine and procaine on MCBs 
Cellular motility was studied using two types of functional assays: lateral motility 
(‗free‘ directional motility in absence of a chemoattractant) and transverse migration 
(directional motility through 8 µm pores, up a chemoattractant gradient). In addition, 
Matrigel invasion assays were carried out to elucidate the possible involvement of 
the degradation of protein basement membrane (represented by the Matrigel in the 
assays).  
 
i. Lateral motility. Lateral motility was assessed according to the ‗wound-heal‘ 
assay after 24 h treatment with each drug. The range of lidocaine and procaine 
concentrations tested was 1 – 100 µM. The effect of each drug concentration on 
lateral motility was normalized to the control level; the results showed that lateral 
motility was reduced by lidocaine and procaine. A significant effect of lidocaine on 
lateral motility was only seen at 100 µM which reduced the motility index by ~ 16 % 
to 84 ± 5.7 % (n = 6; P < 0.05; Figure 3.7A). On the other hand, lateral motility was 
suppressed by procaine starting at the lowest concentration tested (1 µM) which 
reduced the motility index by ~ 14 % to 86 ± 5.5 % (n = 9; P < 0.05; Figure 3.7B). 
Interestingly, higher concentrations of procaine did not give any further effect, i.e. 
the inhibitory effect on lateral motility saturated at ~ 14 % (n = 9; P < 0.05; Figure 
3.7B). 
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Figure 3.6 Lidocaine and procaine did not affect cell viability and cell number  
 
Cell viability was determined by Trypan blue exclusion assay whilst cell number was 
measured according to MTT assay. Cells were treated with drugs for 24 and 48 h. 
Cell viability was calculated by number of dead cells normalized to number of living 
cells. Cell viability was not affected by (A) lidocaine and (B) procaine. Cell number 
was not affected by (C) lidocaine and (D) procaine. Data were collected from n = 4 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (x) indicates non-significance (P 
> 0.05). 
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Figure 3.7 Effects of lidocaine and procaine on lateral motility  
 
(A) Lateral motility was reduced dose-dependently after 24 h treated with lidocaine. 
(B) Effect of procaine on lateral motility of MDA-MB-231 cells was saturated after 1 
µM. Data were collected from n = 8 independent experiment for each condition, 
presented as means ± SEM and were compared to Control using unpaired Student t-
test. (*) indicates significant level at P < 0.05 and (x) indicates non-significance (P > 
0.05). 
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ii. Transverse migration. TTX (10 µM) reduced transverse migration significantly 
by ~ 20 % to 80 ± 0.2 %, compared with untreated cells (n = 4; P < 0.05; Figure 3.8A 
and B). Lidocaine and procaine (50 µM each) reduced transverse migration by ~ 17 
% to 83 ± 2.6 % and ~ 14 % to 86 ± 10.2 %, respectively. However, these changes 
were not statistically significant (P = 0.09 and P = 0.39, respectively, n = 4 each; 
Figure 3.8B). 
 
iii. Matrigel invasion. TTX (10 µM) reduced Matrigel invasion significantly by ~51 
% to 49 ± 2.2 % (n = 3; P < 0.05; Figure 3.8C). Invasion was also reduced by 50 µM 
lidocaine by ~ 86 % to 14 ± 4.7 % (n = 3; P < 0.05; Figure 3.8C). On the other hand, 
although procaine (50 µM) reduced invasion by ~ 42 % to 58 ± 14.8 %, this effect 
was not statistically significant (P = 0.19, n = 3; Figure 3.8C). 
 
3.3.3.3 nNav1.5 mRNA expression was reduced by lidocaine and procaine at 
highest concentration 
Real-time PCRs were conducted to measure nNav1.5 mRNA expression levels. 
Compared with untreated cells, both lidocaine and procaine (1 µM or 10 µM) had no 
effect on nNav1.5 mRNA expression (n = 4; P > 0.05; Figure 3.9). However, at 100 
µM, both lidocaine and procaine reduced nNav1.5 mRNA levels by ~ 56 % (to 44 ± 
10.0 %) and by ~ 36 % (to 64 ± 10.0 %), respectively (n = 4 each; P < 0.05; Figure 
3.9). 
 
3.3.3.4 Subcellular distribution of nNav1.5 protein expression 
Immunocytochemistry followed by confocal microscopy and digital imaging were 
used to determine the subcellular distribution (plasma membrane – PM, and internal  
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Figure 3.8 Effects of 10 µM TTX, 50 µM lidocaine and 50 µM procaine on 
transverse migration and Matrigel invasion 
 
(A) Examples of migrating/invading cells stained by cystal violet. (B) Transverse 
migration was reduced by 10 µM TTX but was not affected by 50 µM lidocaine 
(LDC) and procaine (PRC). Data were collected from n = 4 independent experiment 
for each condition, presented as means ± SEM and were compared to Control using 
unpaired Student t-test. (*) indicates significant level at P < 0.05 and (x) indicates not 
significant. (C) Matrigel invasion was reduced by 10 µM TTX and 50 µM lidocaine 
but was not affected by 50 µM procaine. Data were collected from n = 3 independent 
experiment for each condition, presented as means ± SEM and were compared to 
Control using unpaired Student t-test. (*) indicates significant level at P < 0.05 and 
(x) indicates non-significance (P > 0.05). 
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Figure 3.9 Effects of lidocaine and procaine on nNav1.5 mRNA expression  
 
nNav1.5 mRNA expression level was only affected by lidocaine (white) and 
procaine (black) at highest concentration, 100 µM. Data were collected from n = 4 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (*) indicates significant level at P 
< 0.05 and (x) indicates non-significance (P > 0.05).  
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Figure 3.10 Secondary antibody (2
o
)
 
and BSA control experiment did not give 
NESOpAb signal 
 
Typical confocal images of fixed and permeabilized MDA-MB-231 cells. Panel 
represents, (A) Cells for Control experiment, (B) 2
o
 antibody experiment (without 
NESOpAb) and (C) BSA experiment (without 2
o
 and NESOpAb). Signal for 
NESOpAb is not detected in 2
o
 and BSA experiment. Scale bar for every panel is 30 
µm. BF denoted bright field image, ConA – signal for concovalin A, a plasma 
membrane marker (green) and NESOpAb – signal for nNav1.5 (red). 
 
 
 
 
 
A 
 
 
 
B 
 
 
 
 
C 
BF ConA NESOpAb Overlay 
  
 130 
– INT) of nNav1.5 protein in MDA-MB-231 cells after treatment with the drugs. 
NESOpAb was used as a nNav1.5-specific polyclonal antibody. Confocal images 
from XYZ scans were quantified by cross-sectional (LAS AF Lite) analysis. Control 
experiments for immunocytochemistry did not show any cross-reaction (Figure 
3.10). Confocal images from XYZ scans were quantified by cross-sectional (LAS AF 
Lite) (Figure 3.11). Results revealed that 10 µM TTX reduced relative PM 
immunoreactivity of nNav1.5 by ~34 % to 76 ± 11.8 % (n = 3; P < 0.05; Figure 
3.12A). On the other hand, although there were slight decrease in nNav1.5 
immunoreactivity in PM after treatment with lidocaine and procaine (50 µM each), 
these changes were not statistically significant (P = 0.73 and P = 0.24, respectively, n 
= 3 each; Figure 3.12A). Cross-sectional analyses also showed that ‗internal‘ (INT) 
expression of nNav1.5 was not affected after 24 h treatment with TTX, lidocaine or 
procaine at the same working concentrations as above (n = 3 each; P > 0.05; Figure 
3.12B). 
 
3.3.3.5 VGSC-β1 mRNA expression was not affected by lidocaine and procaine 
Since VGSC-β1 can also function as a cell-adhesion molecule, independently of 
association with VGSC-α, we investigated whether the drugs tested might affect 
VGSC-β1 mRNA expression in MDA-MB-231 cells. There was a tendency for 
lidocaine and procaine (1 – 100 µM) to reduce VGSC-β1 mRNA expression but 
these changes were not significant (n = 4 each; P > 0.05; Figure 3.13). 
 
3.3.3.6 Effects of co-treatment of lidocaine or procaine with TTX on MCBs 
In order to investigate whether VGSC activity was involved in the effects of 
lidocaine and procaine in suppressing MCBs (lateral motility) of MDA-MB-231  
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Figure 3.11 Confocal images of cells treated with 10 µM TTX, 50 µM lidocaine 
and 50 µM procaine on subcellular distribution of nNav1.5 protein  
 
Panel represents, (A) cells for Control experiment, (B) 10 µM TTX (C) 50 µM of 
lidocaine and (D) 50 µM of procaine. Scale bar for every panel is 30 µm. BF denoted 
bright field image, ConA – signal for concovalin A, a plasma membrane marker 
(green) and NESOpAb – signal for nNav1.5 (red). 
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Figure 3.12 Effects of 10 µM TTX, 50 µM lidocaine and 50 µM procaine on 
subcellular distribution of nNav1.5 protein  
 
(A) Plasma membrane nNav1.5 was reduced after 24 h treated with 10 µM of TTX 
but not by 50 µM of lidocaine (LDC) and 50 µM of procaine (PRC).  However, (B) 
internal nNav1.5 was not affected with 10 µM of TTX, 50 µM of lidocaine and 50 
µM of procaine. Data were collected from n = 3 independent experiment for each 
condition, presented as means ± SEM and were compared to Control using unpaired 
Student t-test. (*) indicates significant level at P < 0.05. (x) indicates non-
significance (P > 0.05).  
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Figure 3.13 Effect of lidocaine and procaine on VGSC-β1 mRNA expression  
 
VGSC-β1 mRNA has a tendency to reduce after 24 h treatment with lidocaine 
(white) and procaine (black). However, data were not significant. Data were 
collected from n = 4 independent experiment for each condition, presented as means 
± SEM and were compared to Control using unpaired Student t-test. (x) indicates 
non-significance (P > 0.05).  
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cells, effects of co-treatment with 10 µM TTX were also tested. The lateral motilities 
were reduced to the following percentages: 87 ± 6.0 % (10 µM TTX); 76 ± 8.6 % (50 
µM lidocaine + 10 µM TTX); and 85 ± 9.2 % (50 µM procaine + 10 µM TTX) (n = 4 
each; P < 0.05; Figures 3.14A and 3.14B). In each case, there was no difference 
between the effects of TTX and the co-treatment. Thus, co-treating the cells with 
lidocaine or procaine with 10 µM TTX did not reduce the lateral motility of MDA-
MB-231 cells further compared with 10 µM TTX alone. These effects suggested that 
the effects of lidocaine and procaine involved mainly VGSC activity. 
 
3.3.4 Studies using ranolazine and riluzole 
These agents were tested as inhibitors of the INaP component of VGSC currents.  
 
3.3.4.1 Cell viability and cell number were affected by riluzole but not 
ranolazine 
Images of MDA-MB-231 cells were taken 24 h after treatment with the drugs. Initial 
observation showed no apparent change in cellular morphology for ranolazine or of 
riluzole (100 µM each), compared with DMSO at the highest concentration (0.05 %) 
used (Figure 3.15A - E). Trypan blue exclusion assays and MTT assays were carried 
out to investigate the possible effects of the drug treatments on cell viability and cell 
number. There were no effects on cellular viability 48 h after treatment with 
ranolazine (1 - 100 µM), the viability values remaining between 98 – 100 % (Figure 
3.16A). However, treatment with riluzole (1 - 100 µM) reduced cellular viability in a 
dose-dependent manner. The effect was significant at the highest concentration of 
riluzole used (100 µM) which reduced the cell viability to 95 % (n = 3; P < 0.05; 
Figure 3.16B). Treatment with ranolazine did not affect cell number (n = 3; P > 0.05;  
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Figure 3.14 Co-treatment with 10 µM TTX and 50 µM lidocaine or 50 µM 
procaine did not have additional effect on lateral motility 
 
Co-treating 50 µM of (A) lidocaine and (B) procaine with 10 µM TTX did not 
reduced lateral motility further. Data were collected from n = 4 independent 
experiment for each condition, presented as means ± SEM and were compared to 
Control using unpaired Student t-test. (*) indicates significant level at P < 0.05 and 
(x) indicates non-significance (P > 0.05).  
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Figure 3.15 Treatment with ranolazine and riluzole at highest concentration 
tested (100 µM ) did not change cell morphology 
 
MDA-MB-231 cells were treated with respective drug for 24 h before image was 
taken. Typical image of (A) Control, (B) DMSO at highest concentration used 0.05 
%, (C) TTX 10 µM, (D) ranolazine 100 µM and (E) riluzole 100 µM. 0.05 % DMSO 
did not affect cell morphology after 24 h treatment. 100 µM Lidocaine and procaine 
also did not affect cell morphology of MDA-MB-231 cells. Scale bar for panel on the 
left is 30 µm and for panel on the right is 100 µm. 
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Figure 3.16 Cell viability and cell number were not affected by ranolazine but 
was affected by riluzole  
 
Cell viability was determined by Trypan blue exclusion assay whilst cell number was 
measured according to MTT assay. Cells were treated with drugs for 24 and 48 h. 
Cell viability was calculated by number of dead cells normalized to number of living 
cells. Cell viability was not affected by (A) ranolazine but was affected by (B) 
riluzole at 10 and 100 µM. Cell number was not affected by (C) ranolazine but was 
affected by (D) riluzole at 10 and 100 µM. Data were collected from n = 3 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (*) indicates significant level at P 
< 0.05. 
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Figure 3.16C). However, again, cell number was reduced dose-dependently by 
riluzole. The effect was significant at 100 µM which reduced ‗proliferation‘ by ~ 52 
% (n = 3; P < 0.05; Figure 3.16D). 
 
3.3.4.2 Comparison with MCF-7 cells: Cell viability and cell number were 
affected by riluzole  
Trypan blue exclusion assays and MTT ‗proliferation‘ assays were carried out to 
investigate the possible effects of treatment with riluzole on the weakly/non-
metastatic MCF-7 cells. Similar to MDA-MB-231 cells, cell viability and cell 
number of MCF-7 cells were affected by 10 and 100 µM of riluzole. 10 and 100 µM 
of riluzole reduced cell viability significantly to 94 % (n = 3; P < 0.05) and to 88 % 
(n = 3; P < 0.05), respectively (Figure 3.17A). On the other hand, cell number was 
reduced significantly by ~ 66 % only with 100 µM riluzole to 0.9 ± 0.13 x10
5
 cells (n 
= 3; P < 0.05; 3.17B). 
 
3.3.4.3 Effects of ranolazine and riluzole on MCBs 
i. Lateral motility. Lateral motility was assessed using the ‗wound-heal‘ assay after 
24 h treatment with each drug. Each drug was tested in the concentration range, 1 – 
100 µM and the effect of each concentration was normalized to control (untreated) 
cells. Results showed that lateral motility of MDA-MB-231 cells was reduced by 
both ranolazine and riluzole dose-dependently. Lateral motility was reduced by ~ 15 
% by 1 µM ranolazine, to 85 ± 4.9 % (n = 8; P = 0.10; Figure 3.18A). The effect was 
bigger at higher concentrations; at 10 µM and 100 µM of ranolazine, lateral motility 
was reduced, respectively, by ~ 24 % to 74 ± 4.8 % (n = 8; P < 0.05; Figure 3.18A) 
and by ~ 52 % to 48 ± 2.5 % (n = 8; P < 0.01; Figure 3.18A). Riluzole (1 µM)  
  
 139 
 
 
 
 
 
 
 
 
 
Figure 3.17 Riluzole reduced cell viability and number of MCF-7 cells 
 
Cells were treated with riluzole for 48 h with riluzole ranging from 1 – 100 µM. 
Riluzole reduced (A) cell viability and (B) cell number of MCF-7 cells. Data were 
collected from n = 5 independent experiment for each condition, presented as means 
± SEM and were compared to Control using unpaired Student t-test. (*) indicates 
significant level at P < 0.05 and (x) indicates non-significance (P > 0.05).  
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Figure 3.18 Lateral motility was reduced by ranolazine and riluzole  
 
Lateral motility was reduced dose-dependently after 24 h treatment with (A) 
ranolazine and (B) riluzole. ‗\\‘ indicates proliferation affected by effect riluzole. 
Data were collected from n = 8 independent experiment for each condition, presented 
as means ± SEM and were compared to Control using unpaired Student t-test. (*) 
indicates significant level at P < 0.05 and (**) indicates significant level at P < 0.01. 
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reduced lateral motility by ~ 37 %, to 63 ± 4.6 % (n = 8; P < 0.01; Figure 3.18B). 
Higher concentrations resulted in bigger effects; at 10 and 100 µM, riluzole reduced 
lateral motility by ~ 54 %, to 55 ± 7.4 % and by ~ 65 % to 35 ± 7.8 %, respectively 
(n = 8; P < 0.01; Figure 3.18B).  
 
ii. Transverse migration. Transverse migration was carried out in 24-well culture 
plates with an insert pore size of 8 µm. Following 24 h treatment, each insert was 
stained with crystal violet and photographs of the cells that had migrated to the 
bottom of the insert were taken. The migrated/stained cells were counted using 
ImageJ (Figure 3.19A). Data were normalized to the control/untreated cell number in 
parallel platings/treatments. Transverse migration was reduced significantly (~20 %) 
by 10 µM TTX to 80 ± 0.2 % (n = 4; P < 0.05; Figure 3.19B). Transverse migration 
was also reduced significantly (~13 %) by 10 µM ranolazine to 87 ± 0.1 % (n = 4; P 
< 0.05) and by 1 µM riluzole by ~ 20 % to 80 ± 0.8 % (n = 4; P < 0.05; Figure 
3.19B).   
 
iii. Matrigel invasion. Matrigel invasion assays were carried out to determine the 
effect of drugs treatment on the capacity of MDA-MB-231 cells to digest the 
Matrigel barrier and migrate through inserts of 8 µm pore size in 24-well culture 
plate. The procedure of quantifying invasion was the same as in transverse migration 
assays. Following 24 h of treatment, invasion was reduced significantly (~ 51 %) 
with 10 µM TTX by to 49 ± 2.2 % (n = 3; P < 0.05; Figure 3.19C). Invasion was also 
reduced with 10 µM ranolazine by ~ 73 % to 26 ± 2.2 % (n = 3; P < 0.01; Figure 
3.19C) and with 1 µM riluzole by ~ 66% to 34 ± 10.3 % (n = 3; P < 0.05; Figure 
3.19C). 
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Figure 3.19 Effects of 10 µM ranolazine and 1 µM riluzole on transverse 
migration and Matrigel invasion 
 
(A) Examples of migrating/invading cells stained by crystal violet. (B) Transverse 
migration was reduced after 24 h treated with 10 µM TTX (TTX 10), 10 µM 
ranolazine (RZN 10) and 1 µM riluzole (RZL 1). Data were collected from n = 4 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (*) indicates significant level at P 
< 0.05. (C) Matrigel invasion was reduced after 24 h treatment with 10 µM TTX, 10 
µM ranolazine, 1 µM riluzole. Data were collected from n = 3 independent 
experiment for each condition, presented as means ± SEM and were compared to 
Control using unpaired Student t-test. (*) indicates significant level at P < 0.05 and 
(**) indicates significant level at P < 0.01. 
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3.3.4.4 nNav1.5 mRNA expression was reduced dose-dependently by ranolazine 
and riluzole 
nNav1.5 mRNA expression was reduced dose-dependently after 24 h of treatment 
with ranolazine or riluzole (Figure 3.20). At the lowest concentration tested, 1 µM 
ranolazine did not affect the nNav1.5 mRNA level. However, at 10 µM and 100 µM 
ranolazine, respectively, nNav1.5 mRNA level was reduced by ~ 35 % to 65 ± 10.0 
% (n = 6; P < 0.05) and by ~ 50 % to 50 ± 10.0 % (n = 6; P < 0.01). Similarly, 1 µM 
riluzole did not affect nNav1.5 mRNA level but with 10 µM and 100 µM riluzole, 
nNav1.5 mRNA levels were reduced significantly by ~ 40 % to 60 ± 10.0 % (n = 6; 
P < 0.05) and by ~ 49 % to 51 ± 10.0 %, respectively (n = 6; P < 0.05) (Figure 3.20). 
 
3.3.4.5 Effects of ranolazine and riluzole on subcellular distribution of nNav1.5 
protein expression 
Immunocytochemistry followed by confocal microscopy was used to determine 
subcellular distribution (plasma membrane – PM vs. internal – INT) of nNav1.5 
protein in MDA-MB-231 cells after treatment with the drugs. Again, NESOpAb was 
used as the nNav1.5-specific polyclonal antibody. Confocal images from XYZ scans 
were evaluated using a cross-sectional straight-line analysis (LAS AF Lite) (Figure 
3.21). Results revealed that relative PM immunoreactivity of nNav1.5 protein was 
reduced after treatment with 10 µM TTX by ~ 24 % to 76 ± 11.8 % of total (n = 3; P 
< 0.05; Figure 3.21A). Similarly, PM immunoreactivity of nNav1.5 protein was 
reduced significantly by both (i) 10 µM ranolazine by ~ 11 % to 89 ± 2.0 % (n = 3; P 
< 0.05; Figure 3.21A) and (ii) 1 µM riluzole by ~ 25 % to 75 ± 8.1 % (n = 3; P < 
0.05; Figure 3.22A). However, this analysis suggested that INT expression of 
nNav1.5 protein was not affected after 24 h treatment with the same working 
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Figure 3.20 nNav1.5 mRNA expression was reduced by ranolazine and riluzole  
 
nNav1.5 mRNA expression level was reduced dose-dependently after 24 h treatment 
with ranolazine (white) and riluzole (black). Data were collected from n = 6 
independent experiment for each condition, presented as means ± SEM and were 
compared to Control using unpaired Student t-test. (*) indicates significant level at P 
< 0.05 and (**) indicates significant level at P < 0.01. (x) indicates non-significance 
(P > 0.05). 
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Figure 3.21 Confocal images of cells treated with 10 µM TTX, 10 µM ranolazine 
and 1 µM riluzole on subcellular distribution of nNav1.5 protein 
 
Panel represents, (A) Cells for control experiment, (B) 10 µM TTX; (C) 10 µM 
ranolazine; and (D) 1 µM riluzole. BF denotes bright field image, ConA – signal for 
concovalin A, a plasma membrane marker (green) and NESOpAb – signal for 
nNav1.5 (red). Scale bar for every panel is 30 µm. 
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Figure 3.22 Effects of 10 µM ranolazine and 1 µM riluzole on nNav1.5 protein 
expression  
 
(A) Plasma membrane nNav1.5 protein level was reduced after 24 h treated with 10 
µM of TTX, 10 µM of ranolazine (RZN) and 1 µM of riluzole (RZL).  Data were 
collected from n = 3 independent experiment for each condition, presented as means 
± SEM and were compared to Control using unpaired Student t-test. (*) indicates 
significant level at P < 0.05. However, (B) internal nNav1.5 protein level was not 
affected by 10 µM TTX, 10 µM ranolazine or 1 µM riluzole. Data were collected 
from n = 3 independent experiment for each condition, presented as means ± SEM 
and were compared to Control using unpaired Student t-test. (x) indicates non-
significance.  
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concentrations of TTX, ranolazine and riluzole as above. INT immunoreactivities for 
10 µM TTX, 10 µM ranolazine and 1 µM riluzole were as follows: 104 ± 8.1 % (n = 
3; P = 0.68), 101 ± 3.7 % (n = 3; P = 0.82) and 95 ± 19.6 % (n = 3; P = 0.84) (Figure 
3.22B). 
 
3.3.4.6 Studies of VGSC-β1 mRNA expression 
Since VGSC-β1 can also function independently of VGSC-α as a cell-adhesion 
molecule, we investigated whether ranolazine and riluzole might affect VGSC-β1 
mRNA expression in MDA-MB-231 cells. There was a consistent tendency for 
VGSC-β1 mRNA expression to increase after ranolazine or riluzole treatment for 24 
h. However, there was large variability in the data and the averaged effects were not 
statistically significant (Figure 3.22). Ranolazine (1, 10 and 100 µM) increased, 
VGSC-β1 mRNA level to 118 ± 20.0 % (P = 0.76, n = 3), 136 ± 30.0 % (P = 0.61, n 
= 3) and 200 ± 60.0 % (P = 0.51, n = 3), respectively.  Similarly, riluzole (1, 10 and 
100 µM) increased VGSC-β1 mRNA level to 164 ± 60.0 % (P = 0.57, n = 3), 211 ± 
70.0 % (P = 0.46, n = 3) and 253 ± 80.0 % (P = 0.42, n = 3), respectively (Figure 
3.23). 
 
3.3.4.7 Co-treatment ranolazine and riluzole with TTX on MCBs  
In order to investigate whether VGSC activity could be involved in the effects of 
ranolazine and riluzole in suppressing MCBs of MDA-MB-231 cells, co-treatment 
with 10 µM TTX was carried out. Experiments were conducted on lateral motility. 
Concentrations of ranolazine and riluzole used were 10 µM and 1 µM, respectively. 
From the results obtained, co-treating ranolazine and riluzole with 10 µM TTX did 
not reduce lateral motility of MDA-MB-231 cells further compared to TTX alone. 
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Figure 3.23 Effects of ranolazine and riluzole on VGSC-β1 mRNA expression 
level 
 
VGSC-β1 mRNA had a tendency to increase after treatment with ranolazine (white) 
and riluzole (black). However the effects were not significant. Data were collected 
from n = 3 independent experiment for each condition, presented as means ± SEM 
and were compared to Control using unpaired Student t-test. (x) indicates non-
significance (P > 0.05). 
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Lateral motility was reduced by 10 µM TTX by ~ 23 % to 87 ± 6.0 % (n = 6; P < 
0.05; Figure 3.24A & B). Lateral motility was reduced by TTX (10 µM) + ranolazine 
(10 µM) by ~ 25 % to 85 ± 5.4 % (n = 6; P < 0.05; Figure 3.24A). Finally, TTX (10 
µM) + riluzole (1 µM) reduced lateral motility by ~ 18 % to 82 ± 5.5 % (n = 6; P < 
0.05; Figure 3.24B). For both combination treatments, there was no difference 
between the effects of TTX alone and the co-treatment. These results suggested that 
the effects of ranolazine and riluzole involved mainly blockage of VGSC activity. 
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Figure 3.24 Co-treating 10 µM TTX with 10 µM ranolazine or 1 µM riluzole did 
not have additive effects on lateral motility 
 
Co-treating (A) 10 µM ranolazine and (B) 1 µM riluzole with 10 µM TTX did not 
reduce lateral motility further compared to 10 µM TTX alone. Data were collected 
from n = 6 independent experiments for each condition, presented as means ± SEM 
and were compared to Control / TTX using unpaired Student t-test. (*) indicates 
significant level at P < 0.05 and (x) indicates non-significance (P > 0.05). 
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3.4 Discussion 
 
The main findings of the experiments mainly on strongly metastatic MDA-MB-231 
cells described in this chapter are as follows: 
1. VGSCs activity played an important potentiating role in cellular lateral motility, 
transverse migration and Matrigel invasion – TTX suppressed MCBs. 
2. Similar to TTX, drugs that are known as VGSC blockers (lidocaine, procaine and 
ranolazine) also suppressed MCBs of MDA-MB-231 cells without affecting cell 
growth.  
3. Riluzole (another VGSC blocker) similarly had a dose-dependent significant 
potentiating effect on MCBs but cell viability/growth was reduced by ≥ 10 µM 
riluzole. 
4. Lidocaine, procaine, ranolazine and riluzole suppressed MCBs in a 
concentration-dependent manner. No further effect in co-application with TTX 
suggested that the suppression could involve nNav1.5 activity. 
5. Lidocaine and procaine at the highest concentrations tested (100 µM) reduced 
nNav1.5 mRNA expression but protein expression in plasma membrane was not 
affected by 50 µM lidocaine or procaine.  
6. VGSC-β1 mRNA level was not affected by lidocaine and procaine. 
7. nNav1.5 mRNA expression level was reduced by ranolazine and riluzole dose-
dependently. 
8. nNav1.5 protein expression in plasma membrane of MDA-MB-231 cells was 
reduced by TTX (10 µM), ranolazine (10 µM) and riluzole (1 µM). 
9. Ranolazine and riluzole increased VGSC-β1 mRNA expression.  
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3.4.1 Human breast cancer MDA-MB-231 cell line as a VGSC expressing model 
Metastasis is the spread of cancer cells to distant organs and represents the most 
devastating attribute for BCa patients, as in other cancers. Most patients with 
advanced BCa develop osteolytic bone metastases, which are a common cause of 
morbidity and sometimes mortality. For the present in vitro study of MCBs, the 
human BCa cell line, MDA-MB-231, was chosen because of its strong metastatic 
potential. The cells would form bone metastases when inoculated into the left cardiac 
ventricle of immunodeficient mice (Yin et al. 1999). Originally, MDA-MB-231 cells 
were isolated from the pleural effusion of a patient with disseminated disease 
relapsing several years after removal of the primary tumour (Cailleau et al. 1974). 
Subsequently, it has been shown from patch-clamp recordings on several types of 
human BCa cell lines with different metastatic potential that MDA-MB-231 cells 
expressed a fast inward VGSC current unlike the weakly/non metastatic MCF-7 cells 
(Marino et al. 1994; Roger et al. 2003; Fraser et al. 2005). It has been revealed from 
semi-quantitative PCR analyses that the main VGSC expressed in MDA-MB-231 
cells is the ‗cardiac type‘, Nav1.5. However, importantly, partial sequencing of the 
Nav1.5 DIII/DIV region identified the channel to be the ‗neonatal‘ splice form, 
nNav1.5 (Diss et al. 2004). High levels of nNav1.5 mRNA and protein expression in 
these cells (compared to MCF-7 cells) supported the data from patch-clamp 
recordings (Fraser et al. 2005). Therefore, here, we continued to use the MDA-MB-
231 cells as an in vitro model to evaluate the relation between VGSC 
expression/activity and MCBs. Some experiments were also conducted on MCF-7 
cells for comparison. The role of VGSC activity in MCBs was studied using TTX as 
highly specific blocker. The possible effectiveness of clinically used VGSC blocking 
drugs on MCBs was also investigated and discussed. 
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3.4.2 Use of TTX to study MCBs 
Cancer cells use many different strategies to facilitate metastasis, including loss of 
adhesiveness, gain of cell motility and ability to digest ECM. Several lines of 
evidence have suggested that VGSC activity potentiates the kinds of in vitro cellular 
behaviour that would be involved in the metastatic cascade. Since the discovery of a 
selective natural highly specific blocker for VGSC - TTX, the toxin has been 
extensively used to study VGSCs (Yoshida et al. 1994). At appropriate doses, TTX 
has not been reported to affect other target than VGSC (Le Guennec et al. 2007). 
When treated with TTX, several types of cancer cells expressing VGSC activity 
showed reduced MCBs thus, TTX has been shown to increase cellular adhesion to 
substrate in metastatic PCa cells (Mat-LyLu) and BCa (MDA-MB-231) (Palmer et 
al. 2008; Fraser et al. 2010). TTX also reduced lateral motility, transverse migration 
and Matrigel invasion (Fraser et al. 2003; Fraser et al. 2005; Brackenbury et al. 2007; 
Chioni et al. 2010). Other VGSC-controlled cancer cell characteristics include 
morphological development and process extension (Fraser et al. 1999), galvanotaxis 
(Djamgoz et al. 2001), endocytic membrane activity (Mycielska et al. 2003; Onganer 
& Djamgoz 2005), vesicular patterning (Krasowska et al. 2004), nitric oxide 
production (Williams & Djamgoz 2005) and gene expression (Mycielska et al. 2005; 
House et al. 2010). 
In the present study, using TTX, we initially tested the notion that high 
VGSC activity is responsible for enhancing MDA-MB-231 cell motility and 
invasiveness. Since nNav1.5 is TTX-resistant, µM concentrations of TTX were used. 
Based on patch-clamp recordings which blocked ~ 80 % of the TTX-resistant 
currents (Fraser et al. 2005), a working concentration of 10 µM TTX was chosen. 
Earlier, growth has been shown not to be affected by 10 µM TTX and in another 
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study, 30 µM TTX was demonstrated not to affect proliferation of MDA-MB-231 
cells (Fraser et al. 2003; Fraser et al. 2005; Roger et al. 2004). Similarly, 2 µM TTX 
has been shown not to affect viability and proliferation of neoplastic mesothelial 
cells expressing TTX-sensitive VGSCs (Fulgenzi et al. 2006).  
 
3.4.3 Involvement of VGSC activity in cancer MCBs  
After 24 h treated with 10 µM TTX, MCBs of MDA-MB-231 cells were 
significantly suppressed; lateral motility by ~ 29 %, transverse migration by ~ 20 % 
and Matrigel invasion by ~ 31 % without any effect on cell numbers. 
 
3.4.3.1 Lateral motility and transverse migration 
In advanced BCa, gain of function in cellular motility/migration is important for the 
cancer cells to metastasize. Several have demonstrated the involvement of VGSCs in 
cancer motility and migration; blocking VGSC current with TTX reduced motility 
and migration of cancer cells (Fraser et al. 2003; Chioni et al. 2007; Fulgenzi et al. 
2006). Conversely, by using drugs/agents that enhance VGSC current, cancer 
motility and migration were shown to be enhanced (Fraser et al. 2003; Ding et al. 
2008).  
In the studies described in this chapter, applying 10 µM TTX for 24 h, lateral 
motility was reduced significantly by ~ 29 %. This result is consistent with previous 
reports where a similar effect has been seen on MDA-MB-231 after treatment with 
10 µM TTX for 24 h (Chioni et al. 2007). A similar effect was obtained on PCa cells. 
Thus, Fraser et al. (2003) showed that lateral motility of the highly metastatic rat PCa 
cell line, Mat-LyLu was reduced by ~ 47 % when cells were treated with TTX. In 
another report, TTX was reported to suppress motility of mesothelioma cells 
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expressing VGSC by ~ 13 % (Fulgenzi et al. 2006). Conversely, when VGSC opener 
was applied, for example aconitine (100 µM) and ATX II (25 pM), lateral motility of 
the MAT-LyLu cells was significantly increased by ~ 15 and ~ 9 %, respectively 
(Fraser et al. 2003), consistent with the proposed role of VGSC activity. 
When cancer cells reach basement membrane/ECM barrier, they will need to 
digest it and eventually move through tight spaces (during extravasation or 
intravasasion) to continue their journey to the secondary site(s). It has been reported 
that movement of cancer cells could be promoted by factors such as the electrical 
field and nutrient gradient. Two assays have been used to measure the movement of 
cancer cells according to these parameters: galvanotaxis and chemotaxis (Soon 
2007). It has been shown that VGSC participates in both MCBs. TTX has been 
demonstrated to reduce galvanotaxis of Mat-LyLu and MDA-MB-231 cells 
(Djamgoz et al. 2001; Mycielska & Djamgoz 2004; Fraser et al. 2005) and 
chemotaxis migration of MDA-MB-231 cells (Brackenbury et al. 2007). 
Consistently, in this study, transverse migration of MDA-MB-231 cells was reduced 
by ~ 20 % with 10 µM TTX. Previously, Brackenbury et al. (2007) demonstrated that 
migrating MDA-MB-231 cells expressed more nNav1.5 protein than non-migrating 
cells. Subsequently, chemotactic migration of Mat-LyLu cells was increased when 
VGSC current was enhanced by epidermal growth factor (EGF) (Ding et al. 2008). 
Our results and others clearly confirm VGSC involvement in cancer cell migration. 
Importantly, evidence for the role of nNav1.5 in potentiating migration of MDA-
MB-231 cells was provided when reduced migration was observed after applying the 
polyclonal antibody against nNav1.5 (NESOpAb) as well as by gene silencing 
(siRNA-nNav1.5) (Brackenbury et al. 2007; Chioni et al. 2009; Onkal et al. 2009).  
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Reduced cell adhesion would assist cancer cell motility and migration. Loss 
of functional E-cadherin expression has been link to increase motility and migration 
of BCa cells from primary tumour (Chao et al. 2010; Kowalski et al. 2003; Bulkhom 
et al. 2000). It is now established that apart from modulating channel gating, VGSC-
β subunits could also behave like cell adhesion molecules (CAMs) (Catterall 2000; 
Isom 2002; Brackenbury et al. 2008). Sequencing results showed that β1-subunit 
from both MDA-MB-231 and MCF-7 cell lines were similar (Appendix 1) and 
protein BLAST confirmed that amino acid sequence of the partial β1-subunits from 
both cell lines contained the putative conserved domain of the immunoglobulin V-
set, agreeing that β1-subunits belong to the V-set of the Ig superfamily, which 
includes many CAMs; including contactin and myelin Po (D‘Andrea et al. 1998; 
Kazen-Gillespie et al. 2000; Isom 2000). In MCF-7 cells, expression of β1-subunit 
mRNA has been shown to be higher than in MDA-MB-231 cells, suggesting that β1-
subunit expression could contribute to the higher adhesion of these cells (Chioni et 
al. 2006; Brackenbury et al 2008). Importantly, low-level expression of VGSC-β1 
subunit has been linked with the reduced substrate adhesiveness in MDA-MB-231 
cells (Palmer et al. 2008; Fraser et al. 2010); this would promote cell motility and 
migration. Conversely, high-level expression of VGSC-β1 mRNA in MCF-7 is 
consistent with these cells low metastatic potential and limited migratory capacity 
compared to MDA-MB-231 cells. Moreover, Chioni et al. (2009) have demonstrated 
that stable expression of VGSC-β1 in MDA-MB-231 cells transformed the cells to a 
weaker metastatic type, with increased adhesion and reduced lateral motility. 
Conversely, silencing VGSC-β1 in MCF-7 cells reduced adhesion by ~ 35 % and 
increased migration; importantly, nNav1.5 mRNA and protein expression was also 
increased by ~ 121 % (Chioni et al. 2009). 
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Finally, expression of estrogen or progesterone receptors has also been shown 
to promote BCa cell motility and migration. For example, motility and migration of 
T47-D cells were increased after application of estradiol and progesterone (Sanchez 
et al. 2010; Fu et al. 2010). With regards to VGSC, estrogen has been shown to cause 
increased excitability in neurons by enhancing VGSC inward currents (Kow et al. 
2006). Interestingly, estrogen could also have acute effects on VGSC activity. Thus, 
application of estradiol increased VGSC current amplitude in MDA-MB-231 cells 
and led to reduced adhesiveness (Fraser et al. 2010). These effects were non-genomic 
and were proposed to be mediated by the cell surface receptor, GPR30 to estrogen 
(Fraser et al. 2010). 
 
3.4.3.2 Matrigel invasion 
Using Matrigel-coated filters for invasion assays, we studied whether VGSC 
inhibition would attenuate the proteolytic breakdown of the ECM model. The results 
showed that 10 µM TTX reduced Matrigel invasion significantly by ~31 %. 
Previously, involvement of VGSC activity in cancer cell invasion has been supported 
by several other reports. For example, Roger et al. (2003) showed that invasion of 
MDA-MB-231 cells was reduced up to ~30 % when cells were treated with 30 µM 
TTX. Similarly, invasion was also reduced by 1 µM TTX in the highly invasive rat 
and human PCa cells expressing functional VGSCs (Grimes et al. 1995; Laniado et 
al. 1997; Smith et al. 1998; Bennett et al. 2003). In another report, 10 µM TTX has 
been shown to reduce the invasion of Jurkat cells expressing TTX-resistant VGSC by 
> 90 % (Fraser et al. 2004).  
Invasion is a multi-stage process which both cell motility and digestion of 
ECM proteins would be involved, as well as other cellular activities e.g release of 
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proteases. Cancer cells can secrete proteases to digest ECM thus facilitate invasion. 
Serine and cysteine proteases (e.g urokinase-plasminogen activator (uPA), matrix-
metalloproteinase (MMP) and cathepsin) expression has been implicated in BCa 
cells invasion and metastasis in vitro and in vivo (Nilsson et al. 2007; Shah et al. 
2009; Huang et al. 2010; Stankovic et al. 2010; Daniele et al. 2010). With regards to 
VGSC, a recent study has successfully shown that VGSC plays a role in regulating 
the activity of MMP-9 and decrease invasiveness of MDA-MB-231 cells by TTX 
correlated with reduced MMP-9 mRNA expression (Gao et al. 2009). The 
importance of MMP-9 in BCa metastasis has been associated with its proteolytic 
activity against type IV collagen, which is a major component of epithelial basement 
membranes (Stankovic et al. 2010). VGSC has also been shown to be involved in 
activating another protease, the cysteine cathepsins (Gillet et al. 2009). It was shown 
that co-treatment with specific inhibitors for cathepsins B and S with TTX did not 
have additional reduction on MDA-MB-231 cell invasion, suggesting that cysteine 
cathepsin activity in mediating invasion is VGSC-dependent (Gillet et al. 2009). 
Recently, the activity of VGSC (Nav1.5) has been shown to increase the activity of 
NHE1 to create acidosis that would increase the release of cysteine cathepsins to 
promote invasion of MDA-MB-231 cells (Brisson et al. 2010). 
 
3.4.4 Activity-dependent VGSC regulation and effect on MCBs 
In this study, inhibition of MCBs by TTX led to down-regulation of nNav1.5 mRNA 
and protein expression in plasma membrane by ~58 and ~34 %, respectively. 
Assuming that these changes were functional, it would follow that prolonged 
blocking of VGSC current/activity would suppress MCBs further via down-
regulation of nNav1.5 expression. The phenomenon is likely to be recognized as 
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positive-feedback activity-dependent regulation of expression and functional 
consequences. 
Activity-dependent regulation of ion channels has been well described to be 
important for development and maintenance of neural plasticity (Moody & Bosma, 
2005). As for VGSC in cancer cells, activity-dependent regulation of Nav1.7 on the 
migration of the highly metastatic rat PCa has been reported (Brackenbury et al. 
2006). Consistently, activity-dependent of nNav1.5 on migration of MDA-MB-231 
cells has also been demonstrated (Chioni et al. 2009). Both showed that VGSC-
mediated Na
+
 influx promotes the expression of Nav1.7 and nNav1.5, respectively, 
and trafficking to the plasma membrane through the activation of protein kinase A 
(PKA) thus enhancing VGSC-dependent MCBs in PCa and BCa. Conversely, both 
studies showed that when TTX was used to block the VGSC-mediated Na
+ 
influx, 
inhibition of the activity of PKA occurred thus suppressing the VGSC-mediated 
MCBs. 
Taken together, the available data would suggest that blocking VGSC current 
could be sufficient to suppress VGSC-mediated MCBs. Therefore, we speculated 
that other VGSC blockers could also suppress MCBs in cancer cells. Given that TTX 
is highly toxic, the next stage was to test other VGSC pharmacological blockers that 
could serve as potentially safe inhibitors of BCa metastasis. 
 
3.4.5 Effects of pharmacological blockers of VGSCs 
We showed that VGSC blockers: (1) local anaesthetics (lidocaine and procaine) and 
(2) VGSC-INaP blockers (ranolazine and riluzole) suppressed MCBs of the highly 
metastatic, MDA-MB-231 cells and are discussed below. The effect of each drug on 
cell behaviour/protein expression occurred depending on concentration. 
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3.4.5.1 Lidocaine 
Lidocaine is a common local anaesthetic used in pain management. Initially in this 
study, the rational of using lidocaine was primarily due to earlier evidence showing 
that lidocaine had a preferential block for the neonatal type of VGSC in the immature 
rat brain compared with the adult (Ribiero & Costa 2003). Since the pre-dominant 
type of VGSC expressed in MDA-MB-231 cells is the TTX-resistant Nav1.5 in its 
neonatal splice form (nNav1.5), we anticipated that lidocaine could also effectively 
suppress invasiveness. Interestingly, earlier research also found that infiltration of 
local anaesthetics including lidocaine during cancer surgery could reduce cancer cell 
dissemination and disease recurrence (Mammoto et al. 2002; Exadaktylos et al. 2006; 
Biki et al. 2008; Forget et al. 2009). 
Treatment with 100 µM lidocaine for 24 h was not toxic and did not affect 
the cell number. Lateral motility, transverse migration and Matrigel invasion were 
inhibited by lidocaine. Lateral motility was reduced dose-dependently up to ~16 %. 
50 µM lidocaine suppressed transverse migration and Matrigel invasion by ~17 and 
~86 %, respectively. Co-treating MDA-MB-231 cells with 50 µM lidocaine and 10 
µM TTX gave no further reduction in lateral motility compared with the effect of 
lidocaine alone, thereby suggesting that the effect of lidocaine occurred mainly by 
blockage of VGSC activity. Earlier, lidocaine (25 -200 µM) was shown to suppress 
dose-dependently endocytic membrane activity (Onganer & Djamgoz 2005). 
Reduction of MCBs by 50 µM lidocaine was accompanied by down regulation of 
nNav1.5 mRNA or protein; nNav1.5 mRNA expression was only suppressed by 100 
µM lidocaine. Previously, the half-maximal inhibitory concentration (IC50) of 
lidocaine for the VGSC current in MDA-MB-231 cells was reported to be 20.3 μM 
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(Fraser et al. 2005). We can speculate therefore that suppression of MCBs by 50 µM 
lidocaine involved blocking VGSC current without any change in transcription.  
At the test concentrations used (1 – 100 µM), lidocaine could have other 
modes of action that could contribute to the suppression of MCBs. Mammoto et al. 
(2002) demonstrated that the invasive ability of human fibrosarcoma (HT1080) cells 
which are not TTX-sensitive (i.e do not expressing VGSCs) cancer cells was 
suppressed by lidocaine at concentrations used in surgical operations (5 – 20 mM). 
Accordingly, lidocaine could suppress MCBs through other mode of action than 
blocking VGSCs. Moreover, there have been reports of effects of lidocaine on targets 
other than VGSCs, depending on its concentration. For example, in Xenopus laevis 
oocytes, lidocaine at low concentrations (<10 µM) enhanced glycine receptor 
function whilst at higher concentrations (>10 µM), lidocaine inhibited the functions 
of glycine and GABAA receptors (Hara et al. 2007). With regard to cancer, 
GABAergic system has also been associated in promoting cancer cell growth and 
metastatic regulation (Inamoto et al. 2007; Takehara etal. 2007; Azuma et al. 2003). 
Increased GABAergic activity has been reported in BCa (Mazurkiewicz et al. 1999; 
Jiang et al. 2002). It is possible therefore, that lidocaine could inhibit the GABAergic 
system in MDA-MB-231 cells and thus suppressing MCBs. 
The auxiliary component of VGSC, VGSC-β1 has been associated with 
cancer cells adhesiveness. However, 24 h treatment with lidocaine did not affect the 
expression of VGSC-β1 in MDA-MB-231 cells, although there was a trend for 
reduction. Effects of local anaesthetics on other CAMs have been investigated by 
other groups. Most of the evidence showed that lidocaine reduced cell adhesion. For 
example, in rats treated with lidocaine, intracellular adhesion molecule-1 protein 
expression was reduced significantly after cecal ligation and puncture (experimental 
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sepsis) (Gallos et al. 2004). Lidocaine has also been shown to reduce intercellular 
adhesion molecule-1 (ICAM-1) expression (using flow cytometry) in human 
umbilical vein endothelial cells (HUVECs) (Wei lan et al. 2005). Furthermore, local-
anaesthetics have been shown to dose-dependently and reversibly inhibit adhesion of 
leukocytes to blood vessel walls via interfering with integrins and leukocyte adhesion 
molecule-1 (Cassuto et al. 2006). 
 
3.4.5.2 Procaine 
Procaine is also a local anaesthetic but it has recently been replaced by more 
effective drugs, such as lidocaine (Hodgson et al. 2000). Similar to lidocaine, the 
rational for using procaine in this study was also the earlier evidence showing its 
preferential block for the neonatal type of VGSCs in the immature rat brain, 
compared with the adult (Ribiero & Costa 2003). Previously, Vlachova et al. (1999) 
reported that > 10 µM of procaine was enough to inhibit VGSC in rat sensory neuron 
whilst Brau et al. (1998) reported that 60 µM was the procaine IC50 in sciatic nerves 
fibre of Xenopus laevis. 
After 24 h treatment with procaine, lateral motility of MDA-MB-231 cells 
was reduced. However, the effect was not dose-dependent and the effect was a 
plateau in the concentration range 1 - 100 µM with ~ 14 % reduction. This was 
similar to the maximal effect of lidocaine on lateral motility. However, transverse 
migration and invasion were not affected by 50 µM procaine. The reason(s) for the 
latter lack of effect is not present. Lateral motility and transverse migration assays 
have significant differences – lateral motility is ‗freer‘ than transverse migration 
which involves cell movement through tight (8 µm) spaces and possible mechanical 
effect. This could also explain a possible lack of effect of procaine on the ‗migratory 
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component‘ of Matrigel invasion. As regards the ‗secretory component‘, it is possible 
that procaine failed to acidify the cell-surface pH necessary for cathepsin activation 
(Brisson et al. 2010). Further work is required to elucidate the mechanistic effect of 
procaine on MCBs.  
Similar to lidocaine, nNav1.5 mRNA expression was suppressed by procaine 
but only at the highest concentration tested (100 µM). VGSC-β1 was not affected by 
the procaine treatment. Thus, procaine could suppress some MCBs by inhibiting both 
activity and expression of VGSC (α-subunit). Co-treating MDA-MB-231 cells with 
50 µM procaine + 10 µM TTX gave no further reduction on lateral motility, 
compared with the effects of procaine alone. The effect of procaine consistent with 
being mainly through VGSC. Nevertheless, other possible target(s) of procaine in 
reducing lateral motility could not be ruled out. Similar to lidocaine, procaine (> 10 
µM) has also been shown to inhibit the functioning of glycine and GABAA receptors 
(Hara et al. 2007). There were also reports that high (> 1mM) concentrations of 
procaine could act as a DNA-demethylation agent in cancer in vitro and in vivo. 
Procaine has been shown to demethylate and reactivate the methylation-silenced 
genes of a CpG-island-associated gene (RARβ2) that lead to growth inhibition of 
BCa cell line, MCF-7 (Villar-Garea et al. 2003) and p16 
INK4a 
, HAI-2/PB, 14-3-3-
sigma and NQO1 genes in human hepatoma cell lines that lead to reduce tumour 
volume when injected in nude mice (Tada et al. 2007). In lung cancer cell lines 
(H460 and A549), procaine has also been shown to demethylate promoter of WIF-1, 
thus restoring WIF-1 expression and downregulate Wnt canonical pathway through 
inhibition of cytosolic β-catenin protein and TCF reporter activity (Gao et al. 2009). 
In another report, a derivative of procaine, procainamide has been shown to reverse 
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GSTP1 hypermethylation and restore GSTP1 expression in human PCa, LNCaP cells 
propagated in vitro and in LNCaP xenograft tumours in vivo (Lin et al. 2001). 
 
3.4.5.3 Ranolazine 
In MDA-MB-231 cells, functional activity of Nav1.5 in its neonatal form, nNav1.5 
was shown to be dominant (Fraser et al. 2005; Chioni et al. 2005; Brackenbury et al. 
2007; Onkal & Djamgoz, 2009). Onkal et al. (2009) showed that nNav15 has a much 
slower inactivation compared to adult Nav1.5. Thus, the high expression of nNav1.5 
in BCa could cause similar problems as in angina i.e prolonged VGSC current and 
disruption of ion homeostasis. Ranolazine is being used for treatment of angina and 
as an anti-ischemic drug. In doing so, ranolazine was reported to act as blocker of 
VGSC ―persistent current‖ (INaP) (Undrovinas et al. 2006; Rajamani et al. 2008). In 
this study, after 24 h treatment with ranolazine (1 – 100 µM), lateral motility was 
reduced dose-dependently up to ~52 %. 10 µM ranolazine was enough to reduced 
lateral motility, transverse migration and Matrigel invasion. Furthermore, nNav1.5 
mRNA and protein expression in plasma membrane was reduced by 10 µM 
ranolazine. Altogether, these results strongly indicated that ranolazine suppressed 
MCBs of MDA-MB-231 cells by downregulation of nNav1.5 activity and 
expression. Furthermore, the lack of effect of ranolazine on proliferation also agrees 
with our findings that MCBs suppression by ranolazine was mainly via VGSC. Site 
mutagenesis experiments showed that the binding site for ranolazine in VGSC is the 
intercellular LA receptor (Fredj et al. 2006; Wang et al. 2008). In MDA-MB-231 
cells, minor expressions of Nav1.7 has been also reported (Fraser et al. 2005). Wang 
et al. (2008) reported that ranolazine could also block the neuronal Nav1.7 and 
muscle Nav1.4. However, in MDA-MB-231 cells, nNav1.5 was shown to be 
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primarily responsible for the enhanced invasiveness (Brackenbury et al. 2007). 
Initially, the main mode of action of ranolazine was thought to be the partial 
inhibition of fatty acid oxidase (Sabbah et al 2002).  Furthermore, ranolazine has also 
been shown to inhibit a number of other ion channels including K
+
 channels, delayed 
rectifier (Chen et al. 2009), L-type Ca
2+
 channels (Chen et al. 2009), Na
+
/Ca
2+
 
exchanger (NCX) and Na
+
/H
+
 exchanger (NHE) (Antzelevitch et al. 2004). 
Nevertheless, such effects of ranolazine on MDA-MB-231 cells could be ruled out 
since there would only occur at much higher concentrations of ranolazine, well 
beyond the therapeutic range (1 – 10 µM) (Zacharowski et al. 2001; Sabbah et al. 
2001; Antzelevitch et al. 2004; Burashnikov et al. 2007).  
Ranolazine has been shown to inhibit selectively the pathological increase in 
the INaP (Antzelevitch et al. 2004; Wu et al. 2004; Hale et al. 2006; Song et al. 2006). 
For example, it has been shown that the IC50‘s of ranolazine for the INaP and transient 
peak current of Nav1.5 are 15 µM and 135 µM, respectively (Fredj et al. 2006). 
Furthermore, ranolazine has been shown to inhibit the enhanced VGSC INaP 
produced by ischemia in cardiac myocytes (Antzelevitch et al. 2004; Wu et al. 2004; 
Hale et al. 2006; Song et al. 2006), by mutation associated with Long QT syndrome 
type 3 (LQT3) in cells transiently expressed mutant Nav1.5 (tsA201) (Huang et al. 
2010), by H2O2 (Song et al. 2006) and by sea anemone toxin ATX-II (Fraser et al. 
2004; Song et al. 2004). Recently, Kahlig et al. (2010) demonstrated that ranolazine 
could also selectively block the INaP evoked by epilepsy-associated Nav1.1 mutation. 
As for BCa, Onkal et al. (2009) reported that nNav1.5 has much slower activation 
and inactivation kinetics and recovers from inactivation more slowly than the ‗adult‘ 
form. We speculated that the INaP could contribute to MCBs as in other 
pathophysiological cell behaviours. The range of ranolazine concentration tested in 
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this study was within the IC50 for the INaP but lower than the IC50 of the Nav1.5 peak 
current reported in many cardiac cell/tissue studies (Undrovinas et al. 2006; Fredj et 
al. 2006). Therefore, we conclude that the suppression of MCBs in MDA-MB-231 
cells by the range of ranolazine concentration tested occurred mainly via inhibition 
of the nNav1.5 INaP.  
Contradictory to our findings, however ranolazine was shown to increase the 
occurrence of intestinal tumours in mouse model (Suckow et al. 2004). This 
contradiction could be due (i) to the high concentration of ranolazine used (10 and 30 
mg/kg, corresponding to 20 – 60 µM) and (ii) to the nature of the animal model. 
  
3.4.5.4 Riluzole 
Several modes of action have been suggested for riluzole in the dose range of 1 µM 
to 1 mM. Accordingly, starting from a very low concentration, riluzole has been 
associated with (1) inhibition of VGSC INaP, (2) potentiation of calcium-dependent 
K
+
 current, (3) inhibition of neurotransmitter (glutamate) release, (4) inhibition of 
transient Na
+
 current, (5) inhibition of voltage-gated Ca
2+
 current and (6) inhibition 
of voltage-gated K
+
 current (Doble et al. 1992; Debono et al. 1993; Hubert et al. 
1994; Zona et al. 1998; Stefani et al. 1997; Benoit et al. 1991; Herbert et al. 1994). 
However, only (1) – (4) occurred commonly at clinically relevant doses: plasma 
levels of 1 - 2 μM (Bellingham 2011). 
In this study, riluzole has been shown to suppress lateral motility dose-
dependently. However, at concentration higher than 1 µM, riluzole started to affect 
both cell viability and cell number that would limited other functional assays. The 
suppression of cell viability and growth by riluzole has been associated with its mode 
of action to cause endoplasmic reticulum (ER) stress; riluzole at 10 µM induced 
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apoptotic cell death via ER stress in PCa (Akamatsu et al. 2009). Therefore, to 
exclude the effect of growth suppression on functional assays, 1 µM of riluzole was 
chosen for transverse migration and Matrigel invasion. Furthermore, clinically 
relevant concentrations of riluzole in the plasma have been suggested to be in the 
range of 1 - 2 μM (Bellingham 2011). At 1 µM, migration and invasion were 
suppressed by ~ 20 and ~ 66 %, respectively. Previously, riluzole at much higher 
concentration (25 µM) was shown to significantly suppress migration, invasion and 
colony formation of fresh melanoma cells. Although, the non-therapeutic range dose 
used also inhibited cell proliferation (Le et al. 2010). 
Interestingly, riluzole has been shown to suppress growth and progression of 
cancer types expressing VGSCs e.g PCa and melanoma (Akamatsu et al. 2009; Le et 
al 2010). This is consistent with inhibition of VGSC being a significant anti-cancer 
mode of action of riluzole in these cancers at therapeutic concentrations. 
Furthermore, in the case of BCa, reduced expression of nNav1.5 mRNA and protein 
in plasma membrane by 1 µM of riluzole, accompanied MCB suppression, thereby 
supporting that both activity and expression could be suppressed by 1 μM riluzole. 
We conclude that although riluzole could have multiple mechanism of action, 
suppression of MCBs at therapeutic concentrations is likely to involve mainly the 
inhibition of VGSC (nNav1.5) INaP. 
Within the therapeutic range, riluzole could also inhibit glutamate release; in 
fact, this is thought to be the initial mode of action of riluzole in treating amyotrophic 
lateral sclerosis (ALS) (Hebert et al. 1994; Bensimon et al. 1994; Bryson et al. 1996). 
Glutamate is an amino acid and a predominant excitatory neurotransmitter in the 
central nervous system (CNS) (Esquenazi et al. 2002; Li et al. 2005). Glutamate 
release by cancer cells is not a new concept - malignant glioma cells have been 
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shown to secrete glutamate to its microenvironment to kill the surrounding brain 
cells, to create area for their further growth and to serve as an autocrine and paracrine 
signal promoting further cell invasion (Ye & Sontheimer 1999; Lyon et al. 2007). 
Several cancer cell lines including MDA-MB-231 cells have been shown to release 
significant quantities of glutamate into their extracellular environment that may 
facilitates their metastasis (Seidlitz et al. 2009). In fact, due to its inhibitory effect on 
glutamate release, riluzole has now in clinical trial targeting the growth of melanoma 
and BCa. Therefore, in suppression of MCBs by 1 µM riluzole could also involve 
inhibition of glutamate release. Importantly, however, release of glutamate could be 
controlled upstream by VGSC activity, as at excitatory synapses (Araya et al. 2007).  
We have discussed that riluzole is a potent drug with multiple modes of 
actions. Riluzole suppressed MCBs at concentrations much lower than those that 
affected cell viability and cell number. Our findings indicated that 10 – 100 µM 
riluzole were toxic to the weakly metastatic, MCF-7 cells. It would be interesting to 
determine if the cytotoxicity effect of riluzole different between cancers and normal 
cells. 
Increasing evidence suggest that the VGSC INaP could serve as a target for 
many pathophysiological conditions, including angina, ALS, pain and possibly the 
metastatic disease. Similar to ranolazine, riluzole has been proven to serve as an 
inhibitor of VGSCs INaP (Urbani & Belluzzi 2000; Spadoni et al. 2002; Weiss & 
Saint 2010; Weiss et al. 2010). In rat neurons, IC50 for INaP was reported to be around 
550 nM - 2 μM, whereas IC50 for transient current is above the therapeutic 
concentration > 2 μM (Urbani & Belluzzi 2000; Spadoni et al. 2002). Importantly, in 
hearts of adult rats, subjected to 30 min global ischaemia, riluzole blocked the 
enhanced VGSC INaP with an IC50 of 2.7 M, whereas the block of the transient 
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component was only apparent at concentrations above 30 M (Weiss et al. 2010). 
We could conclude, therefore, that VGSC INaP inhibition contributed to suppression 
of MCBs in MDA-MB-231 cells by riluzole at least at concentration within the range 
of IC50 for TTX-resistant INaP.  
 
3.5 Concluding remarks: Clinical implications 
Overexpression of VGSCs in BCa and other cancers has been proven to be 
associated with parameters related to metastasis. In BCa, the embryonic form of 
cardiac type, nNav1.5 is highly expressed and plays a role in potentiating cell 
motility, migration and invasion. Subsequently, inhibition of nNav1.5 activity by 
TTX repressed these VGSC-mediated MCBs. As in many hyperexcitability 
disorders, VGSC blockers have been found to be useful in controlling the symptom 
of the diseases. VGSC blockers i.e lidocaine, procaine, ranolazine and riluzole that 
already proven safe in the treatment of hyperexcitability diseases have been shown 
could also suppress metastatic parameters of BCa comparable to TTX. 
We have shown that TTX suppresses MCBs by not only blocking VGSC 
current conductance in MDA-MB-231 cells but also down regulate nNav1.5 mRNA 
and/or protein expression in the plasma membrane. Similar effects were obtained by 
the other VGSC blockers: lidocaine, procaine, ranolazine and riluzole. Moreover, we 
have shown that persistent current in BCa could play important role in VGSC-
mediated metastatic parameters. Inhibition of INaP by ‗specific‘ INaP blocker, 
ranolazine and riluzole brought to suppression of MCBs. 
Functional VGSC in cancer cells are a potential anti-metastatic target. 
Importantly, inhibiting VGSC activity to suppress MCBs has been shown to have 
minimal toxicity. Such a mode of action would be highly favourable since many 
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drugs used in cancer therapy have a systemic effect that could also kill non-
cancerous cells. Although TTX has been shown to be a powerful VGSC blocker to 
suppress VGSC-mediated MCBs, TTX analogues are now only been proposed to be 
used in cancer treatment mainly for its analgesics properties – cancer pain related 
(Hagen et al. 2008). Given that many VGSC blockers have already been used and 
proven to be safe in the medical field, it is tempting to undertake them for cancer 
therapy.  
In this study, VGSC-mediated MCBs of MDA-MB-231 cells were 
suppressed by lidocaine, procaine, ranolazine and riluzole at low concentrations 
within the approximate therapeutic ranges. Lidocaine is effective as an 
antiarrhythmic agent in a concentration range of 5-20 µM (Gianelly et al. 1967; 
Jewitt et al. 1968; Bellet et al. 1971). As a local anaesthetic, lidocaine has been 
reported to be affective at plasma concentrations of as low as 10 µM (Ferrante et al. 
1996) but can also be used at even greater than 100 µM (Schmidtmayer and Ulbricht, 
1980; Courtney, 1981; see Hille, 1978). Although use of procaine has been replaced 
mostly by more effective local anaesthetics such as lidocaine, the drug is still being 
used to help relieve pain and vascular spasm at concentrations of <4 mM (Hodgson 
et al. 2000). In the treatment of chronic angina, ranolazine in used are in the range 2 
to 10 µM (Chaitman et al. 2004a and b; Rousseau et al. 2005). Finally, effective
 
therapeutic plasma concentration of riluzole for ALS patients is approximately 2 µM 
(Mohammadi et al. 2002). Although strict consideration is needed when using 
riluzole due to its effect on blocking the glutamate receptor, which play an important 
role in proliferation (Herbert et al. 1994), this mode of action has made riluzole in 
clinical trial for melanoma and BCa (Le et al. 2009).  
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In overall conclusion, lidocaine, procaine, ranolazine and riluzole could be 
beneficial as clinically relevant candidate drugs in the future to restrain metastatic 
BCa.  
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Chapter 4 
 
EFFECTS OF RANOLAZINE AND RILUZOLE ON METASTATIC CELL 
BEHAVIOURS UNDER HYPOXIA 
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4.1 Introduction 
 
Cancer emerges as a result of genetic alterations, uncontrolled cell growth and 
survival. However, at some stage, growth of the cancer beyond 0.5 – 1 mm would be 
limited due to insufficient oxygen supply by diffusion, i.e. onset of hypoxia. 
Importantly, hypoxia has been shown to be a central trigger for promoting cancer cell 
survival, tumour neo-vascularization, glucose metabolism and ultimately, metastasis 
(Pouysségur et al. 2006; Chan & Giaccia 2007; Gort et al. 2008; Lu & Kang 2010). 
The multiple effects of hypoxia are controlled by hypoxia-inducible factors (HIFs), 
which are ‗master transcription factors‘ expressed during stress signaling resulting 
from lack of O2. A role for hypoxic microenvironment in the pathogenesis and 
progression of human cancers was first proposed when well-oxygenated cancer cells 
were found to exhibit a greater response to radiotherapy, compared to anoxic cells 
(Gray et al. 1953). Furthermore, a commonly prescribed chemotherapy treatment for 
breast cancer (BCa), cyclophosphamide, was shown to increase in effectiveness 
when combined with agents that increased tissue oxygenation (Teicher 1994).  
Within the HIF family, the HIF-1α induced hypoxia response pathway is 
best-characterized (Semenza 2003; Pouyssegur et al. 2006; Lisy & Peet 2008). Under 
normoxic condition, HIF-1α is hydroxylated, which promotes von Hippel-Lindau 
(VHL) tumour-suppressor protein binding to HIF-1α, thus targeting it for 
proteosomal degradation (Brahimi-Horn et al. 2007). Under hypoxia, HIF-1α 
stabilizes and heterodimerizes with HIF-1β to form the transcription factor. Activated 
HIF-1α binds to DNA at hypoxia response element (HRE) sites, leading to enhanced 
transcription of genes involved in pH regulation, glucose transport, glycolysis and 
vasculogenesis, in turn allowing the cells to adapt to the changes in the hypoxic 
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condition (Dang et al. 2008). Two key downstream HIF-1α-activated genes that have 
been widely described and tumour-associated are glucose transporter-1 (GLUT-1) 
and carbonic anhydrase-9 (CA9) (Lopez-Lazaro 2009). 
Hypoxia has also been shown to modulate expression / activity of several 
types of ion channels, including voltage-gated sodium channels (VGSCs) in neurons 
and other cell types (Hammarstrom & Gage 2002; Fearon & Brown 2004; Zhou et al. 
2006; Wang et al. 2007). Of the two main components of the VGSC current – 
transient and persistent - hypoxia was shown to increase the amplitude of the 
persistent current, INaP (Horn & Waldrop 2000; Hammarstrom & Gage 2002; Saint 
2006; Wang et al. 2007; Saint 2008; Saint 2009; Weiss et al. 2010). INaP, which is the 
slow inactivating component that follows the transient inward current results from 
the channels remaining partially open or repeatedly re-opening, thus, causing a 
prolonged influx of Na
+
 into the cell. During cardiac ischemia, for example, the 
amplitude of VGSC (Nav1.5) INaP was reported to increase by 3 - 4 fold (to become 
>2 % of the transient current) (Ju et al. 1996), leading to disruption of ionic 
homeostasis (especially Ca
2+
 overload) manisfesting as ―heart-burn‖ or angina (Saint 
2006; Saint 2009).  
In human BCa, VGSC, particularly neonatal Nav1.5 (nNav1.5) was shown to 
be highly functionally expressed in the plasma membrane of BCa cells in vitro and in 
vivo and potentiated the cells‘ metastatic behaviour (Fraser et al. 2005; Brackenbury 
et al. 2007). From an electrophysiological study, nNav1.5 was reported to have 
slower inactivation kinetics, compared to the adult Nav1.5, and this would result in 
prolonged Na
+
 influx, similar to INaP (Onkal et al. 2009). Thus, in metastatic BCa 
cells, also, the activity of the over-expressed nNav1.5 (i) could enhance the flow of 
Na
+
 into cells and (ii), similar to cardiac ischemia, the cumulative amplitude of INaP 
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could cause disruption of ionic homeostasis. Consequently, INaP could make a 
significant contribution to Na
+
 influx in the development of the aggressive phenotype 
in BCa. In metastatic prostate cancer (PCa) and BCa, positive-feedback 
autoregulation of Na
+
 influx has been shown to play a role in maintaining VGSC 
expression in plasma membrane that supports VGSC-dependent metastatic potential 
of these cancers (Brackenbury & Djamgoz 2006; Chioni et al. 2010). Taken together, 
therefore, the possibility arises, similar to the strategy for cardiac ischemia, that 
targeting INaP in BCa therapy could produce anti-metastatic effects. At present, the 
only method available for selective suppression of INaP is pharmacological.   
Ranolazine and riluzole are two types of drugs that are increasingly being 
used to inhibit INaP, both experimentally and clinically (Wu et al. 2004; Hale & 
Kloner 2006; Song et al. 2006; Belardinelli et al. 2006; Shryock & Belardinelli 2008; 
Saint 2008; Weiss et al. 2010). In the studies described in Chapter 3, involving 
experiments carried out under normal oxygen conditions (normoxia), ranolazine and 
riluzole were shown to decrease the metastatic ability of MDA-MB-231 cells at 
concentrations comparable to the therapeutic doses used for angina and amyotrophic 
lateral sclerosis (ALS). As INaP would be increased under hypoxia, the effects of 
these drugs under hypoxia were also investigated, as described in this chapter. Two 
types of hypoxia were induced: (i) chemical, using H2O2 (which has been reported 
previously to ‗stabilize‘ HIF-1α and thus elicit a hypoxic condition); and (ii) gaseous 
(using 2 % instead of 95 % oxygen in the incubating chamber). 
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4.2 Aims and scope 
 
The overall aim was to determine the effects of two drugs (ranolazine and riluzole) 
that were previously reported to inhibit INaP. The strongly metastatic human BCa 
MDA-MB-231 cells were used again as a model. The specific objectives were as 
follows: 
1. To determine the effects of hypoxia on the metastatic cell behaviours 
(MCBs);  
2. To determine the effects of hypoxia on the levels of nNav1.5 mRNA and 
VGSC protein expression in these cells;  
3. To determine the effect of ranolazine and riluzole on MCBs under hypoxia; 
4. To determine the effects of ranolazine and riluzole on the levels of nNav1.5 
mRNA and VGSC protein expression under hypoxia; and  
5. To determine the effects of hypoxia and the two drugs on the intracellular 
localization of VGSC (nNav1.5) protein. 
 
4.3 Results 
In most experiments, hypoxia was induced by exposing the cultures to 2 % oxygen in 
a dedicated hypoxia incubator. Some initial experiments were carried out using H2O2. 
 
4.3.1 Initial experiments 
Based on previous reports (Gao et al. 2004; Zhou et al. 2007; Page et al. 2008) that 
H2O2 could induce hypoxia chemically, initial hypoxia experiments using H2O2 were 
conducted.  
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4.3.1.1 H2O2 did not affect cell viability and cell number 
Concentrations of H2O2 tested were 1 – 100 µM. Trypan blue exclusion assays and 
MTT assays were conducted to test possible effects of H2O2 on cellular viability and 
cell number. Viability of MDA-MB-231 cells was not affected by 1 – 10 µM of H2O2 
(Figure 4.1A). However, cell viability was reduced by 100 µM H2O2 to 98 ± 0.2 % (P 
< 0.05, n = 4; Figure 4.1A). Growth (cell number) was also not affected by 1 – 100 
µM H2O2 after 24 and 48 h of treatment (Figure 4.1B).  
 
4.3.1.2 H2O2 reduced single-cell adhesion 
Effects of H2O2-induced hypoxia were investigated on single-cell adhesion using the 
Single-Cell Adhesion Measuring Apparatus (SCAMA); lateral motility was 
measured by ‗wound-heal assay‘. Single-cell adhesion was reduced dose-
dependently after 24 h of treatment with H2O2 (Figure 4.2A). H2O2 (10 and 100 µM) 
significantly reduced single cell adhesion by 13 ± 1.5 % (P < 0.05, n = 4) and by 20 
± 3.5 % (P < 0.05, n = 4), respectively (Figure 4.2A). In contrast, lateral motility was 
not affected by the H2O2 treatments (P > 0.05, n = 4; Figure 4.2B).  
 
4.3.1.3 nNav1.5 and VGSC-β1 mRNA levels were not affected by H2O2 
In order to determine the possible effects of H2O2 on nNav1.5 and VGSC-β1 mRNA 
levels, real-time PCRs were conducted. A working concentration of 50 µM H2O2 was 
used. Results showed that both nNav1.5 and VGSC-β1 mRNA expression levels 
were not affected after 24 h treatment with 50 µM H2O2 (P > 0.05, n = 3; Figures 
4.3A and 4.3B).  
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Figure 4.1 Effects of H2O2 on cell viability and cell number 
 
MDA-MB-231 cells were treated with 1 – 100 µM H2O2. (A) Cell viability was 
measured using Trypan blue exclusion assay. Up to 10 µM, H2O2 had no effect on 
viability. However, at 100 µM H2O2, cell viability was reduced. Data are presented 
as means ± SEMs (n = 3 independent experiments for each condition) and were 
compared using unpaired Student t-test. (*) indicates statistical significance (P < 
0.05). Cell numbers at 24 and 48 h were measured using the MTT method. (B) Cell 
number was not affected by H2O2 up to 100 µM.  
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Figure 4.2 Effects of H2O2 on single-cell adhesion and lateral motility 
 
MDA-MB-231 cells were treated with H2O2 (1 – 100 µM) for 24 h before 
measurement. (A) Single-cell adhesion was reduced by H2O2. ΔDNP % represents 
change of detachment negative pressure in percentage. However (B) lateral motility 
was not affected by H2O2. Data are presented as means ± SEM (n = 4 independent 
experiments for each condition) and were compared using unpaired Student t-test. (*) 
indicates statistical significance (P < 0.05); (x) indicates non-significance (P>0.05). 
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Figure 4.3 Lack of effect of H2O2 on nNav1.5 and VGSC-β1 mRNA expression 
levels 
 
(A) nNav1.5 mRNA expression level was not affected after 24 h treatment with 50 
µM H2O2. (B) VGSC-β1 mRNA expression level was also not affected by 50 µM 
H2O2. mRNA expression levels were normalized to control. Data are presented as 
means ± SEMs (n = 3 independent experiment for each condition) and were 
compared using unpaired Student t-test. (*) indicates statistical significance (P < 
0.05); (x) indicates non-significance (P>0.05). 
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4.3.1.4 The effects of ranolazine on single-cell adhesion was greater in hypoxia 
Ranolazine was shown to increase single-cell adhesion of normoxic MDA-MB-231 
cells dose-dependently (Figure 4.4). In the present study, we questioned whether the 
effect of ranolazine might be greater on hypoxic MDA-MB-231 cells. Indeed, when 
co-treated with 50 µM H2O2, the effects of ranolazine (0.01 – 100 µM) were greater 
and the dose-response curve shifted to the left (Figure 4.4). The increase in the 
effectiveness of ranolazine was ~ 10-fold and this was significant (n = 4, Figure 4.4). 
 In subsequent experiment, we investigated the effects of ranolazine and 
riluzole under hypoxia induced by exposing the cells to gaseous hypoxia (2 % O2). 
 
4.3.2 Increased expression of HIF-1α and CA9 as markers of hypoxia  
Cellular responses to hypoxia are regulated mainly by HIF-1α (Brahimi-Horn et al. 
2007; Gordon et al. 2007; Dang et al. 2008; Lu & Kang 2010). Therefore, expression 
of HIF-1α is an important marker for hypoxic condition. In addition, CA9 has been 
shown to be upregulated by hypoxia via HIF-1α and CA9 could be an endogenous 
marker for hypoxia (Rajaganeshan et al. 2009; McGuire & Fitzpatrick 2009; Dubois 
et al. 2009; Hong et al. 2009; Hoogsteen et al. 2009; Silva et al. 2010). Accordingly, 
expression levels of HIF-1α (protein) and CA9 (mRNA and protein) were used as 
markers to confirm that hypoxic conditions were achieved in the planned 
experiments. Since HIF-1α protein is a transcription factor, the protein should be 
abundant in the nucleus. Therefore, HIF-1α protein expression was studied by 
Western blotting on nuclear extracts from MDA-MB-231 cells pre-exposed to 
gaseous hypoxia for 24 h. Western blots for CA9 protein expression were performed 
on total protein lysates. Results from the Western blots showed that HIF-1α and CA9 
protein expression levels were indeed increased by hypoxia (Figure 4.5A). Real-time  
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Ranolazine [µM] Average SEM P value (vs Control) 
0.1 0.4 5.62 0.594 x 
0.5 3.8 2.53 0.778 x 
1 9.0 2.69 0.009 *** 
5.9 14.8 2.95 0.000306 *** 
10 24.5 2.81 1.59x10-6 *** 
20 23.6 3.65 3.09x10-5 *** 
40 13.6 4.76 0.046182 * 
80 25.9 1.38 4.81x10-5 *** 
100 12.3 5.48 0.089 x 
160 27.2 5.58 0.008 *** 
Treatment Average SEM P value (vs Control) 
H2O2 50 + RZN 0.01 -3.9 1.35 0.063 
x 
H2O2 50 + RZN 0.1 7.7 6.79 0.037 
* 
H2O2 50 + RZN 1 19.9 5.29 0.001 
*** 
H2O2 50 + RZN 10 20.2 3.18 0.000147 
***  
H2O2 50 + RZN 100 25.9 2.37 0.000120 
*** 
 
 
Figure 4.4 Effects of ranolazine on single-cell adhesion in hypoxia 
 
Single-cell adhesion was measured using SCAMA. Earlier, H2O2 was shown to 
reduce single-cell adhesion (Figure 4.3A). Single-cell adhesion was increased after 
24 h treatment with ranolazine dose-dependently (blue-dotted line). Data are 
presented as means ± SEMs and were compared using unpaired Student t-test (n = 7 
independent experiment for each condition). Co-treating 50 µM of H2O2 with 
ranolazine (red-dotted line) increased the single-cell adhesion ~10-folds greater (bold 
arrow). Data are presented as means ± SEMs and were compared to Control using 
unpaired Student t-test (n = 4 independent experiments for each condition). In the 
table, (*) indicates statistical significance (P < 0.05), (**) indicates significance at P 
< 0.01, (***) indicates significance at P < 0.001 and (x) indicates non-significance. 
 
 
-10 
-5 
0 
5 
10 
15 
20 
25 
30 
35 
0.01 0.1 1 10 100 1000 
Concentration [µM] 
Δ
 D
N
P
 (
%
) 
50 µM H2O2 + Ranolazine 
Ranolazine 
  
 183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.5 Effects of gaseous hypoxia on HIF-1α and CA9 expression levels 
 
(A) Western blot was carried out on nuclear extracts to determine HIF-1α protein 
expression; total protein extract was used to determine CA9 protein expression. HIF-
1α and CA9 protein expressions were increased after 24 h exposure to hypoxia. The 
lane numbers denote: (1) 24 h normoxia and (2) 24 h hypoxia (O2, 2 %). (B) CA9 
mRNA expression level was increased after 24 h exposure to hypoxia. Data are 
presented as means ± SEMs and were compared using unpaired Student t-test ( n = 3 
independent experiments for each condition). (*) indicates statistical significance (P 
< 0.05). 
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PCR showed that CA9 mRNA expression was also increased significantly by ~ 360 
% to 4 ± 0.9 fold relative to normoxia (P < 0.05, n = 3; Figure 4.5B). 
 
4.3.3 Cell viability and proliferative activity were not affected by hypoxia  
Trypan blue exclusion and MTT assays were carried out to investigate the possible 
effects of 2 % O2 (48 h) hypoxia, respectively, on cell viability and cell number. 
After plating, MDA-MB-231 cells were first incubated in the usual normoxia 
incubator (95 % O2 and 5 % CO2 at 37 
o
C) overnight. The next day, cells were 
transferred to the hypoxia incubator (2 % O2). Long-term (48 h) hypoxia did not 
affect cell viability (P > 0.05, n = 3; Figure 4.6A). Cell number also was not affected 
by the hypoxia (P > 0.05, n = 3; Figure 4.6B).  
 
4.3.4 Hypoxia enhanced metastatic cell behaviours  
Effects of gaseous hypoxia on MCBs of MDA-MB-231 cells were investigated. 
After 24 h of hypoxic treatment, lateral motility was increased by ~ 22 % to 122.8 ± 
0.01 % (P < 0.05, n = 5; Figure 4.7A); transverse migration was increased by ~ 12 % 
to 112.1 ± 0.02 % (P < 0.05, n = 3; Figure 4.7B); and Matrigel invasion was 
increased by ~ 25 % to 125.5 ± 0.01 % (P < 0.05, n = 3; Figure 4.7C). Thus, hypoxia 
enhanced all MCBs studied. 
 
4.3.5 Hypoxia increased nNav1.5 but reduced VGSC-β1 mRNA expression  
The effects of gaseous hypoxia (24 h) on VGSC (nNav1.5) mRNA and protein and 
VGSC-β1 mRNA expression levels were studied. Results showed that hypoxia 
increased nNav1.5 mRNA expression significantly by ~90 % to 2 ± 0.2 –fold, 
compared to normoxia (P < 0.05, n = 3; Figure 4.8A). However,  
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Figure 4.6 Prolonged (48 h) exposure to gaseous hypoxia did not affect cell 
viability and cell number  
 
Cell viability was measured using Trypan blue exclusion assay after exposing the 
cells to gaseous hypoxia (2 % O2) for 48 h. (A) Lack of effect of hypoxia on MDA-
MB-231 cell viability. Data are presented as means ± SEMs and were compared to 
Control using unpaired Student t-test (n = 3 independent experiments for each 
condition). (x) indicates statistical non-significance (P>0.05). Cell numbers after 24 h 
and 48 h exposure to hypoxia were measured using the MTT method. (B) Hypoxia 
24 h and 48 h did not affect cell number. Data are presented as means ± SEMs and 
were compared using unpaired Student t-test (n = 3 independent experiments for 
each condition). (x) indicates non significance (P>0.05). 
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Figure 4.7 Gaseous hypoxia enhanced metastatic cell behaviours 
 
Gaseous hypoxia was induced by exposing the cells to 2 % O2 for 24 h. All 
metastatic cell behaviours measured increased: (A) Lateral motility; (B) transverse 
migration; and (C) Matrigel invasion. Data are presented as means ± SEMs and were 
compared using unpaired Student t-test (n = 5 independent experiments for each 
condition). (*) indicates statistical significance (P < 0.05). 
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Figure 4.8 Gaseous hypoxia (2 % O2) increased nNav1.5 mRNA expression but 
did not affect nNav1.5 plasma membrane and internal protein expression  
 
(A) nNav1.5 mRNA expression level was increased significantly after 24 h hypoxia. 
(B) protein expression at plasma membrane (PM) and internal (INT) was not affected 
after 24 h hypoxia. Expression of nNav1.5 was normalized relative to Control. Data 
are presented as means ± SEMs and were compared using unpaired Student t-test (n 
= 3 independent experiments for each condition) (*) indicates statistical significance 
(P < 0.05); (x) indicates non-significance. 
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immunocytochemistry with confocal microscopy suggested that nNav1.5 protein 
expression in plasma membrane and cytoplasm was not affected by the hypoxic 
condition (P > 0.05, n = 3; Figure 4.8B). VGSC-β1 mRNA expression level was 
reduced significantly by ~ 30 % to 0.7 ± 0.09 -fold compared to normoxia (P < 0.05, 
n = 3; Figure 4.9). 
 
4.3.6 Effects of ranolazine and riluzole on MCBs under hypoxia 
In the previous chapter, ranolazine and riluzole were shown to suppress lateral 
motility, transverse migration and Matrigel invasion of MDA-MB-231 cells under 
normoxia. In the present study, both drugs were applied under hypoxia to test the 
hypothesis that the expected INaP increased under hypoxia would be blocked by 
ranolazine and riluzole, so their effects in suppressing MCBs would be greater. 
 
4.3.6.1 Cell number  
Effects of ranolazine and and riluzole on growth (cell number) were tested under 
hypoxia. MTT assays were carried out as described earlier. Similar to normoxia, 
ranolazine under hypoxia did not affect cell number (P > 0.05, n = 4; Figure 4.10A). 
However, cell number was affected by riluzole dose-dependently. Cell number was 
reduced significantly by ~57 % at the highest concentration (100 µM) of riluzole 
used (P < 0.001, n = 4; Figure 4.10B).  
 
4.3.6.2 Lateral motility  
The effects of ranolazine and riluzole on lateral motility were tested under both 
normoxia and hypoxia in parallel to be able to compare directly the effect of both 
drugs under both conditions. Lateral motility of the untreated control was increased  
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Figure 4.9 Gaseous hypoxia reduced VGSC-β1 mRNA expression 
 
Expression of VGSC-β1 mRNA was normalized to Control. Hypoxia reduced 
VGSC-β1 mRNA expression significantly. Data are presented as means ± SEMs and 
were compared using unpaired Student t-test (n = 3 independent experiments). (*) 
indicates significance (P < 0.05). 
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Figure 4.10 Effects of ranolazine and riluzole on cell number (‘growth’) in 
hypoxia 
 
Cell numbers were measured by the MTT method. MDA-MB-231 cells were treated 
with 1, 10 and 100 µM ranolazine and riluzole for 24 h under hypoxia. (A) 
Ranolazine did not affect cell number. (B) Cell number was affected by 100 µM 
riluzole. Data are presented as means ± SEMs and were compared using unpaired 
Student t-test (n = 4 independent experiments for each condition). (***) indicates 
significance at P < 0.001. 
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Treatment 
[µM] 
 
Average 
 
SEM 
P value 
(vs Control) 
P value 
(vs Normoxia) 
Control 100.0    
Control Hyp 122.8 5.32 0.013 *  
     
1 88.8 3.89 0.063 x  
1 Hyp 81.4 13.08 0.013 * 0.133 x 
     
10 84.9 7.67 0.121 x  
10 Hyp 64.1 8.68 0.000 *** 0.035 * 
     
100 76.3 9.39 0.086 x  
100 Hyp 66.5 14.91 0.010 ** 0.161x 
 
 
Figure 4.11 Effect of ranolazine on lateral motility was greater in hypoxia 
 
(A) Lateral motility was reduced by ranolazine in both normoxia and hypoxia. 
Hypoxia increased lateral motility of MDA-MB-231 cells. The effect by 10 µM of 
ranolazine in reducing the lateral motility was greater under hypoxia. Data are 
presented as means ± SEMs and were compared using unpaired Student t-test (n = 4 
independent experiments for each condition). In the table, the levels of statistical 
significance are as follows: (*)P < 0.05; (**)P < 0.01; (***)P < 0.001; (x) indicates 
non significance. 
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Treatment 
[µM] 
 
Average 
 
SEM 
P value 
(vs Control) 
P value 
(vs Normoxia) 
Control 100.0    
Control Hyp 126.9 9.43 0.046 *  
     
1 89.0 5.11 0.099 x  
1 Hyp 80.0 7.19 0.005 ** 0.336 x 
     
10 75.5 6.80 0.023 *  
10 Hyp 64.6 3.54 0.001 *** 0.205 x 
     
100 26.9 6.17 0.000 ***  
100 Hyp 19.1 5.23 0.000 *** 0.360 x 
 
 
Figure 4.12 Riluzole reduced lateral motility in both normoxia and hypoxia 
 
(A) Hypoxia increased lateral motility of MDA-MB-231 cells. Lateral motility was 
reduced under both normoxia and hypoxia. The break in the concentration axis (―//‖)     
indicates that growth was affected. Data are presented as means ± SEMs and were 
compared using unpaired Student t-test (n = 5 independent experiments for each 
condition). In the table, the levels of statistical significance are as follows: (*) P < 
0.05; (**) P < 0.01; (***) P < 0.001; (x) indicates non significance. 
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significantly under hypoxia by >20 % (P < 0.05; n = 4/5; Figure 4.11 and 4.12). 
Lateral motility was reduced dose-dependently by both ranolazine and riluzole under 
normoxia and hypoxia (n = 4/5; Figures 4.11 and 4.12). Accordingly, under hypoxia, 
1, 10 and 100 µM ranolazine reduced lateral motility by ~18, ~35 and ~33 %, 
respectively. Whilst under normoxia, 1, 10 and 100 µM ranolazine reduced lateral 
motility by ~11, ~15 and ~23 % with, respectively. The effect of 10 µM ranolazine in 
suppressing lateral motility was ~24 % greater compared to normoxia (P < 0.05; n = 
4; Figure 4.11). The changes of lateral motility (Δ lateral motility %) by ranolazine 
under normoxia and hypoxia were compared; there was a trend for a greater effect of 
ranolazine under hypoxia (Figure 4.13A). 
Under normoxia, 1, 10 and 100 µM riluzole reduced lateral motility by ~11, 
~25 and ~73 %, respectively (n = 5; Figure 4.12). Under hypoxia, 1, 10 and 100 µM 
riluzole reduced lateral motility by ~20, ~35 and ~81 %, respectively (n = 5; Figure 
4.12). Thus, although there was a general trend for a greater effect under hypoxia, the 
differences (Δ lateral motility - %) were not significant (n = 5; Figure 4.12 and 
Figure 4.13B). Furthermore, the apparent effect of 100 µM riluzole in both normoxia 
and hypoxia on lateral motility would be ‗contaminated‘ by its effect on growth. 
 
4.3.6.3 Transverse migration  
Similar to lateral motility, the effects of ranolazine and riluzole on transverse 
migration under normoxia and hypoxia were studied in parallel. Migrated cells were 
stained by crystal violet and pictures were taken and analyzed using ImageJ (Figures 
4.14A 4.15A). Transverse migration of untreated control cells was increased 
significantly under hypoxia (P < 0.05, n = 3; Figure 4.14B and 4.15B). Migration 
was reduced dose-dependently by ranolazine and riluzole under normoxia and  
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Figure 4.13 Changes of lateral motility with ranolazine and riluzole under 
normoxia and hypoxia 
 
Changes of lateral motility (Δ lateral motility - %) of ranolazine and riluzole were 
compared under normoxia and hypoxia. There was a trend for a greater effect of (A) 
ranolazine and (B) riluzole on lateral motility. Data are presented as means ± SEMs 
and were compared using unpaired Student t-test (n = 3 independent experiments for 
each condition).  
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Treatment [µM] 
 
Average 
 
SEM 
P value  
(vs Control) 
P value  
(vs Normoxia) 
Control 100.0    
Control Hyp 112.1 1.64 0.018 *  
     
1 106.1 6.40 0.516 x  
1 Hyp 86.9 1.47 0.002 ** 0.030 * 
     
10 94.7 1.63 0.189 x  
10 Hyp 79.5 3.38 0.030 * 0.007 ** 
     
100 87.1 1.65 0.081 x  
100 Hyp 76.5 4.94 0.063 
x
 0.054 
x
 
 
 
Figure 4.14 Transverse migration was reduced by ranolazine in hypoxia 
 
(A) Migrated cells stained with crystal violet after 24 h treatment with ranolazine 
under normoxia and hypoxia. (B) Transverse migration was increased by hypoxia. 
Ranolazine reduced transverse migration under normoxia and hypoxia. The effect 
was greater under hypoxia for 1 and 10 µM ranolazine.  Data are presented as means 
± SEMs and were compared using unpaired Student t-test (n = 3 independent 
experiments for each condition), In the table, the levels of statistical significance are 
as follows: (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (x) indicates non 
significance. 
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Treatment [µM] 
 
Average 
 
SEM 
P value 
(vs Control) 
P value 
(vs Normoxia) 
Control 100.0    
Control Hyp 124.0 11.14 0.043 *  
     
1 88.0 3.88 0.090 x  
1 Hyp 69.2 9.47 0.021 * 0.176 x 
     
10 85.3 5.35 0.110 x  
10 Hyp 64.1 9.82 0.016 * 0.153 x 
     
100 44.8 2.62 0.002 *  
100 Hyp 31.6 3.20 0.010 
**
 0.035 
*
 
 
 
Figure 4.15 Transverse migration was reduced by riluzole under hypoxia  
 
(A) Images of migrated cells stained with crystal violet. (B) Hypoxia increased 
lateral motility of MDA-MB-231 cells. Lateral motility was reduced dose-
dependently by riluzole under both normoxia and hypoxia. The effect was greater 
under hypoxia. ―//‖ indicates that growth was affected by 100 µM riluzole. Data are 
presented as means ± SEMs and were compared using unpaired Student t-test (n = 3 
independent experiment for each condition).  In the table, the levels of statistical 
significance are as follows: (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (x) indicates 
non significance. 
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hypoxia (n = 3, Figure 4.14B and 4.15B). Under normoxia, 1 µM ranolazine had no 
effect on migration but at 10 and 100 µM, ranolazine reduced transverse migration 
by ~5 and ~13 %, respectively (n = 3, Figure 4.14B). Under hypoxia, 1, 10 and 100 
µM ranolazine reduced transverse migration by ~13, ~20 and ~23 %, respectively (n 
= 3, Figure 4.14B). Differences in the effects of ranolazine on transverse migration 
(Δ transverse migration - %) under normoxia and hypoxia were compared. Under 
hypoxia, the effects of 1 and 10 µM ranolazine in suppressing migration were ~69 % 
and ~16 % greater compared to normoxia (n = 3, Figure 4.14B). Thus, there was a 
trend of for the effects of ranolazine being greater under hypoxia (Figure 4.16A).  
Under normoxia, tranverse migration was reduced by ~12, ~15 and ~55 %, 
respectively by 1, 10 and 100 µM riluzole (n = 3, Figure 4.15B). Under hypoxia, 1, 
10 and 100 µM riluzole reduced transverse migration by ~31, ~36 and ~68 %, 
respectively (n = 3, Figure 4.15B). There was a general trend for a greater effect of 
riluzole on transverse migration (Δ transverse migration - %) under normoxia 
compared with hypoxia (Figure 4.16B). We should note, however, that evaluation of 
the effects of 100 µM riluzole (in both normoxia and hypoxia) would be 
compromised by the effects of the drug on growth. 
 
4.3.6.4 Matrigel invasion  
Effects of ranolazine and riluzole on the capacity of MDA-MB-231 cells to digest 
Matrigel and move through it under normoxia and hypoxia were tested in parallel. 
Invaded cells were stained with crystal violet and counted after 24 h treatment. 
Earlier, effect of ranolazine and riluzole on lateral motility and transverse 
migration were tested in the range 1 – 100 µM. However, in Matrigel invasion 
assays, working concentrations of ranolazine and riluzole near the therapeutic range  
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Figure 4.16 Changes of transverse migration with ranolazine and riluzole under 
normoxia and hypoxia 
 
Changes of transverse migration (Δ transverse migration - %) caused by ranolazine 
and riluzole were compared under normoxia and hypoxia. There was a trend for a 
greater effect of (A) ranolazine and (B) riluzole on transverse migration. Data are 
presented as means ± SEMs and were compared using unpaired Student t-test (n = 3 
independent experiments for each condition). 
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were chosen: 10 µM and 1 µM, respectively. TTX (10 µM) was included in the 
assays as a control. 
Invasion of untreated control cells was increased significantly under hypoxia 
compared to normoxia (P < 0.05, n = 3; Figure 4.17). In the control for the effect of 
blocking VGSC activity, 10 µM TTX reduced invasion under both normoxia and 
hypoxia, by ~51 % to 49 ± 11.7 % (P < 0.01, n = 3) and by ~82 % to 18 ± 8.3 % (P < 
0.05, n = 3), respectively (Figure 4.17). Thus, the effect of TTX in suppressing 
invasion appeared greater under hypoxia but this was not statistically significant (P = 
0.12, n = 3; Figure 4.17). 
Invasion was significantly suppressed by 10 µM ranolazine and 1 µM riluzole 
under both normoxia and hypoxia. Under normoxia, 10 µM ranolazine reduced 
invasion by ~ 74 % to 26 ± 2.2 % (P < 0.05, n = 3; Figure 4.17). Under hypoxia, 
invasion was reduced by 10 µM ranolazine by ~ 70 % to 30 ± 13.1 %. There was no 
significant difference in the effects of 10 µM ranolazine under hypoxia compared to 
normoxia (P = 0.058, n = 3; Figure 4.17). Under normoxia, 1 µM riluzole reduced 
invasion by by ~66 % to 34 ± 10.3 %; under hypoxia, the reduction was ~75 % to 25 
± 5.5 % (for both: P < 0.01, n = 3; Figure 4.17). Again, there was no difference in the 
effects of 1 µM riluzole on invasion under hypoxia compared with normoxia (P > 
0.05, n = 3; Figure 4.17). 
 
4.3.7 Effects of ranolazine and riluzole on VGSC expression under hypoxia 
4.3.7.1 nNav1.5 mRNA and protein expression 
Real-time PCR was carried out to compare the effects of ranolazine and riluzole on 
nNav1.5 mRNA expression. The effects on protein expression and subcellular 
localization were evaluated using immunocytochemistry followed by confocal  
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Treatment Average SEM 
P value  
(vs Control) 
P value  
(vs Normoxia) 
Control 100.0 0.00   
Control Hyp 125.5 8.45 0.010**  
     
TTX 10 48.7 11.66 0.048*  
TTX 10 Hyp 18.1 8.31 0.010** 0.107x 
     
RZN 10 25.9 2.21 0.001***  
RZN 10 Hyp 29.8 13.35 0.058x 0.852x 
     
RZL 1 33.6 10.29 0.023*  
RZL 1 Hyp 25.1 5.49 0.001*** 0.518x 
 
 
Figure 4.17 Effects of drugs on Matrigel invasion under normoxia and hypoxia  
 
Hypoxia increased invasion of MDA-MB-231 cells. 10 µM TTX (TTX 10), 10 µM 
ranolazine (RZN 10) and 1 µM riluzole (RZL 1) reduced Matrigel invasion under 
both normoxia and hypoxia. Data are presented as means ± SEMs and were 
compared to Control using unpaired Student t-test. n = 3 independent experiment for 
each condition. The levels of statistical significance are as follows: (*) P < 0.05; (**) 
P < 0.01; (***) P < 0.001; (x) indicates non significance. 
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microscopy and digital image analysis. Effects under normoxia and hypoxia were 
compared. Effects of TTX on nNav1.5 mRNA and protein expression were also 
tested. 
Ranolazine - nNav1.5 mRNA expression was reduced dose-dependently by 
ranolazine under normoxia (Figure 4.18A). A low concentration (1 µM) had no 
effect. Higher concentrations (10 and 100 µM) of ranolazine suppressed nNav1.5 
mRNA expression significantly under normoxia by ~35 % to 65 ± 10.0 % and by 
~50 % to 0.5 ± 0.06-fold relative to control (for both: P < 0.05, n = 4; Figure 4.18A), 
respectively. Interestingly, there was no apparent effect of ranolazine (1 – 100 µM) 
on nNav1.5 mRNA expression under hypoxia (P > 0.05, n = 4; Figure 4.18A).  
Riluzole - nNav1.5 mRNA expression was reduced dose-dependently by riluzole 
under normoxia and hypoxia. Under normoxia, nNav1.5 mRNA expression was only 
significantly suppressed by 100 µM riluzole; expression was reduced by ~49 % to 
0.5 ± 0.09-fold relative to control (P < 0.05, n = 4; Figure 4.18B). Under hypoxia, 1, 
10 and 100 µM riluzole reduced nNav1.5 mRNA expression by ~54 % to 0.5 ± 0.24-
fold relative to control, ~71 % to 0.3 ± 0.14-fold relative to control and ~ 83 % to 0.2 
± 0.12-fold relative to control, respectively. Again, only 100 µM riluzole gave 
significant effect under hypoxia (P < 0.05, n = 4; Figure 4.18A). Thus, the reduction 
in nNav1.5 mRNA expression by 100 µM riluzole was ~60 % greater under hypoxia 
compared with normoxia. However, this effect is likely to be due to suppression of 
growth (‗cell number‘) by 100 µM riluzole. 
As a control for the effect of overall VGSC blockage, 10 µM TTX reduced 
nNav1.5 mRNA expression significantly under normoxia and hypoxia. Under 
normoxia, nNav1.5 mRNA expression was reduced by TTX by ~47 % to 0.5 ± 0.03-
fold relative to control (P < 0.01, n = 4; Figure 4.18C). Under hypoxia, nNav1.5  
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Figure 4.18 Effects of ranolazine, riluzole and TTX on nNav1.5 mRNA 
expression under hypoxia 
 
Gaseous hypoxia was induced over 24 h.(A & B) Ranolazine and riluzole reduced 
nNav1.5 mRNA expression under normoxia. Under hypoxia, riluzole only had a 
greater effect on the nNav1.5 mRNA level. (C) 10 µM TTX reduced nNav15mRNA 
expression more in hypoxia than in normoxia. Data are presented as means ± SEMs 
and were compared using unpaired Student t-test (n = 4 independent experiments for 
each condition).  (*) indicates statistical significance (P < 0.05). 
 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
Control TTX 
Hypoxia 
* 
** 
** 
n
N
a
v
1
.5
 m
R
N
A
 e
x
p
re
ss
io
n
  
(-
fo
ld
 r
el
a
ti
v
e 
to
 c
o
n
tr
o
l)
 Normoxia 
0 
0.5 
1.0 
1.5 
2.0 
2.5 
Control 1 10 100 
Normoxia 
Hypoxia 
* 
x 
Ranolazine [uM] 
x 
* 
x 
n
N
a
v
1
.5
 m
R
N
A
 e
x
p
re
ss
io
n
 
(-
fo
ld
 r
el
a
ti
v
e 
to
 c
o
n
tr
o
l)
 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
Control 1 10 100 
Hypoxia 
* 
* 
* 
x 
x 
n
N
a
v
1
.5
 m
R
N
A
 e
x
p
re
ss
io
n
 
(-
fo
ld
 r
el
a
ti
v
e 
to
 c
o
n
tr
o
l)
 
Normoxia 
A 
 
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
 
C 
Riluzole [uM] 
  
 203 
mRNA expression was reduced by TTX by ~ 94 % to 0.06 ± 0.05-fold relative to 
control (P < 0.01, n = 4; Figure 4.18C). Thus, the effect of TTX in reducing nNav1.5 
mRNA expression was ~87 % greater in hypoxia compared to normoxia (P < 0.05, n 
= 3; Figure 4.18C). 
Cross-sectional analysis of XYZ scans revealed that there was considerable 
variability in the effects of the various treatments on nNav1.5 protein expression in 
plasma membrane. Following exposure to hypoxia, nNav1.5 protein expression in 
plasma membrane was reduced slightly by ~9 % to 91 ± 9.5 % without statistical 
significance (P = 0.43, n = 3; Figure 4.19A).  
Ranolazine - Under normoxia, expression was reduced significantly by ~11 
% to 89 ± 2.0 % after 24 h treatment with 10 µM ranolazine (P < 0.05, n = 3; Figure 
4.19A). Under hypoxia, also, nNav1.5 protein in plasma membrane was reduced by 
10 µM ranolazine by  ~14 % to 86 ± 9.5 %, but this was not statistically significant 
(P = 0.35, n = 3; Figure 4.19A). There was no significant difference between effects 
of 10 µM ranolazine on nNav1.5 protein expression in plasma membrane under 
normoxia and hypoxia (P > 0.05, n = 3; Figure 4.19A). nNav1.5 protein expression 
in cytoplasm (INT) was not affected by 10 µM ranolazine under both normoxia and 
hypoxia (P > 0.05, n = 3; Figure 4.19B).  
Riluzole - Under normoxia, nNav1.5 protein expression in plasma membrane 
was reduced significantly by ~25 % to 75 ± 8.1 % after 24 h treatment with 1 µM 
riluzole (P < 0.05, n = 3; Figure 4.19A). There was no difference between the effects 
of 1 µM riluzole on nNav1.5 protein expression in plasma membrane under 
normoxia compared to hypoxia (P > 0.05, n = 3; Figure 4.19A). There was no effect 
of 1 µM riluzole on the cytoplasmic (INT) expression of nNav1.5 under normoxia 
and hypoxia (P > 0.05, n = 3; Figure 4.19B). 
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Figure 4.19 Effects of drugs on nNav1.5 protein expression in plasma membrane 
and cytoplasm under normoxia and hypoxia 
 
(A) Treatment with 10 µM TTX, 10 µM ranolazine and 1 µM riluzole reduced 
plasma membrane (PM) nNav1.5 protein after 24 h treatment under normoxia whilst 
under hypoxia only TTX reduced nNav1.5. (B) Internal (INT) nNav1.5 protein 
expression was not affected under normoxia and hypoxia. Data are presented as 
means ± SEMs and were compared using unpaired Student t-test (n = 3 independent 
experiments for each condition). (*) indicates statistical significance (P < 0.05). 
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Finally, cross-sectional analysis of XYZ scans revealed that nNav1.5 protein 
expression in plasma membrane was reduced significantly after 24 h treatment with 
10 µM TTX both under normoxia (by ~24 % to 76 ± 11.8 %) and under hypoxia (by 
~27 % to 73 ± 10.6 %) (for both: P < 0.05, n = 3; Figure 4.19A). There was no 
difference between these effects (P > 0.05, n = 3; Figure 4.19A). The cytoplasmic 
(INT) expression of nNav1.5 was not affected by TTX under both normoxia and 
hypoxia (P > 0.05, n = 3; Figure 4.19B).  
 
4.3.7.2 VGSC-β1 mRNA expression 
Effects ranolazine and riluzole on VGSC-β1 mRNA expression under normoxia and 
hypoxia were studied using real-time PCR. The concentrations of both drugs tested 
were 1 - 100 µM. Effect of 10 µM TTX was also investigated. Although there was a 
trend for increased VGSC-β1 mRNA expression by ranolazine and riluzole under 
normoxia, the changes were not significant (P > 0.05, n = 3; Figure 4.20A 4.20B). 
Similarly, there was no effect of ranolazine and riluzole on VGSC-β1 mRNA 
expression under hypoxia (P > 0.05, n = 4; Figure 4.20A and 4.20B). There were no 
difference in the effects of both ranolazine and riluzole on VGSC-β1 mRNA 
expression in normoxia vs. hypoxia (P > 0.05, n = 4; Figure 4.20A and 4.20B). 10 
µM TTX also did not affect VGSC-β1 mRNA expression under normoxia (P > 0.05, 
n = 4; Figure 4.20C). However, when treated with TTX under hypoxia, VGSC-β1 
mRNA expression was reduced significantly (P < 0.05, n = 4; Figure 4.20C). Thus, 
the effect of TTX in reducing VGSC-β1 mRNA expression under hypoxia was ~79 
% greater compared to normoxia (P < 0.05, n = 4; Figure 4.20C).  
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Figure 4.20 Effects of ranolazine, riluzole and TTX on VGSC-β1 mRNA 
expression under normoxia and hypoxia 
 
 (A & B) Ranolazine and riluzole had no effect on VGSC-β1 mRNA expression 
under normoxia and hypoxia (24 h). (C) 10 µM TTX reduced VGSC-β1 mRNA 
expression more in hypoxia than in normoxia. Data are presented as means ± SEMs 
and were compared using unpaired Student t-test (n = 4 independent experiments for 
each condition). (*) indicates statistical significance (P < 0.05); (x) indicates non-
significance. 
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4.4 Discussion 
 
The main findings of the studies on MDA-MB-231 cells described in this chapter are 
as follows: 
 
1. Following 24 h treatment with H2O2: (i) Single cell-adhesion was reduced dose-
dependently, (ii) the effect of ranolazine in increasing adhesion was greater (~10-
fold) when co-treated with H2O2 and (iii) nNav1.5 and VGSC-β1 mRNA levels 
were not affected. 
2. Expressions of (i) HIF-1α protein and (ii) CA9 mRNA and protein were 
increased after 24 h exposure to gaseous hypoxia (2 % O2) confirming induction 
of hypoxic condition. 
3. Hypoxia increased (i) nNav1.5 mRNA expression but (ii) reduced VGSC-β1 
mRNA level. However, the subcellular distribution of nNav1.5 protein was not 
affected. 
4. Hypoxia enhanced MCBs: Lateral motility, transverse migration and Matrigel 
invasion. 
5. Lateral motility, transverse migration and Matrigel invasion were suppressed 
significantly by ranolazine and riluzole under hypoxia. 
6. The inhibitory effects of (i) ranolazine on lateral motility and (ii) ranolazine and 
riluzole on transverse migration were generally greater under hypoxia. 
7. VGSC-β1 mRNA expression and subcellular distribution of nNav1.5 protein and 
were not affected by ranolazine and riluzole under hypoxia. 
8. The effect of 10 µM TTX in suppressing nNav1.5 mRNA expression was greater 
under hypoxia compared with under normoxia. 
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9. VGSC-β1 mRNA expression was not affected by 10 µM TTX under normoxia 
but was reduced significantly under hypoxia. 
 
4.4.1 Induction of hypoxia  
In the present study, both chemical hypoxia (initial studies) and gaseous hypoxia 
were used. Induction times were 24 – 48 h and a variety of effects were observed. 
Importantly, these effects were functional (e.g MCBs) as well as transcriptional (e.g 
mRNA levels). It is likely, therefore, that the effects of hypoxia are continuum, from 
transcriptional to functional, depending on ‗dose‘ and duration of treatment. 
 
4.4.1.1 Initial experiments involving H2O2 
There is some evidence showing that similar to hypoxia, H2O2 can enhance INaP (Ma 
et al. 2005; Song et al. 2006). Enhanced INaP has been accepted as an important basis 
of increased Na
+
 influx that can lead to pathological ionic imbalance (Na
+
 and Ca
2+
 
overload), as in cardiac ischemia (Saint 2006; Saint 2008; Saint 2009). In metastatic 
BCa, increased Na
+
 influx was proposed to play an important role in the positive-
feedback autoregulation of VGSC expression in potentiating VGSC-dependent 
MCBs (Brackenbury et al. 2007; Chioni et al 2010). Such increased of Na
+
 influx 
during metastasis may contribute to the higher sodium concentrations in BCa 
compared to non-cancerous tissue reported previously (Cameron et al. 1980; 
Oukerwerk et al. 2007). Several studies have shown that application of H2O2 to 
cancer including BCa cells enhances proliferation, resistance to apoptosis, increase 
angiogenesis and invasion/metastasis; conversely, increased levels of H2O2-
detoxyfying enzymes in cancer cells would reverse these effects (Lopez-Lazaro 
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2007). Therefore, in order to gain an insight to the role of INaP in MCBs, the effects 
of H2O2 on MCBs were tested. 
It was previously shown that the highly metastatic MDA-MB-231 cells are 
less adhesive than the weakly metastatic MCF-7 cells (Chioni et al. 2006; Palmer et 
al. 2008). After 24 h treatment with H2O2, adhesiveness of MDA-MB-231 cells, 
measured by SCAMA, was reduced significantly by up to 20 %. Further reduction in 
adhesiveness would be consistent with promotion of metastatic potential. 
Nevertheless, H2O2 had no effect on lateral motility, suggesting that the presumed 
promotion metastatic potential by H2O2 was still at an early stage, where the cells 
may not have yet gained the ability to increase motility.  
The slower inactivating of nNav1.5 was suggested to promote Na
+
 influx into 
MDA-MB-231 cells (Onkal et al. 2008). Such a characteristic of nNav1.5 could 
further increase the amplitude of INaP. The proposed role of INaP in controlling MCBs 
was demonstrated in a pharmacological approach, using initially the INaP inhibitor, 
ranolazine. Treatment with ranolazine increased single-cell adhesion dose-
dependently by up to >27 %. The concentrations of ranolazine used (0.1 – 10 µM) 
are close to the range for INaP inhibition: IC50 = 15 µM (Fredj et al. 2006). 
Interestingly, when MDA-MB-231 cells were co-treated with ranolazine and H2O2 
(50 µM), the increased in single-cell adhesion was ~10-fold greater. These results 
further support the proposed role of INaP in promoting metastatic potential, including 
under hypoxic conditions. 
 
4.4.1.2 Gaseous hypoxia  
Tumour hypoxia occurs for a number of reasons. Mostly, in solid tumours, including 
BCa, hypoxia occurs due to rapid cell growth surpassing the available vasculature 
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producing greater distance for O2 diffusion between capillaries and tumour cells.  
Tumour hypoxia would stabilize the transcriptional factor HIF-1α that would activate 
signalling pathways ultimately to promote cancer cell survival. Accordingly, HIF-1α 
is a major endogenous marker for hypoxia. Indeed, when MDA-MB-231 cells were 
cultured for 24 h in a hypoxia incubator (supplied with 2 % O2), nuclear HIF-1α 
protein expression was increased significantly, confirming that the cells achieved 
hypoxic condition. Similarly, increased expression of HIF-1α protein has been 
associated with hypoxia in a variety of solid tumours including in BCa, in vitro and 
in vivo (Zhong et al. 1999; Talks et al. 2000; Semenza 2002). Importantly, the role of 
hypoxia has been associated with transcriptional regulation of cellular response for 
survival and progression of cancer to an aggressive and invasive phenotype (Yokoi 
& Fidler 2004; Yoshiba et al. 2009; Kato et al. 2010). For example, in hypoxic 
cancers, to promote rapid growth, HIF-1α induced expression of vascular endothelial 
growth factor (VEGF) to recruit new blood vessels (Osinsky et al. 2011). Another 
response to the metabolic change in cancer is HIF-1α induced expression of genes 
for regulating pericellular pH, carbonic anhydrase-9 (CA9) (Gatenby et al. 2004; 
Rosftad et al. 2006; Moellering et al. 2008; Shin et al. 2011). It has been shown that 
CA9 is tightly controlled by HIF-1α making it another endogenous marker for 
tumour hypoxia (Chiche et al. 2009). In the present study, CA9 expressions were 
also measured. Indeed, hypoxia increased the expression of CA9 mRNA and protein, 
correlating with the upregulation of HIF-1α. This further confirmed that hypoxic 
condition was established by the 2 % O2 treatment.  
 
4.4.2 Effects of hypoxia on VGSC-dependent MCBs 
Metastatic potential of MDA-MB-231 cells was increased after 24 h exposure to 
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hypoxia. As regards VGSC-dependent MCBs, hypoxia increased significantly lateral 
motility, transverse migration and Matrigel invasion by 10 -15 %. Moreover, from 
the initial experiments with H2O2, adhesion was reduced by up to 20 %. 
 
4.4.2.1 Adhesion 
Previously, VGSC activity has been shown to play a role in adhesion of metastatic 
BCa cells (Palmer et al. 2008; Pan & Djamgoz 2008; Chioni et al. 2009; Fraser et al. 
2010). We have shown in the initial experiments with H2O2 that chemical hypoxia 
also decreased adhesion. Other studies have shown that hypoxia (chemical and 
gaseous) would increase INaP amplitude (Horn & Waldrop 2000; Hammarstrom & 
Gage 2002; Saint 2006; Wang et al. 2007; Saint 2008; Saint 2009; Weiss et al. 2010). 
Furthermore, the INaP blocker had a 10-fold greater effect in hypoxia, compared with 
normoxia. Taken together, these results are consistent with INaP being the main 
VGSC component that controls adhesion. How VGSC activity/ INaP would might 
control cellular adhesiveness is not clear at present. One possibility is that the 
VGSC-induced activation of PKA phosphorylates a cell adhesion molecule (CAM) 
and thus reduces its adhesion to substrate. Such a CAM may be an integrin (Whittard 
& Akiyama 2001) or the VGSC β-subunit (Brackenbury et al. 2008; Brackenbury & 
Isom 2008; Chioni et al. 2010; Patino & Isom 2010).  
Interestingly, VGSC-β1 was shown earlier to function as a CAM responsible 
for the ‗strong‘ adhesiveness of the weakly/non-metastatic BCa, MCF-7 cells (Chioni 
et al. 2006; Chioni et al. 2009). VGSC-β1 mRNA expression was reduced 
significantly by 30 % in MDA-MB-231 cells after 24 h of exposure to gaseous 
hypoxia. Thus, the reduced adhesiveness of hypoxic MDA-MB-231 cells could also 
be due to down-regulation of VGSC-β1 expression. Indeed, hypoxia has been shown 
  
 212 
to reduce the expression of other important CAMs such as E-cadherin to promote 
cancer invasiveness (Beavon 1999; Chen et al. 2010). Accordingly, in an in vitro 
study on hypoxic BCa cells, Chen et al. (2010) demonstrated that E-cadherin level 
was reduced by increased expression of E-cadherin repressors, Snail and Slug, via 
hypoxia-mediated Notch signalling. In another report, hypoxia caused loss of 
expression of CD151, a member of the tetraspanin family that plays important roles 
in cell adhesion in colorectal cancer (Chien et al. 2008). 
We should finally note that changes in mRNA expression may not always 
lead to corresponding changes in protein levels or signalling (Rajasekhar & Holland 
2004). So, further work is required to gain an integrated overall understanding of the 
functional consequences of hypoxia and its different regimes. 
  
4.4.2.2 Lateral motility 
Numerous reports have demonstrated increased motility of cancer cells under 
hypoxia, and over-expression of HIF-1α is generally associated with the 
acquired/enhanced motility (Niizeki et al. 2002; Funasaka et al. 2005; Wang et al. 
2007; Kirschmann et al. 2005). Accordingly, hypoxia-induced activation of HIF-1α 
could lead to transcription of genes related to cell motility. For example, in 
pancreatic cancer cells, increased cell motility under hypoxia was associated with 
increased expression of the autocrine motility factor (Niizeki et al. 2002; Funasaka et 
al. 2005). In lung cancer, increased cell motility of A549 cell line was associated 
with increased epidermal growth factor (Wang et al. 2007). Also in BCa, hypoxia via 
HIF-1α has been shown to increase the expression of lysyl oxidase (LOX) that 
facilitated
 
cell motility (Kirschmann et al. 2005). 
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In the present study, lateral motility of MDA-MB-231 cells increased 
significantly by ~10 % after 24 h hypoxia. Concomitantly, hypoxia increased 
nNav1.5 mRNA expression. Assuming that this mRNA ultimately resulted in 
functional VGSC (nNav1.5) activity, it would follow that use-dependent further 
increase in metastatic potential could occur during/following hypoxia. Indeed, many 
studies have reported that prolonged hypoxia increase the expression and activity of 
VGSC that lead to increase neuronal excitability (Xia et al. 2000; Zhang et al. 2001; 
Zhao et al. 2004; Zhao et al. 2005). 
Loss of adhesiveness would be necessary to facilitate cancer cell detachment 
and motility. Subsequently, however, it needs to be dynamically regulated during the 
cell motility. For example, hypoxic loss of E-cadherin expression has been 
demonstrated to enhance motility and other metastatic behaviours of BCa cells 
(Krishnamachary et al. 2006; Esteban et al. 2006).  
The INaP inhibitor, ranolazine (10 µM) reduced lateral motility by ~24 % 
more under hypoxia compared with normoxia, consistent with the hypoxic 
enhancement of INaP being the underlying cause of the increased motility. Enhanced 
INaP could produce increased Na
+
 influx that would potentiate the positive-feedback 
autoregulation of VGSC expression/activity and thus increase motility. Although 
nNav1.5 protein expression in plasma membrane was only slightly increased after 24 
h, a significant effect on invasiveness was already observed. Given that hypoxia 
could occur for much longer periods in cancer, more nNav1.5 protein could be 
synthesized and become functional during disease progression. 
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4.4.2.3 Transverse migration 
Under hypoxia, transverse migration of MDA-MB-231 cells increased significantly 
by ~15 %. Similar to lateral motility, increased migration under hypoxia was 
accompanied by increased nNav1.5 mRNA expression (by ~90 %) and reduced 
VGSC-β1 mRNA expression (by ~30 %). Consistently, the greater effect of 
ranolazine (1 and 10 µM) in suppressing migration under hypoxia, compared with 
normoxia (~69 % and ~16 %), suggested that enhanced INaP played a significant role 
in promoting transverse migration. 
In a recent report, Cronin et al. (2010) demonstrated that migration of MDA-
MB-231 and MCF-7 cells were increased after exposure to 5 % O2 hypoxia and this 
involved upregulation of HIF-1α and induction of chemokine receptor 4 (CXCR4) 
(Cronin et al. 2010; Tafani et al. 2010). Hypoxia also enhanced migration of 
colorectal carcinoma cells, an effect mediated by human enhancer of filamentation 1, 
a HIF-1α-regulated gene (Kim et al. 2010). In lung cancer also, hypoxia via HIF-1α 
induced the expression of chemokine receptor 7, which has been shown to play a 
critical role in cellular chemotaxis (Li et al. 2009). We propose that VGSC (nNav1.5) 
expression can be added to the HIF-1α-induced genes promoting BCa cell migration. 
 
4.4.2.4 Matrigel invasion 
In addition to adhesion, lateral motility and transverse migration, VGSC activity also 
plays an essential role in potentiating invasiveness of various carcinomas (Grimes et 
al. 1995; Laniado et al. 1997; Smith et al. 1998; Bennett et al. 2003; Fraser et al. 
2004; Gao et al. 2009; House et al. 2010). In fact, in colon cancer, House et al. 
(2010) concluded that VGSC (Nav1.5) is a ―key regulator of gene transcriptional 
network that controls colon cancer invasion‖. Similarly, Nav1.5 in its neonatal form, 
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nNav1.5 has been shown to play a significant role in potentiating cellular invasiness 
in BCa (Roger et al. 2003; Gao et al. 2009; Gillet et al 2009; Brisson et al. 2010). 
After 24 h exposure to hypoxia, Matrigel invasion of MDA-MB-231 cells 
increased significantly by ~15 %. Increased invasion was accompanied with 
increased nNav1.5 mRNA expression and reduced VGSC-β1 mRNA expression. 
Similar to adhesion, lateral motility and transverse migration, hypoxia-induced 
increase in INaP could be responsible for the enhanced invasiveness of MDA-MB-231 
cells and the greater effect of ranolazine. This is consistent with the effect of the 
other INaP inhibitor, riluzole (1 µM). In another report, HIF-1α induced up-regulation 
of CXCR4 was shown to correlate with increased invasion of MDA-MB-231 and 
MCF-7 cells after exposure to 5 % O2 hypoxia (Cronin et al. 2010). Increased 
expression of LOX under hypoxia has also been associated with increased invasion of 
BCa in vitro (Santhanam et al. 2010). 
Previously, in facilitating BCa invasion, the role of VGSC (Nav1.5) activity 
in MDA-MB-231 cells has been linked to increasing the activity of low pH-activated 
MMP-9 and cystein-cathepsin (Gao et al. 2009; Gillet et al. 2009). Accordingly, the 
activity of Nav1.5 in MDA-MB-231 cells increased the activity of the Na
+
-H
+
 
exchanger NHE1 to promote pericellular acidosis thus increasing the activity of low 
pH-activated proteases to enhance invasion (Brisson et al. 2010). Conversely, 
inhibiting NHE1 by 5-(N-ethyl-N-isopropyl) amiloride (EIPA) was shown to 
suppress invasion of HepG2 cells under hypoxic conditions (Yang et al. 2010). 
Another pH regulator, CA9 has been shown to increase in expression and activity in 
hypoxic cancer (Chia et al. 2001; Svastova et al. 2004). Importantly, in BCa, high 
activity and expression of CA9 has been associated with increased 
metastasis/invasion in vivo (Hussain et al. 2007; Trastour et al. 2007; Tan et al. 2009; 
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Pacchiano et al. 2011). Similarly, in the present study, increased invasion of MDA-
MB-231 cells under hypoxia was accompanied by increased CA9 mRNA and protein 
expression. These results suggested that increased CA9 activity and expression under 
hypoxia might be involved in the pericellular acidosis enhancing the activity of 
proteases and in turn, facilitating BCa cell invasiveness. Studies on CA9 are 
presented in Chapter 5. 
 
4.4.3 Effects of VGSC persistent current blockers 
The use of INaP blockers, ranolazine and riluzole in the present study provided an 
insight to the potential significance of enhanced INaP in hypoxic BCa cells and 
potentiation of MCBs. Furthermore, the tendency for the increased effectiveness of 
these drugs in hypoxic BCa cells raised the possibility of both drug being useful 
against metastatic BCa. Possible INaP inhibition as the main mode of action of these 
drugs in hypoxic BCa cells is discussed below. 
 
4.4.3.1 Effects of ranolazine under hypoxia 
The initial mechanism of action of ranolazine in treating heart failure/angina was 
reported to be as a partial inhibitor of fatty acid oxidase suppressing Ca
2+
 overload 
during angina (Sabbah et al. 2002). Subsequently, ranolazine was also found to act as 
an inhibitor of INaP and, presently this is thought to be its main mode of action (Maier 
2009). The latter followed from the discovery of abnormally increased of INaP in 
cardiac ischemic and effect of ranolazine in suppressing it. 
Previously, the slower inactivation kinetics of nNav1.5 in MDA-MB-231 
cells was suggested to contribute to INaP that would promote Na
+
 influx to potentiate 
the positive-feedback loop of VGSC-dependent component of metastatic cascade 
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(Onkal et al. 2009). Under normoxia, 10 µM ranolazine would break the loop thus 
significantly eliminating the VGSC-dependent MCBs of MDA-MB-231 cells. These 
effects were accompanied by down-regulation of nNav1.5 mRNA and protein 
expression after treatment with 10 µM ranolazine. The IC50 value of ranolazine for 
Nav1.5 INaP reported to be ~15 µM (Fredj et al. 2006), is consistent with the effect of 
ranolazine on MCBs being through inhibition of INaP.  
Accordingly, INaP was likely to be enhanced by hypoxia in MDA-MB-231 
cells, as in other cell types (Horn & Waldrop 2000; Hammarstrom & Gage 2002; 
Saint 2006; Wang et al. 2007; Saint 2008; Saint 2009; Weiss et al. 2010). 
Furthermore, under hypoxia, the effects of ranolazine (1 - 10 µM) on lateral motility 
and transverse migration were ~20 % significantly greater than in normoxia. 
However, there was no significant difference in the effects of ranolazine on Matrigel 
invasion under normoxia and hypoxia. These effects would suggest that the 
contribution of VGSC activity to potentiation of MCBs, especially invasiveness, is 
already near maximal and cannot be increased substantially, even by hypoxia. Such a 
conclusion was reached earlier from the use of VGSC openers in studies on MCBs of 
MDA-MB-231 cells (Fraser et al. 2005) and rat PCa cells (Fraser et al. 2003). 
 
4.4.3.2 Effects of riluzole under hypoxia 
Similar to ranolazine, riluzole has been used frequently as an INaP inhibitor in 
protecting neurones and cardiac cells from ischemia (Urbani & Belluzzi 2000; 
Spadoni et al. 2002; Weiss & Saint 2010; Weiss et al. 2010). Under normoxia, within 
the IC50 for INaP, 1 µM riluzole significantly suppressed MCBs. Suppression of 
MCBs by riluzole was accompanied by down-regulation of nNav1.5 mRNA and 
protein expression, suggesting that at this concentration, riluzole could break the 
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positive-feedback loop at both transcriptional and signalling levels, thus suppressing 
the VGSC-dependent MCBs.  
As INaP would be increased in hypoxia, the effects of riluzole were tested on 
hypoxic MDA-MB-231 cells. Riluzole (1 µM) had a tendency to produce greater 
effects on MCBs in hypoxia vs. normoxia by some 10 – 20 %. There was a similar 
trend for nNav1.5 mRNA expression. All together, these results indicated that effects 
of 1 µM riluzole in suppressing VGSC-dependent MCBs were most likely to be via 
inhibition of INaP.  
At higher concentrations, riluzole also affected cell number (growth). 
Moreover, at concentrations higher than the therapeutic dose (1 – 2 µM), riluzole 
would start to inhibit transient current which would interfere with the effect on INaP 
(as well as the functional assays). Previously, riluzole at a high concentration (25 
µM) was shown to suppress proliferation, migration and invasion of melanoma cells 
expressing metabotropic glutamate receptor-1 (GRM1) (Le et al. 2010). In melanoma 
cells, GRM1 or its signaling may be associated with glutamate release (Namkoong et 
al. 2007). It has also been reported that suppression of glutamate release by 
pharmacological agents in cancer cells can correlate with reduction in cell growth 
(Namkoong et al. 2007). Therefore, excess extracellular glutamate seen in many 
human malignancies, including BCa, is important perhaps by creating 
paracrine/autocrine loops to promote cell growth (Rzeski et al. 2001). Thus, other 
than as an INaP inhibitor, riluzole has been proposed to work as inhibitor of glutamate 
release (Cheah et al. 2010; Bellingham 2011). Subsequently, in the study by Le et al. 
(2010), proliferation of melanoma cell was suppressed by 25 µM riluzole through 
inhibition of glutamate signalling via MAPK and PI3K/AKT pathways that 
ultimately decreased migration and invasion of melanoma cell lines. However, in the 
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present study, since 1 µM riluzole under hypoxia had no effect on cell number, it is 
unlikely that an effect on glutamate release was involved. Overall, however, release 
of vesicular glutamate at synapses is well known to involve VGSC activity (e.g. 
Araya et al. 2007), so it would be interesting to determine whether the reported anti-
MCBs effects of riluzole in melanoma involve INaP, at least in part. 
 
4.5 An overview 
Under hypoxia, various cellular mechanisms are compromised. Therefore, adaptive 
response under hypoxia is important for cancer cells in order to survive. However, 
adaptation of cancer cells to hypoxia through HIF-1α has been shown to activate 
several genes that facilitate their transformation to a more invasive phenotype 
(Zhong et al. 1999; Birner et al. 2000; Bos et al. 2003; Kurokawa et al. 2003; Kuwai 
et al. 2003; Wenger et al. 2005). The results presented in this chapter would suggest 
that VGSC could be a part of the adaptive response to hypoxia promoting more 
invasive BCa. 
Influx of Na
+
 through VGSC has been suggested to have a positive-feedback 
autoregulation to ensure maximum VGSC expression in potentiating VGSC-
dependent MCBs in PCa and BCa (Brackenbury & Djamgoz 2007; Chioni et al. 
2010). In the present study, INaP component of the VGSC current was suggested to 
increase the ‗feeding‘ of Na+ into this loop. In the initial experiment with H2O2, the 
role of INaP in potentiating MCBs was indicated. Thus, enhancing INaP with H2O2, (i) 
promoted the invasiveness of MDA-MB-231 cells by reducing single-cell adhesion 
and (ii) increased the effectiveness of ranolazine.  
The occurrence of INaP in MDA-MB-231 cells (contributed by the slower 
inactivation of nNav15) was deduced when MCBs were suppressed by the INaP 
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inhibitors, ranolazine and riluzole. Furthermore, INaP would be enhanced by hypoxia. 
The role of enhanced INaP in potentiating invasiveness of hypoxic MDA-MB-231 
cells was demonstrated when exposure to gaseous hypoxia was found to increase 
MCBs (lateral motility, transverse migration and Matrigel invasion) whilst, 
ranolazine and riluzole inhibited these with greater efficacy, compared with 
normoxia. Additionally, upregulation of nNav1.5 mRNA expression under gaseous 
hypoxia could, ultimately, further increase the VGSC-dependent MCBs. 
Hypoxia could also increase the invasiveness of MDA-MB-231 cells by 
increasing the expression of the pH regulator, CA9. Given that VGSC (Nav1.5) 
activity has been shown to affect the activity of another pH regulator, NHE1, in 
potentiating MDA-MB-231 cells invasiveness (Brisson et al. 2010), we suggested 
that there could also be a link between VGSC (nNav1.5) and CA9. This is 
investigated in the following chapter. Altogether, the involvement of VGSC in 
potentiating MCBs in normoxia and hypoxia is illustrated in Figure 4.19.  
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Figure 4.21 VGSC-dependent regulation of MCBs under normoxia and hypoxia  
 
In normoxia (A) high-level expresion and activity of nNav1.5 contribute to increased 
Na
+
 influx. Additionally, the much slower inactivation of nNav1.5 may contribute to 
enhance INaP that would further lead to increased Na
+
 influx. In BCa, Na
+
 influx and 
positive-feedback autoregulation of VGSC via PKA ensures a high level of VGSC 
expression/activity that, in turn, would maximize the contribution to enhancement of 
metastatic potential. In hypoxia (B) enhanced INaP further increase the Na
+
 influx 
thus promoting the positive-feedback autoregulation of functional VGSC expression. 
Hypoxia through HIF-1α also induces expression of CA9 that can acidify the cancer 
cell microenvironment. Both enhanced INaP and acidosis can increase MCBs under 
hypoxia. 
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Chapter 5 
 
POSSIBLE ASSOCIATION OF VGSC AND CARBONIC ANHYDRASE-9 IN 
CONTROL OF METASTATIC CELL BEHAVIOUR 
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5.1 Introduction 
 
Hypoxia is generally accepted to play an important role in increasing cancer cell 
invasiveness (Vaupel & Mayer 2007; Chaudary & Hill 2007; Brahimi-Horn et al. 
2011). Consequently, mechanisms of hypoxia in cancer have been considered as 
potential therapeutic targets to suppress cancer progression/metastasis. The discovery 
of hypoxia inducible factors (HIFs), particularly the HIF-1α as the master 
transcriptional factor, has opened a wide door for understanding the molecular 
mechanism of cancer cell behaviour under hypoxia. In fact, adaptation and 
transformation of cancer in hypoxic environments closely relate to alteration in gene 
expression through HIF-1α (Kizaka-Kondoh et al. 2003; Brahimi-Horn et al. 2011). 
Indeed, in hypoxic cancer cells, HIF-1α has been shown to induce the expression of 
genes that are important in metabolism [e.g glucose transporter-1 (GLUT-1) (Airley 
et al. 2001; Chung et al. 2009)], neovascularization [e.g vascular endothelial growth 
factor (VEGF) (Shang et al. 2006; Chung et al. 2010)] and pH regulation. Regarding 
the latter, carbonic anhydrase-9 (CA9) has been shown to play a significant role 
(Wingo et al. 2001; Hilvo et al. 2008).  
Despite increased anaerobic metabolism that promotes the accumulation of 
lactic acid and CO2 by hypoxia, intracellular pH (pHi) of cancer cells is maintained at 
a relatively neutral level (~ pH 7.1). Since acidic pHi would cause apoptosis, in order 
to ensure survival, normal pHi is achieved in cancer cells through HIF-1α-mediated 
increased expression of pH regulators such as Na
+
/H
+
 exchanger (NHE), H
+
-
transporters and monocarboxylic transporter (MCT). In addition, expression of a 
surface membrane acid-base balance enzyme, CA9, was also found to be up-
regulated by HIF-1α in hypoxic cancer cells (Ivanov et al. 2001; Sennounce et al. 
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2004; Robey et al. 2009; Chiche et al. 2010; Brahimi-Horn et al. 2011). CAs, 
including CA9, are a family of enzymes that rapidly and reversibly catalyze the 
following biochemical reaction: 
 
H2O + CO2                        H
+
 + HCO3
-
 
 
CA9 is a plasma membrane-bound protein with a catalytic domain that faces the 
interstitial space. Generally, in hypoxic cancer cells, CO2 produced by the cells 
diffuses out passively. With the high-level expression of CA9 in the plasma 
membrane of tumour cells, this CO2 reacts with H2O to be converted to HCO3
- 
and 
H
+
 (Swietach et al. 2009). HCO3
- is an important ‗buffer‘ molecule, and the HCO3
- 
produced is recycled back into the cells through a trans-membrane HCO3
- 
carrier e.g. 
Na
+
/HCO3
−
 co-transporter (NBC). In normal cells, the accompanying H
+
 dissipates 
from the system through blood capillaries (Vaughan-Jones et al. 2009). However, 
due to the aberrant/disrupted nature of blood capillaries in hypoxic tumours, 
excessive metabolic products (including H
+
 from the CA9 reaction) can accumulate 
in the pericellular spaces. The term ―H+-trapping‖ describes the restriction and 
accumulation of H
+
 in the tumour micro-environment (extracellular space) resulting 
from (i) increased expression and activity of CA9 and (ii) transport of HCO3 into 
cells via MCT, leaving the excess extracellular H
+
 ‗unpaired‘ around hypoxic cancer 
cells (Svastova et al. 2008; Giatromanolaki et al. 2001; Ivanov et al. 2001; 
Pastorekova et al. 2008; Swietach et al. 2010). Consequently, the extracellular pH 
(pHe) of cancer cells becomes acidic. Thus, the ‗hypoxic‘ state of cancer correlates 
positively with the level of acidosis in the extracellular environment. Accordingly, 
CA9 
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the pHe of cancer cells is in the range 6.0 to 6.9, whereas the pHi of normal tissues is 
significantly nearer neutrality, 7.1 to 7.5 (Brahimi-Horn & Pouysségur 2006). 
Many studies have reported a positive correlation between high CA9 
expression/ activity, pHe acidosis and enhanced invasiveness of hypoxic cancer cells, 
including in BCa (Svastova et al. 2004; Gatenby et al. 2006; Rofstad et al. 2006; 
Shin et al. 2008; Robey et al. 2009; Martin et al. 2010; Lou et al. 2011). Shin et al. 
(2008) showed that cancer cells over-expressing CA9 produced a more acidic pHe in 
the culture medium, compared with CA9-negative cells under hypoxic conditions. 
Conversely, inhibition of CA9 reversed the extracellular acidification process of 
hypoxic MDCK cells over-expressing CA9 (Svastova et al. 2004). Similarly, in 
strongly metastatic human BCa MDA-MB-231 cells, inhibition of CA9 blocked the 
acidification of pHe in respond to hypoxia (Li et al. 2009). Importantly, the CA9-
induced acidification of the cancer cell microenvironment has been associated with 
increased invasiveness. For example, in a recent report, increased invasiveness was 
observed when CA9 was over-expressed in cervical cancer, leading to reduced 
adhesion and increased cell motility via aberrant Rho-GTPase signal transduction 
(Shin et al. 2011). Conversely, knocking-down CA9 expression in MDA-MB-231 
cells alkalinized pHe and suppressed the cells‘ invasiveness (Hsieh et al. 2010).  
In the previous chapter, it was shown that increased invasiveness of MDA-
MB-231 under hypoxia was accompanied by upregulation of nNav1.5 and CA9 
mRNA expression. Using TTX and other VGSC blockers (lidocaine, procaine, 
ranolazine and riluzole), nNav1.5 expression and activity were shown to play a 
significant role in promoting BCa invasiveness. High-level expression and activity of 
CA9 also have been shown to contribute to the increased invasiveness/metastasis of 
hypoxic BCa in vitro and in vivo (Rakha et al. 2009; Lou et al. 2011). Thus, it would 
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appear that there could be a possible functional association between CA9 and 
nNav1.5. Testing of such a possibility using the MDA-MB-231 cell model was the 
main subject of the present study. In order to do so, the following inhibitors were 
used: Acetazolamide (a ‗classic‘ general inhibitor of CAs), siRNA (CA9-specific 
inhibitor) and TTX (VGSC-specific inhibitor). Matrigel invasion assays were 
performed to evaluate the functional aspects.  
 
5.2 Aims and scope 
 
The overall aim was to determine whether there is an interaction between VGSC and 
CA9 in the control of MDA-MB-231 cell invasiveness under hypoxia.  The specific 
objectives were as follows: 
6. To test the effect of VGSC activity on CA9 expression; 
7. To determine the effect of inhibiting CA activity generally on CA9 and 
nNav1.5 expression and cellular invasion;  
8. To investigate the effect of inhibiting CA9 specifically on CA9 and nNav1.5 
expression and cellular invasion; and 
9. To evaluate the possible interaction between CA/CA9 and VGSC in the 
invasiveness of MDA-MB-231 cells. 
 
5.3 Results 
 
It was shown in the previous chapter that when MDA-MB-231 cells were exposed to 
hypoxia for 24 h, CA9 and nNav1.5 mRNA expressions were increased significantly 
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(Chapter 4, Section 4.3.2). The studies of this chapter addressed the central question 
of a possible connection between CA9 and VGSC.  
 
5.3.1 CA9 expression was not affected by TTX  
MDA-MB-231 cells were exposed to gaseous hypoxia for 24 h in the presence of 
TTX (10 µM) and CA9 mRNA expression level was measured using RT-PCR as 
before. Under these conditions, TTX treatment (i.e. blocking VGSC activity) did not 
affect CA9 mRNA expression (P > 0.05, n = 3; Figure 5.1).  
 
5.3.2 Effects of inhibiting ‘total’ CA activity 
CA activity as a whole was inhibited using acetazolamide. The working 
concentration of acetazolamide used was 100 µM (Parkkila et al. 2000; Robertson et 
al. 2004; Hulikova et al. 2011). 
 
5.3.2.1 Lack of effect of acetazolamide on cell number 
The possible effect of acetazolamide on cell number was tested in order to be able to 
evaluate subsequent data on invasion. Cells were treated with 100 µM acetazolamide 
for 24 h during hypoxia. Cell numbers were measured using the MTT method. 
Results showed that cell number was not affected by 100 µM acetazolamide under 
hypoxia (P > 0.05, n = 4; Figure 5.2A).  
 
5.3.2.2 Lack of effect of acetazolamide on Matrigel invasion  
Boyden chamber assays were conducted to investigate the effect of 100 µM 
acetazolamide on the ability of MDA-MB-231 cells to digest Matrigel barrier when 
CA activity was inhibited. Matrigel invasion assays were performed on cells treated  
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Figure 5.1 TTX did not affect CA9 mRNA expression level 
 
CA9 mRNA expression was not affected by 10 µM TTX during 24 h exposure to 
hypoxia.  Data are presented as means ± SEMs (n = 3 independent experiments for 
each condition) and were compared to Control using unpaired Student t-test. (x) 
indicates non-significance (P > 0.05). 
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Figure 5.2 Cell number was not affected by acetazolamide and invasion was 
reduced by TTX but not acetazolamide 
 
(A) MDA-MB-231 cells were exposed to hypoxia for 24 h whilst being treated with 
100 µM of acetazolamide (AZ 100) and MTT assay was conducted. Acetazolamide 
did not affect the cell number. Data are presented as means ± SEMs (n = 3 
independent experiments for each condition) and were compared to Normoxia using 
unpaired Student t-test. (x) indicates non-significance (P > 0.05). (B) Invasion was 
carried under hypoxia for 24 h. Invading cells were stained with crystal violet and 
counted using a microscope. Invasion was reduced by 10 µM TTX (TTX 10) but not 
by 100 µM of acetazolamide (AZ 100). Data are presented as means ± SEMs (n = 3 
independent experiments for each condition) and were compared to Control using 
unpaired t-test. (**) indicates high level of significance (P < 0.01); (x) indicates non-
significance (P > 0.05). 
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with 100 µM acetazolamide, with 10 µM TTX applied separately as a control. 
Untreated / control cells were prepared and monitored in parallel. The assays were 
conducted in hypoxia for 24 h. Results showed that invasion was reduced 
significantly by 10 µM TTX by ~ 72 % to 28 ± 6.8 % (P < 0.01, n = 3; Figure 5.2B). 
Invasion  also appeared to be reduced by 100 µM acetazolamide by ~ 40 % to 60 ± 
19.7 % but this was without statistical significance (P = 0.18, n = 3; Figure 5.2B).  
 
5.3.2.3 CA9 mRNA was reduced by 100 µM of acetazolamide under normoxia 
but not under hypoxia 
Real-time PCR was conducted to measure CA9 mRNA expression after treating the 
cells with 100 µM acetazolamide in parallel under normoxia and hypoxia. CA9 
mRNA expression was reduced significantly by acetazolamide under normoxia; the 
reduction was ~39 % to 0.6 ± 0.08–fold relative to control (P < 0.05, n = 3; Figure 
5.3A). On the other hand, the level of CA9 mRNA under hypoxia was not affected 
by acetazolamide (P > 0.05, n = 3; Figure 5.3B).  
 
5.3.2.4 nNav1.5 mRNA was reduced by 100 µM of acetazolamide under hypoxia 
but not under normoxia 
Similarly, real-time PCR was conducted to measure nNav1.5 mRNA expression 
level after treatment with 100 µM acetazolamide. Experiments were carried out 
under normoxia and hypoxia in parallel. Under normoxia, treatment with 
acetazolamide did not affect nNav1.5 mRNA expression level (P > 0.05, n = 3; 
Figure 5.3A). However, under hypoxia, treatment with 100 µM acetazolamide 
significantly reduced nNav1.5 mRNA expression level by ~73 % to 0.3 ± 0.07 –fold 
relative to control (P < 0.05, n = 3; Figure 5.3B).  
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Figure 5.3 Effects of acetazolamide on CA9 and nNav1.5 mRNA expression level 
under normoxia and hypoxia 
 
(A) CA9 mRNA expression was reduced by 100 µM acetazolamide (AZ) under 
normoxia but nNav1.5 mRNA was not affected. (B) Under hypoxia, nNav1.5 mRNA 
expression was reduced but CA9 level remained unchanged by acetazolamide. Data 
are presented as means ± SEMs (n = 3 independent experiments for each condition) 
and were compared to Normoxia using unpaired Student t-test. (*) indicates 
statistical significance (P < 0.05); (x) indicates non-significance (P > 0.05). 
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These results suggested complexities in the effects of acetazolamide on CA 
and nNav1.5 expression in MDA-MB-231 cells in relation to hypoxia.  
 
5.3.3 Effects of silencing CA9 expression 
The experiments with acetazolamide gave an overview of the potential role of CAs in 
VGSC expression and cellular invasiveness. In the remainder of the studies, the 
siRNA technique was used to elucidate specifically the role of CA9. 
 
5.3.3.1 Control experiments for siRNA treatment  
Several control experiments were prepared to test the specificity of the siRNA 
(siCA9), using: 1) untreated control cells, (2) mock-transfection (with only 
Oligofectamine 2000) and (3) unspecific target ―siControl‖ (Figure 5.4A&B). 
Expression of CA9 and nNav1.5 mRNAs were measured using real-time PCR using 
samples under normoxia (48 h after transfection) that represent the beginning of 
planned functional assay (Matrigel invasion assay). Samples to represent transfection 
when functional assays ended were incubated in hypoxia for another 24 h (72 h after 
transfection). CA9 and nNav1.5 mRNA expression levels were compared to 
untreated-control. These results showed that both CA9 and nNav1.5 mRNA 
expression levels were not affected by the control transfection procedures under both 
normoxia and hypoxia (P > 0.05, n = 3; Figure 5.4A&B). 
 
5.3.3.2 CA9 mRNA expression was reduced by siRNA under both normoxia and 
hypoxia 
CA9 mRNA expression was measured to confirm the knock-down of CA9 at mRNA 
level. Similarly, CA9 mRNAs were measured using real-time PCR using samples 
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Figure 5.4 CA9 siRNA reduced nNav1.5 and CA9 mRNA expression level under 
normoxia and hypoxia 
 
Control experiments for siRNA transfections: Untreated cell (UC), mock transfection 
(MT) and non-targeting transfection / siControl (siC) had no effect on CA9 and 
nNav1.5 mRNA expression levels under normoxia (A) and hypoxia (B). CA9 and 
nNav1.5 mRNA expression levels in of MT and siC were calculated by normalizing 
to UC data. (C&D) CA9 and nNav1.5 mRNA expression levels were reduced 
significantly after 48 h treatment with siRNA (siR) under 48 h normoxia (C) and 48 
+ 24 h hypoxia (D). Data are presented as means ± SEMs (n = 3 independent 
experiments for each condition) and were compared to Normoxia using unpaired 
Student t-test. (*) indicates statistical significance (P < 0.05); (x) indicates non-
significance (P > 0.05). 
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under normoxia (48 h after transfection) that represent the beginning of planned 
functional assay (Matrigel invasion assay) and samples to represent transfection 
when functional assays were finished were incubated in hypoxia for a further 24 h 
(72 h after transfection). CA9 mRNA level was reduced by the CA9 siRNA 
treatment under normoxia by ~84 % to 0.2 ± 0.08 –fold relative to siControl (P < 
0.05, n = 3; Figure 5.4C). Under hypoxia, CA9 mRNA was reduced by ~74 % to 0.3 
± 0.10–fold relative to siControl (P < 0.05, n = 3; Figure 5.4D).  
 
5.3.3.3 nNav15 mRNA was reduced by siRNA CA9 under both normoxia and 
hypoxia  
Using the same samples as above, nNav1.5 mRNA expression levels were measured 
in parallel with CA9 mRNA. nNav1.5 mRNA was reduced with CA9 siRNA under 
normoxia by ~92 % to 0.1 ± 0.01 –fold relative to siControl (P < 0.05, n = 3; Figure 
5.4C). Under hypoxia, nNav1.5 mRNA was reduced by ~ 85 % to 0.2 ± 0.07 –fold 
relative to siControl (P < 0.05, n = 3; Figure 5.4D).   
These experiments suggested (i) that the siRNA treatment did significantly 
reduce the target gene (CA9) expression and (ii) that nNav1.5 mRNA expression was 
also reduced significantly.  
 
5.3.3.4 CA9 protein expression was reduced with siRNA 
Western blot was conducted to confirm knock-down of CA9 with siRNA (siCA9) at 
protein level. The experiment was carried out using samples representing transfection 
cells (72 h after transfection) when functional assay was finished in hypoxia. Results 
of Western blot showed that in siCA9 cells, CA9 protein band intensity was reduced 
by ~ 40 % compared to siControl (Figure 5.5). 
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Figure 5.5 CA9 protein expression was reduced with siRNA under hypoxia 
 
Typical western blot carried out to determine the effect of siRNA on CA9 protein 
expression. 60 µg of total protein lysates was loaded in each lane. 1: 200 and 1:5000 
dilution factor of CA9 and actinin antibody was used respectively. Band intensity 
was measured using ImageJ. Histogram shows quantitative protein expression of 
CA9 normalized to actinin. These data are typical of 3 independent experiments. 
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5.3.3.5 Matrigel invasion was suppressed by CA9 siRNA  
Matrigel invasion assays were conducted on cells over 24 h, following 48 h 
transfection with CA9 siRNA (siCA9). Transfection of siCA9 did not affect number 
of MDA-MB-231 cells when cultured under normoxia or hypoxia (P > 0.05; n = 3, 
Figure 5.6A). On the other hand, Matrigel invasion was suppressed significantly by 
siCA9 by ~90 % to 10 ± 5.2 % (P < 0.01, n = 3; Figure 5.6B).  
 
5.3.4 Possible HRE consensus sites within the Nav1.5 promoter region  
In order to elucidate possible regulation of nNav1.5 by HIF-1α, we searched for 
possible HRE consensus ―CGTG‖ sites (Roland et al. 2005) using an online data 
base of published promoter region for Nav1.5 (Yang et al. 2004). We found 15 
possible, spread-out HRE consensus sequences that could be possible binding sites 
for HIF-1α (Figure 5.7). 
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Figure 5.6 siCA9 reduced Matrigel invasion without affecting the cell number  
 
(A) Cell number was measured according to MTT assay. Treatment with siRNA 
under normoxia and hypoxia did not alter the cell number when compared to 
untargeted siControl. (B) Invasion was carried under hypoxia for 24 h. Invading cells 
were stained with crystal violet and counted using a microscope. Invasion was 
reduced significantly by siRNA CA9 (siCA9). Data are presented as means ± SEM 
(n = 3 independent experiments for each condition) and were compared to Normoxia 
using unpaired Student t-test. (**) indicates high-level statistical significance (P < 
0.01); (x) indicates non significance (P > 0.05). 
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taggaagtgcctgtctccagacacctgttgcctgtctctgcactctgaggcctctctaggaccacaag
gtgtgcttttatggatgaacttctacaggttcagagctctggttccccatcccctgggcttctctccc
cctgtttaaattcagggtgcatgtagacttaccaggctcagcccacctctcctgctggcaacatccag
ttgcccaatactaaacaggagagtgaaaaccccacttctgctacatatggacggaagggaggcaggta
tccacccctactcccagcagcttctatcctagccttgtctcctgcttgacccaatgtcagtttgcaag
tagaagcttcattctgaggccgagaagcccgtgatggaagttcttaggggaggtaggaccttcctgct
actgtactctcctgcctggtaggtgtgactctgggaaggcggctgcacgtgggttgaaacgttgacac
tgcctgcacttccccttctggccgatagtgggagctgctagccaacctgaggctcgtcaggcgctaaa
ggctggcagccgacctgtgtggtccatccgtctgtaccccagacaccccactcaactcggggccggag
aggcccatgtcctgaactttcctgtggactgactttcctactgatcccctcctgcaagcagagcagcc
cctccgtatgtacctaaggcgtccaacgaagccccacacccaggtcgcaaacggacgctgtcccccac
ccccctctttgccctcccacctcttcaagatccccatcatggaggagcaggtcccagcctctgggctc
ccaaacccagcacctctgtgccctctgagaccctggcacccatttggctctctaagagcggttcttgc
ttttgggagccctgaaaatgtggcagaaaagtgtaccatcccttccaatgactgtacttttttcgtgg
gcaaaagctgatggcctgttttttgttgttgttttgttttgtttttgtttttgtttttagaagcgcaa
gatttattgtgaagagggaaagaacaaagcttccacagcgtggaaggggacccaagcgggttgccctg
atggcctgttttgtttaaacaagaagtgtgtccccataggtcctgggcatgggcatgggagcaactgt
ttgtcagcgtatgtctccgtgtgtgtgtgcctgtgaccatgtctctgagtgagaaacagtgggtgtgt
aagtatgtgactccaggctctgcatgtgtcaaggtgaaggttgtatgtggctcaagagggtggaagta
tatatataaagaggtatatacatgtatatatatgtatgtgtgtgtgtgtgtttgcgcgcgcgcgtgtg
tgggtgtctctgtgttggttgcctgcttgcttctgggtctgggtgtgtgtttggttctgtcagcatgt
gcgtccgtgtgttcaggtagatgtgtaccattgtgcagatttctgtggcatcactaagtgtgtctcca
ggaaagtgtggttcgagtgagtgtgtgtgtctctgtgtcagtgtgtcagtggatgtgtgtctaagtca
tgtgggtgtctaagtttgtcagagtgtcttcctcagtgtcagtgtgtgtcaatgatgtgtctgtctgt
gtctgtgtgggtgtgtgggggtgtgtatctgtctcagggtgcatgtgtgtgtctgtgtcagtgcaggt
atgcctatggcagcgtgtgtctgtctcggcatgagtgtcagtgtatgcccgtgtccacgtgggtgggt
gggtgtctggtagccttcccaagtcagcaaggttgcgtgtgtgtgtgtgtatactctggcgggtgctg
gtgtgtatgccagtgtttgttaatgtgagcctgtccgcgtccgcgtgggtggccatctgtggtgaagc
gtcgccgggtcgccgtgtgtgtacccccgcctatgtctgtctgtccgcggccgcgtgtgcggctgtct
gtggctgtgagcccccgggtcagtgtgggagtgtgcgccccggcgggcgctggtgtgtcccccctccg
agcgggcggagcaccacgtgcggagccctgggcgcgtcgctctggggcggagccagcccggggcccca
agccccaggccgaacccaggcggggcccgccccgaccccgcccccgaccccgcccccagcccgagccc
gcgccgcctgcccagcccgggagcccgaacagagccgcggagccgagacggcggcggcgcccgtagga
tgcagggatcgctcccccggggccgctgagcctgcgcccagtgccccgagccccgcgccgagccgagt
ccgcgccaagcagcagccgcccaccccggggcccggccgggggaccagcaggtgagcgagtgcccccg
cgcccggcagccctggcccggccggagccccctccgcctgccgccgcccaactttcctccccgagggc
cgaagcctccagtccctgcgtgctcctccctgccccgggtccgcccagccgctccctccccgatcagt
gccccagagagccggagggggagaaggggcgcagatccgcccggctggagggtatccccgggggagac
gtctctaaacaccgtgcgccccccttcccttccctttccttccgggtttcccggtgcgctgtcgaggg
ccgggggagggggagctgcggccccagcttcccggccatccctggcgcaggctcggggagggtctggg
attgggacccggataccggaggccggagaccccaaggtcagagcggcgactaggcgcgccatgaatgt
ggttccagagagcgg 
 
 
 
Figure 5.7 Possible consensus core HRE sites in the Nav1.5 promoter region  
 
The promoter region of human Nav1.5 (Yang et al. 2004) is in grey and the 
consensus core HRE sites (―CGTG‖) sites are indicated in yellow (Roland et al. 
2005). There are 15 possible binding sites for HIF-1α in the core Nav1.5 promoter 
region. 
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5.4 Discussion 
 
In the studies described in this chapter, the main findings were as follows: 
1. Treatment with 10 µM TTX did not affect CA9 mRNA expression. 
2. Treatment with 100 µM acetazolamide did not affect invasion.  
3. Acetazolamide (100 µM) reduced CA9 mRNA expression level under 
normoxia but not hypoxia. 
4. Acetazolamide did not affect nNav1.5 mRNA expression level under 
normoxia but did so under hypoxia. 
5. Silencing CA9 inhibited nNav1.5 mRNA expression and also significantly 
suppressed Matrigel invasion. 
 
5.4.1 HIF-1α, CA9 and nNav1.5 expression in normoxic and hypoxic MDA-MB-
231 cells  
HIF-1α expression has been shown to be present in invasive BCa cells, including the 
MDA-MB-231 cell line, even when cultured under normoxic conditions (Cooper et 
al. 2004; Robey et al. 2005; Zia et al. 2007). As in previous studies, we detected HIF-
1α protein expression in MDA-MB-231 cells under normal culture conditions 
(Chapter 4, Section 4.3.2; Figure 4.5A). It has been shown that loss of the VHL 
tumour suppressor gene, which is important in the degradation of HIF-1α when the 
O2 level is sufficient, associates with hypoxia-independent HIF-1α expression in 
cancer cells such as in renal cancer and BCa (Hartman et al. 2010; Banumathy & 
Cairns 2010; Vickers & Heng 2010). Indeed, loss of VHL was reported to stabilize 
HIF-1α in MDA-MB-231 cells (Zia et al. 2007), leading to a basal level of HIF-1α 
expression in this cell line under normoxia.  
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It has been estimated that at least 1 – 1.5 % of the human genome could be 
regulated by HIF-1α (Denko et al. 2003; Gardner & Corn 2008). One of the 
immediate HIF-1α target genes is CA9 and, indeed, HIF-1α-response element (HRE) 
has been identified in the promoter region of the CA9 gene (Wykoff et al. 2000). 
Furthermore, several studies have reported co-localization of HIF-1α and CA9 
expression in cancer, including in BCa, cells in vitro and in vivo (Generali et al. 
2006; Chia et al. 2001; Bui et al. 2003; Giatromanolaki et al, 2001; Olive et al, 2001; 
Loncaster et al. 2001; Chen et al. 2005; Turner et al, 2002; Hui et al, 2002; 
Haapasalo et al. 2006). High-level expressions of both HIF-1α and CA9 have been 
associated with invasiveness and poor prognosis in BCa (Lou et al. 2011). Similarly, 
upregulation of functional expression of VGSC (nNav1.5) has been shown to play an 
important role in potentiating BCa invasiveness (Fraser et al. 2005; Brackenbury et 
al. 2007). Consistently, simultaneous expression of HIF-1α, CA9 and nNav1.5 were 
detected in the strongly metastatic MDA-MB-231 cells under normoxia. Importantly, 
when these cells were exposed to hypoxia, the expression of all three factors (HIF-
1α, CA9 and nNav1.5) were increased in concert, and cellular invasiveness was 
enhanced. This result indicated that HIF-1α, CA9 and nNav1.5 could be in a 
biochemical network controlling the invasive behaviour of BCa cells.  
High levels of HIF-1α expression in hypoxic cancers have already been 
demonstrated to strongly correlate with acquisition of metastatic potential in vivo 
(Semenza 2009). In vitro, hypoxia-induced enhancement of cancer cell invasiveness 
was most likely through HIF-1α-induced metastatic genes (Santhanam et al. 2010; 
Cronin et al. 2010; Tafani et al. 2010). It follows from the present study that one such 
novel gene in MDA-MB-231 cells is neonatal SCN5A (nNav1.5).  
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Association of HIF-1α and nNav1.5. There is evidence that in HIF-1α-
partial deficient mice, the carotid body response to hypoxia was deficient (Kline et 
al. 2002). Given that VGSC also plays an important role in the response of the 
carotid body to hypoxia, the study of Kline et al. (2002) would indicate that HIF-1α 
could play a role in regulating VGSC expression/activity. Indeed, several other 
studies have reported increased expression and activity of VGSCs after prolonged 
(>24 h) exposure to hypoxia (Xia et al. 2000; Zhang et al. 2001; Zhao et al. 2004; 
Zhao et al. 2005). In one such study, increased expression of several types of VGSC 
(Nav1.1, Nav1.2, and Nav1.3) was observed in CA1 neurons of mice after 4 weeks 
exposure to hypoxia (Zhao et al. 2004). Generally, transcriptional induction by HIF-
1α would start by its binding to HRE / ―CGTG‖ sites of target genes (Semenza & 
Wang 1992). Previously, the promoter region for Nav1.5 has been published by 
Yang et al. (2004) and according to their sequence, 15 possible consensus ‗core‘ 
HRE / ―CGTG‖ sequences that could be possible HIF-1α binding sites could be 
revealed (Figure 5.8). Taken together, from the available data, we can conclude that 
nNav1.5 is a likely target of HIF-1α, leading ultimately to increased invasiveness of 
hypoxic BCa cells. 
Association of CA9 and VGSC. Previously, Gillet et al. (2009) and Roger et 
al. (2007) demonstrated that the functional upregulation of VGSCs in MDA-MB-231 
cells and small-cell lung cancer cells (H460) would promote invasion through the 
activity of pH-dependent cathepsin. There is also evidence that the VGSC (Nav1.5) – 
mediated Na
+
 permeation could control BCa cell invasiveness by increasing the 
activity of pH regulator, NHE (Brisson et al. 2010). In particular, Brisson et al. 
(2010) demonstrated that blocking Nav1.5 activity with TTX and siRNA reduced the 
activity of NHE1 and suppressed invasion. NHE1 has been shown to play a role in 
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regulating the pHi as to maintain it as near to normal as possible by extruding excess 
H
+
 produce by the metabolically active cancer cells into the extracellular 
environment (Harguindey et al. 2005). Accordingly, active H
+
-extruding by NHE1 
would facilitate intracellular acidosis (Sennounce et al. 2004). However, VGSC 
activity, in the first instance, would be expected to slow down NHE1 activity, acidify 
pHi and increase ―H+ efflux‖, especially as Nav1.5 and NHE1 were shown to co-
exist in caveola (Brisson et al. 2010). However, instead, TTX and siRNA were found 
to reduce H
+
 efflux (Brisson et al. 2010). This would imply that VGSC activity 
would promote H
+
 efflux for which NHE1 alone could not be responsible. Assuming 
that it was enhanced ―H+ trapping‖ that stimulated the acidic-mediated proteases 
(such as cystein-cathepsin and MMP-9) and promoted invasiveness, there must be 
additional mechanisms involved in the presumed VGSC-mediated activation of 
proteases. In particular, the role of CA9 and/or MCT in this process would be 
worthwhile investigating. 
 
5.4.2 CA9 also plays a role in MDA-MB-231 cells invasion  
Several studies have shown that nNav1.5 plays a role in potentiating invasiveness of 
the strongly metastatic BCa, MDA-MB-231 cells (references given in Chapter 1). 
We have found that under hypoxia, which enhanced invasiveness, also upregulated 
nNav1.5 mRNA expression (Chapter 4). With increasing evidence that CA9 could 
also play a role in cancer invasion, in order to elucidate the role of CA9 in 
invasiveness of hypoxic BCa cells, first, a classic general CA inhibitor, 
acetazolamide, was used.  
Acetazolamide was shown earlier to inhibit in vitro invasion of renal cancer 
(Parkkila et al. 2000) and in vivo metastasis of Lewis lung cancer in mice (Xiang et 
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al. 2002). In contrast, our results demonstrated that 100 μM acetazolamide had no 
effect on Matrigel invasion of MDA-MB-231 cells. Furthermore, acetazolamide had 
no effect on CA9 mRNA expression. The most likely reason for these lacks of effects 
is the sensitivity of CA9 to 100 µM acetazolamide. Parkkila et al. (2000) 
demonstrated that 10 µM acetazolamide suppressed invasion of renal cancer cell 
lines that expressed CA2 and CA12 but not in renal cancer cell line (A-498) 
expressing CA9. Similarly, Robertson et al. (2004) demonstrated that invasion of 
CA9-overexpressing BCa cell lines was not suppressed by 100 µM acetazolamide. 
Previously, in an extensive review on CAs and its inhibitors by Supuran (2008), the 
dissociation constant of the enzyme-inhibitor (Ki) of CA9 for acetazolamide was 
reported to be ~4x and ~2x higher than CA12 than CA2, respectively. Thus, it would 
appear (i) that CA9 is not so sensitive to acetazolamide (Lou et al. 2011) and (ii) that 
CA9 is the main CA expressed and controlling invasiveness in MDA-MB-231 cells. 
In order to further examine the role of CA9 in BCa invasion, small-interference RNA 
(siCA9) was used to knock-down CA9 expression. Real-time PCR and Western blots 
showed that CA9 mRNA and protein expression levels were successfully reduced by 
the siCA9 by >70 % and ~40 %, respectively. Importantly, invasion of siCA9-treated 
cells was suppressed significantly by ~ 90 %, compared with the siControl-treated 
cells.  
Over-expression of CA9 in hypoxic cells has been associated with the ability 
of CA9 to acidify pHe (Svastova et al. 2004). In turn, acidic pHe has been shown to 
correlate positively with increased cancer cell invasion (Gatenby et al. 2006; Rofstad 
et al. 2006; Robey et al. 2009; Martin et al. 2010). Recently, an extensive in vitro and 
in vivo study showed that treatment with sulphonamide-based specific inhibitors for 
CA9 and stable depletion of CA9 expression (by shCA9) in the mouse metastatic 
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BCa 4T1 cell line resulted in inhibition of hypoxia-induced acidification of pHe (Lou 
et al. 2011), When the shCA9-4T1 cells were injected into mice or when 
sulphonamide-based inhibitors were given to mice after intravenous injection of 4T1 
cells, formation of lung metastases was repressed. These results, taken together with 
the present data on MDA-MB-231 cells suggest that upregulation of CA9 is a 
significant event in hypoxia-induced enhanced invasiveness of BCa cells.  
 
5.4.3 CA9 vs CA12 in BCa 
Amongst the various known CAs, CA9 has high catalytic activity with the highest 
known proton transfer rate (Wingo et al. 2001). The catalytic domain of CA9 is 
situated outside the cell and possesses a high CO2 hydrase catalytic activity. These 
characteristics make CA9 an ideal potential player in the regulation of tumour pH 
(Hilvo et al. 2008). However, another surface membrane CA, namely CA12, 
expression can also be induced by hypoxia (Ivanov et al. 2000) and has been 
associated with BCa (Hsieh et al. 2010). In BCa, an in vivo study showed that high-
level expression of CA9 is associated with triple-negative BCa and this correlated 
with poor prognosis (Rakha et al. 2009). On the other hand, expression of CA12 in 
BCa tissue was associated with ERα-positive status (Gruvberger et al. 2001; van‘t 
Veer et al. 2002; Tozlu et al. 2006) which accounts for lower grade disease, lower 
relapse rates and better overall patient survival (Wykoff et al. 2001; Watson et al. 
2003; Creighton et al. 2006). Importantly, in ERα-expressing BCa (MCF-7 and T-
47D) cells, CA12 gene expression was shown to be robustly stimulated by estradiol 
(E2) cells via hormone-responsive enhancer located at 6 kb upstream of the start site 
of transcription of the CA12 gene (Barnett et al. 2008). Interestingly, when MCF-7 
cells were exposed to hypoxia, regional loss of ERα expression occurred and CA9  
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expression was induced (Cooper et al. 2004).  
In several studies using the highly metastatic and ERα negative cell line, 
MDA-MB-231 cells, hypoxia has been shown to solely induce surface-membrane 
CA9 expression (Li et al. 2009; Li et al. 2010; Li et al. 2011). However, in one recent 
report, CA12 expression was shown to be higher than CA9 and that knocking down 
CA12 decreased the invasion and migration capability of these cells (Hsieh et al. 
2010). Furthermore, there was also a report that CoCl2-induced hypoxia had no effect 
on CA9 protein expression in MDA-MB-231 cells (Chen et al. 2010). The plausible 
reason for the disparity between reports could be ―genetic drift‖ (Masramon et al. 
2006). Genetic drift or genetic instability is the change in the frequency of gene 
variant in population due to random sampling. The phenomenon has been considered 
to have a key role in the generation of genetic and phenotypic heterogeneity in 
cancer cells (Masramon et al. 2006). The MDA-MB-231 cells used in the study of 
Hsieh et al. (2010) were cultured in 10 % FBS whilst the cells used in our 
experiments had been maintained in 5 % FBS over long time. The biochemistry of 
the culture medium has been shown to be critical for the expression of the metastatic 
machinery in cancer cells (Pan & Djamgoz 2008). Indeed, it is also known that 
increasing FBS concentration from 5 to 10 % greatly reduces functional VGSC 
(nNav1.5) expression in MDA-MB-231 cells (S.P. Fraser, personal communication). 
The acute sensitivity of cancer cells to the chemical constitution of their environment 
reflects the importance of tumour-stroma interactions in cancer progression (Karnoub 
et al. 2007).    
Taken together, we concluded that in BCa, expression of CA9 vs. CA12 
would be determined by differentiation, tumour grade, tumour subtype, phenotypic 
heterogeneity and culture conditions. Both CA9 and CA12 can be considered to play 
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a dynamic role in regulating pH in cancer cells. Indeed, in a xenograph model of 
colon cancer, shRNA-mediated depletion of CA9 expression resulted in a partial 
reduction in tumour growth and compensatory upregulation of CA12 (Chiche et al. 
2009). Conversely, depletion of expression of both proteins resulted in greater 
inhibition of tumour growth, suggesting that both CA9 and CA12 are important for 
the regulation of tumour growth under hypoxia (Chiche et al. 2009).  
 
5.4.4 CA9-VGSC (nNav1.5) interaction 
When CA9 expression was suppressed by siRNA (siCA9), nNav1.5 mRNA level 
was also reduced and invasion was also greatly suppressed. The question arose, 
therefore, of a possible association of VGSC and CA9 in BCa. We considered two 
models to help in the discussion: 1) a serial model and (2) a parallel model (Figure 
5.8). In the serial model, VGSC and CA9 would interact in series to control MCBs. 
The serial model was divided into two possibilities, depending on the order of the 
involvement of VGSC and CA9: A) CA9 expression/activity controlling VGSC 
activity/expression; and (B) VGSC expression/activity controlling CA9 
expression/activity. In the parallel model, we postulated that CA9 and VGSC operate 
in two separate pathways and control MCBs independently. In the previous chapter, 
under hypoxia, suppression of invasion by 10 µM TTX was accompanied by 
downregulation of nNav1.5 mRNA and protein expression (Section 4.3.6.4 and 
4.3.7.1). In this present chapter, applying similar concentration of TTX also 
suppressed invasion of hypoxic MDA-MB-231 cells but did not affect CA9 mRNA 
expression. This result would suggest that CA9 expression/activity is independent or 
upstream of VGSC expression/activity. Therefore, serial model (A) can be excluded.  
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On the other hand, knock-down of CA9 (by siCA9) in MDA-MB-231 cells 
also down-regulated nNav1.5 mRNA expression in both normoxia and hypoxia. 
Again, these results suggest that CA9 is upstream of nNav1.5 in the control of 
invasiveness. Thus, the serial model (B) is a possibility. However, the parallel model 
cannot be ruled out at present, since this could still involve a positive effect of CA9 
on VGSC (nNav1.5) expression/activity (dotted line in Figure 5.8). We should note 
that there have been reports on extracellular acidosis inhibiting VGSC current in 
normal neurons and muscles (Benitah et al. 1997). It is possible that the oncogenic 
VGSC behaves differently. It is generally accepted that hypoxic cancer cells have 
increased tolerance to acidification (pH ~6.8) that not only allows them to survive 
and proliferate but also facilitates invasiveness (Helmlinger et al. 1997; Chiche et al. 
2009; Li et al. 2011). Evidently, the idea that the ‗neonatal‘ channel (nNav1.5) re-
expressed in highly metastatic BCa has higher tolerance to hypoxia/low pHe was 
supported in this present study, when increased expression of nNav1.5 in hypoxic 
MDA-MB-231 cells was observed. In addition, the idea was also supported by their 
high-level expression and activity in metastatic BCa cells and tissues (Fraser et al. 
2005). Indeed, a recent study showed that blocking VGSC activity can counteract the 
depolarizing effect of anoxia on membrane potential, i.e. functional VGSC 
expression can facilitate the cells‘ response to metabolic stress (Douglas et al. 2011). 
 
5.5 Concluding remarks 
 
In this chapter, we demonstrated that nNav1.5 expression was dependent on CA9, in 
accordance with the following basic scheme: 
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Normoxia → Hypoxia → CA9 ↑ → nNav1.5↑ → Invasion 
 
However, the functional association of CA9 with VGSC (nNav1.5) is likely to 
complex and dynamic but would be worthy of further investigation. 
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Figure 5.8 Possible schematic models of functional association between CA9 and 
nNav1.5 in control of invasiveness  
 
Model (1) is ―serial‖; model (2) is ―parallel‖. In the serial model, VGSC and CA9 
interact in series to control invasiveness. The serial model was divided into two 
possibilities, depending on the order of the involvement of VGSC and CA9: (A) CA9 
expression/activity controlling VGSC activity/expression; and (B) VGSC 
expression/activity controlling CA9 expression/activity. In the parallel model, CA9 
and VGSC operate in two separate pathways and control invasiveness independently; 
however, an interaction between the two (dotted line) is still possible. 
 
 
 
 
 
 
Model 1: Serial 
 
 
A) 
 
 
 
 
B) 
 
 
 
 
Model 2: Parallel  
 
 
 
 
 
 
 
Normoxia → Hypoxia → VGSC ↑ → CA9 ↑ → Invasion 
Normoxia → Hypoxia → CA9 ↑→ VGSC ↑ → Invasion 
Normoxia → Hypoxia  
VGSC ↑ 
CA9 ↑ 
Invasion ↑ 
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Chapter 6 
 
GENERAL DISCUSSION AND CONCLUSION 
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The present study aimed to investigate the role of voltage-gated Na
+
 channel 
(VGSC), ‗neonatal‘ Nav1.5 (nNav1.5), expression/activity in metastatic cell 
behaviours (MCBs) of human breast cancer (BCa). The MDA-MB-231 cell line was 
used as a model. The central emphasis was the VGSC persistent current (INaP) and its 
inhibition by non-toxic drugs. Thus, the following main results were obtained: 
 
1. The general VGSC blocker, tetrodotoxin (TTX) suppressed MCBs (lateral 
motility, transverse migration and Matrigel invasion) significantly without 
affecting growth. These effects were accompanied by down-regulation of 
nNav1.5 mRNA and protein expression. These data confirmed that VGSC 
(nNav1.5) activity controlled (enhanced) both MCBs and the VGSC‘s own 
expression. 
2. Local anesthetics (lidocaine and procaine) and INaP blockers (ranolazine and 
riluzole), all at clinical doses, also suppressed MCBs and down-regulated 
nNav1.5 mRNA and/or protein expression. 
3. Hypoxia enhanced VGSC-dependent MCBs significantly with an accompanying 
increase in nNav1.5 expression mRNA.  
4. The effects of ranolazine and riluzole in suppressing MCBs were generally 
greater, compared with normoxia, consistent with (i) hypoxia promoting INaP and 
(ii) INaP being the main VGSC component responsible for the enhancement of 
MCBs. 
5. Hypoxia induced expression of the pH regulator, carbonic anhydrase 9 (CA9) 
and enhanced MCBs. 
6. Acetazolamide had no effect on invasiveness of hypoxic MDA-MB-231 cells or 
CA9 mRNA expression.  
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7. Silencing CA9 with siRNA (siCA9) suppressed nNav1.5 mRNA expression and 
invasiveness of hypoxic MDA-MB-231 cells. 
 
Overall, therefore, these studies demonstrated that BCa metastasis in hypoxia 
is controlled, at least in part, by an intricate functional ‗network‘ involving nNav1.5 
and CA9 (Figure 6.1). 
 
6.1 High-level VGSC expression / activity can serve as the basis of a novel target 
for suppressing metastatic BCa  
Worldwide, BCa is the second most common human cancer and fifth in the causes of 
death amongst cancer patients (McPherson et al. 2000; Cronin et al. 2010). The 
majority of BCa- related deaths are a result of
 
complications resulting from recurrent 
(e.g. drug resistant) or metastatic disease. In addition, the adverse effects of 
chemotherapy sometimes can be highly invasive and some BCa patients can have 
low tolerance to treatment. At present, there is much interest in targeting cancer cells 
with a view to promoting programmed cell death - apoptosis. However, many 
available anti-cancer agents, including some standard therapies, end up also killing 
healthy cells. Accordingly, research increasingly is aiming to target / prevent 
metastasis. This necessitates understanding the mechanisms underlying MCBs. In 
this regard, VGSC (nNav1.5) expression / activity constitutes a novel clinical target 
(Onkal & Djamgoz 2009).  
There is increasing evidence suggesting epigenetic up-regulation of VGSC 
expression/activity in metastatic human cancers, including BCa, prostate cancer 
(PCa), lung cancer (small-cell, non-small-cell and mesothelioma), ovarian cancer, 
cervical cancer and colon cancer (Grimes et al. 1995; Laniado et al. 1997; Abdul &  
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VGSC / INaP
Metastatic cell 
behaviours
HYPOXIA CA9
 
Figure 6.1 Interaction of VGSC and other components in promoting breast 
cancer metastasis  
 
In metastatic BCa cells, high-level expression and activity of VGSC (nNav1.5) were 
shown to play a role in promoting MCBs. In particular, INaP appeared to be 
responsible for promoting invasiveness. As a solid cancer, BCa would ultimately 
develop hypoxia which would enhance INaP. Hypoxia may also increase the 
expression of CA9 that would further promote MCBs. The suggested functional 
interactions are likely to be dynamic, depending upon 'dose' and duration.    
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Hoosein 2002; Roger et al. 2003; Diss et al. 2005; Fraser et al. 2005; Onganer & 
Djamgoz 2005; Brackenbury & Djamgoz 2006; House et al. 2010). Mostly using the  
highly specific VGSC blocker natural toxin, tetrodotoxin (TTX), inhibition of VGSC 
activity has been shown to lead to suppression of MCBs. Importantly, TTX 
suppressed MCBs significantly without any affect on the cancer cell growth (i.e. 
proliferation), consistent with primary and secondary tumourigenesis being 
controlled differently (Welch 2004; Welch 2006; Onkal & Djamgoz 2009). 
In BCa, VGSC expression and activity have been found not only in vitro but 
also in vivo (Fraser et al. 2005). As well as suppressing MCBs, TTX also down-
regulated nNav1.5 expression. This was confirmed in the present study and, in 
agreement with other reports, the findings further suggested that VGSC blockers 
could be beneficial as suppressors of metastatic BCa. In fact, VGSC blockers are 
now becoming an appropriate agent for targeting metastasis (Onkal & Djamgoz 
2009). More generally, VGSC blockers have already been found to be safe and 
useful as drugs for diverse clinical applications where abnormal excitability of tissue 
leads to pathological dysfunction e.g epilepsy, heart diseases. Indirectly, a number of 
studies have shown that application of local anesthetics during surgical resection of 
cancers can decrease reoccurrence and metastasis (Exadaktylos et al. 2006; Biki et al. 
2008). In the present study, two common local anesthetics; lidocaine and procaine 
were demonstrated to suppress MCBs of MDA-MB-231 cells without affecting 
cellular viability or proliferative activity, similar to TTX. Furthermore, suppression 
of MCBs by both drugs was accompanied by down-regulation of nNav1.5 mRNA 
expression.  
There are also several anti-epileptics / anti-convulsants (e.g phenytoin, 
carbamazepine, hydroxyamides and hydantoin) that are VGSC blockers that could 
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serve as anti-metastatic drugs (Abdul & Hoosein 2001; Anderson et al. 2003). In the 
present study, two novel VGSC blockers were used: riluzole, a drug to treat 
amyotrophic lateral sclerosis (ALS) (Besimon et al. 1994; Lacomblez et al. 1996; 
Meininger et al. 2000) and ranolazine (an anti-angina drug) (Antzelevitch et al. 2004; 
Siddiqui & Keam 2006). Both drugs were shown to suppress lateral motility, 
transverse migration and invasion of MDA-MB-231 cells. Ranolazine caused 
suppression of MCBs without affecting the cell growth and was not cytotoxic. 
Suppression of MCBs by ranolazine was accompanied by down-regulation of 
nNav1.5 mRNA and protein expression. Riluzole also suppressed MCBs and down-
regulated nNav1.5 expression, similar to ranolazine and TTX. However, at 
concentrations higher than 10 µM, riluzole also reduced cell viability and cell 
number. Interestingly, riluzole is already in clinical trial for melanoma and BCa and 
the trials are still ongoing (Yip et al. 2009; http://www.cancer.gov/clinicaltrials).  
Thus, the strategy for targeting VGSCs in cancers using anti-convulsant or 
blockers arrhythmia could be promising. However, in such a strategy, serious 
precautions must be taken in order to protect other VGSC-expressing normal, 
‗excitable‘ cells such as neurones and muscles. We demonstrated that lidocaine, 
procaine, ranolazine and riluzole suppressed MCBs of MDA-MB-231 cells at 
concentrations close to the effective
 
therapeutic plasma concentrations as in 
anesthesia, chronic-angina and ALS (Chaitman et al. 2004a; 2004b; Mohammadi et 
al. 2002). 
In addition, electrophysiologically, nNav1.5 inactivation is much slower than 
the normal/adult cardiac Nav1.5 (Onkal et al. 2009). In this present study, we showed 
pharmacologically that the VGSC (nNav1.5) persistent current (INaP) plays a 
significant role in promoting MCBs. Accordingly, targeting INaP would be a much 
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safer strategy than targeting the transient component responsible for heart beat. 
Indeed, INaP inhibitors, ranolazine and riluzole, have been shown effectively to inhibit 
pathologically enhanced INaP (as in cardiac ischemia and ALS) with very small side 
effects (Saint 2008; Maier 2009; Weiss & Saint 2010; Reddy et al. 2010; Weiss et al. 
2010). In this study, both ranolazine and riluzole were shown to suppress MCBs at 
concentrations around the IC50‗s for INaP.  
Taken together, these findings would suggest that clinically acceptable doses 
of lidocaine, procaine, ranolazine and riluzole could be beneficial to BCa patients 
and other carcinomas expressing high levels of VGSC activity.  
 
6.2 Appropriateness of drugs with greater effect on hypoxic BCa  
The hypoxia-induced factor (HIF-1α) and CA9 have already been established as 
‗prognostic markers‘ for tumour hypoxia in several carcinomas including BCa 
(Tomes et al. 2003; Vleugel et al. 2005; Brennan et al. 2006; Tan et al. 2009). Our 
present findings would suggest strongly that nNav1.5 could be added to this list for 
metastatic BCa. The discovery of drugs that could selectively target cancer cells (and 
not normal cells) is very important. At the moment, the steroid hormone receptor and 
growth factor receptor expression status have helped greatly in developing targeted 
therapies for BCa patients. For example, tamoxifen (against estrogen receptor) and 
Herceptin / traszumab (against HER-2) have been proven to be highly effective in 
improving BCa therapy and are widely used. In recent years, ‗bioreductive‘ drugs 
such as tirapazamine that exploit cancer hypoxia have also been receiving attention. 
These drugs are activated by reductive enzymes (reductase) present in a hypoxic 
environment thus generating toxic metabolites that cause damage and death 
selectively to (hypoxic) cancer cells (Mckeown et al. 2007). Tirapazamine has been 
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in clinical trial as an experimental drug in combination with other chemotherapeutic 
drugs (e.g cisplatin) for non-small cell lung carcinoma, head and neck cancer and 
cervical cancer (Rischin et al. 2010a; Rischin et al. 2010b). On the whole, the clinical 
trials just ended recently. The combination of tirapazamine and cisplatin with 
radiation for locally advanced cervical cancer was associated with more toxicity but 
not for head and neck cancer. 
In the second result chapter of this thesis, we showed that when MDA-MB-
231 cells were exposed to hypoxia, their MCBs were enhanced significantly. The 
increase in MCBs was accompanied consistently by raised nNav1.5 mRNA and 
reduced VGSC-β1 mRNA expression levels. The endogenous hypoxia markers HIF-
1α and CA9 were also increased during hypoxia. Thus, HIF-1α, CA9 and nNav1.5 
have all been shown to be involved in metastatic BCa.  
Of particular interest is increased INaP during hypoxia. In the cardiac muscle, 
neurons and carotid body cells, hypoxia was shown to increase INaP amplitude (Ju et 
al. 1996; Hammarstrom & Gage 1998; Kawai et al. 1999; Horn & Waldrop 2000; 
Mironov and Langohr 2005; Paton et al. 2006; Saint 2006; Faustino et al. 2006; 
Wang et al. 2007; Weiss et al. 2010; Weiss & Saint 2010). A similar effect was 
found for human Nav1.5 INaP over-expressed in HEK293 (Fearon & Brown 2004). 
The enhanced INaP amplitude has been shown to play a pathological role in heart 
diseases (e.g. cardiac ischemia and LQT syndrome), and a similar situation is likely 
to occur during BCa progression. Several pharmacological agents, at appropriate 
doses, have been found to selectively inhibit INaP; these include ranolazine and 
riluzole (Saint 2008; Maier 2009; Weiss & Saint 2010; Reddy et al. 2010; Weiss et 
al. 2010). In MDA-MB-231 cells, similar to cardiac myocytes, hypoxia was 
demonstrated to increase INaP (Onkal 2010). Furthermore, the tendency for these 
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agents to exert greater inhibitory effects on MCBs under hypoxia, compared with 
normoxia, would suggest that both INaP blockers could be clinically viable as drugs 
effective against metastatic (hypoxic) BCa.  
This thesis is first to test the possibility of exploiting INaP as an inhibitor of 
MCBs in metastatic BCa, in vitro. We have shown that ranolazine increased single-
cell adhesion ~10-fold more effectively under hypoxia cf. normoxia. The effects of 
ranolazine and riluzole on lateral motility and transverse migration were also greater 
under hypoxia. From these results, we concluded (1) that INaP plays a significant role 
in enhancing MCBs in BCa and (2) that specific INaP inhibitors, ranolazine and 
riluzole, could be useful as drugs for suppressing BCa progression under hypoxic 
conditions. This would complement the use of INaP blockers as therapeutic agents 
against other VGSC-associated diseases, such as angina (cardiac ischemia), LQT3 
syndrome and ALS (Maier 2009; Weiss & Saint 2010; Weiss et al. 2010).  
 
6.3 Possible link between Na
+
 influx and MCBs related to Ca
2+
 transport 
In the CELEX hypothesis discussed earlier in the thesis, increased 
activity/expression of VGSC and concurrent downregulation/loss of outward current 
due mainly to voltage-gated potassium channels (VGPC) are suggested to drive the 
aggressiveness/hyperactivity of metastatic cancer cells, putting forward Na
+
 as the 
main regulator in cancer metastatic transformation.  However, Ca
2+
 has also now 
been accepted to be one of the crucial regulators of cancer migration and invasion, 
although the sources of Ca
2+
 and the mechanism by which it modulates cancer 
metastasis are still in the beginning to be understood.  
Ca
2+
-dependent mechanism of malignant migration, aberrant expression of 
Ca
2+
-handling proteins and/or Ca
2+
-dependent effectors, leading to the increased 
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turnover of focal adhesions and more effective proteolysis of ECM components play 
a part in aggressive transformation (Prevarskaya et al. 2011). In MDA-MB-231 cells, 
there have been several reports on increased expression of Ca
2+ 
channels. These 
channels are involve in the calcium influx such as L-type voltage-gated calcium 
channels which is activated through plasma membrane depolarization (Yang & 
Huang 2005) and store-operated calcium channels (SOC) STIM1– ORAI1 that is 
activated by receptor-activated Ca
2+
 store depletion (Yang et al. 2009). Whilst 
expression of calcium channels involve mainly in calcium release in this cell line was 
reported to be ryanodine receptor (RYR) which is activated by cADPR-induced 
release (Mueller et al. 1999). All of these channels were linked with in vitro BCa 
increased aggressiveness. As for Na
+
/Ca
2+
exchange (NCX), although, there have 
been reports on a noteworthy level of NCX expression in cancer cells e.g ovarian 
cancer cell lines (Marian et al. 2007) however, as in MDA-MB-231 cells there have 
been no reports yet.  
Nevertheless, we speculated that the increased activity of VGSCs in 
metastatic BCa would be similar to cardiac ischemia. During cardiac ischemia, the 
increased [Na]i (especially through INaP) reduces the electrochemical energy gradient 
available to the NCX, leading to decreased Ca
2+
 extrusion from the cell or in extreme 
cases, reversal of NCX. Both situation would ultimately leads to Ca
2+
 overload (the 
‗coupled exchanger' hypothesis (Lazdunski et al. 1985)). Increased Ca2+ loading 
increases SR calcium to the point where the SR ‗overflows' and produces 
spontaneous oscillatory Ca
2+
 release, which activates NCX. Since NCX is 
electrogenic (Kang and Hilgemann, 2004) under these conditions it can produce 
membrane currents powerful enough to generate arrhythmias (Verkerk et al. 2000; 
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Szabo et al. 1994). In the case of BCa, these membrane currents are speculated to 
drive cancer cells to become more agreesive.  
Indeed, by using calcium channel blockers e.g verapamil, modulation of 
Ca
2+
-dependent signaling pathways in cancer metastasis could be determined. For 
example, treatment with verapamil has demonstrated that Ca
2+
-dependent signaling 
pathways regulate tumor- or host-dependent production of proteases and tumor cell 
proliferation (verapamil inhibit the development of BCa metastasis in vitro and in 
vivo (Farias et al. 1998; Todaro et al. 2003). However, in another report, with regards 
to VGSC, 100 uM verapamil (over IC50 at 37.6 ± 2.5 μM) inhibit VGSC current 
totally in MDA-MB-231 cells but have no effect on other ionic channels except 
VGSC (Roger et al. 2004). This finding is interesting because for the first time they 
recommended that electrophysiology analysis is needed in experiments to confirm 
mechanism of action of verapamil (or other drugs) on [Ca
2+
]i (or any ionic current) 
blocking. 
 
6.4 Possible link of carbonic anhydrase-9 with VGSC particularly nNav1.5 in 
BCa metastasis 
The adaptation of cancer cells to hypoxia has been shown to result in increased 
aggressiveness. In fact, acidosis of the tumour extracellular environment is a 
condition that is closely related to hypoxic cancer cell invasiveness. During hypoxia, 
in solid cancers, such as BCa, components of the pH-regulator system, e.g Na
+
/H
+
 
exchanger (NHE), monocarboxylic transporter (MCT) and CA9, have been shown to 
be up-regulated and these serve to re-set the pH balance of the cancer cell. The net 
effect is acidification of the pericellular space which, in turn, can facilitate cancer 
cell invasiveness by activating enzymes that digest the extracellular material. 
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With regard to VGSC, previously, Nav1.5 was reported previously to 
increase the activity of NHE1 and thus induce acidosis and promote invasion via 
increase activity of the pH-driven cathepsin (Brisson et al. 2010). The surface 
membrane-CA9 also has been reported to play a role in acidification of the tumour 
extracellular environment. CA9 efficiently catalyzes the hydration of CO2 to 
bicarbonate (HCO3
-
) and H
+
. Accordingly, we showed that inhibition of CA9 by 
gene silencing indeed reduced the invasiveness of hypoxic MDA-MB-231 cells. This 
effect established a clear-cut role for CA9 in BCa metastasis. Furthermore, CA9 
expression/activity was found to be important in promoting the expression/activity of 
nNav1.5. Thus, indeed, CA9 and nNav1.5 are parts of a biochemical network 
promoting metastatic BCa (Figure 6.1).  
 
6.5 Future perspectives 
The present study has raised many questions and may be extended further, for 
example, as follows:  
1. Other VGSC / INaP blockers, including drugs (e.g. gabapentin; Devulder et al. 
2001) and those from nutritional and natural sources (e.g. resveratrol; Athar et al. 
2009; Tang et al. 2008a; Tang et al. 2008b) may be tested. 
2. The mRNA-based studies on the VGSC blockers/drugs can be extended to 
protein and signaling levels, including mode of action studies (e.g. Yip et al. 
2009).  
3. The role of pH (intracellular and pericellular) can be studied by pH measurement 
and imaging (e.g. Swietach et al. 2009). 
4. The role of CA12 in BCa metastasis can be studied (e.g. Barnett et al. 2008). 
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5. The presumed intermediary role of HIF-1α in regulating nNav1.5 expression 
under hypoxia can be tested by silencing HIF-1α (e.g. Park et al. 2011). 
6. Effects of different regimes of hypoxia (from acute to chronic) can be studied.  
7. The proposed functional association of nNav1.5 and CA9 can be studied by 
knocking down nNav1.5 expression.  
8. The in vitro studies of the VGSC blockers can be extended to in vivo testing, e.g. 
by xenografts (e.g. Dubois et al. 2009). 
9. The in vitro and in vivo studies can be placed in a clinical setting by studies on 
co-localization of nNav1.5, HIF-1α and CA9 in human BCa tissue biopsy 
samples (Fraser et al. 2005; Rakha et al. 2009). 
 
It would be of a great interest to identify as many as VGSC blockers that have 
a potential to inhibit metastasis of BCa. The identification does not only can be on 
the already known VGSC blockers, but also could be from nutritional and natural 
source. For example, docosahexaenoic acids (DHA), an omega-3 polyunsaturated 
fatty (PUFA), which is abundant in fish oil, was shown to block functional VGSCs 
by suppressing its mRNA and plasma membrane protein expression, leading to 
reduced migration of metastatic BCa cells (Isbilen et al. 2006). Similar results were 
reported with eicosapentaenoic (EPA), another omega-3 acid PUFA. EPA was 
shown to block VGSC current and induced down-regulation of VGSC mRNA 
expression in PCa cells, thus inhibiting their metastatic potential (Nakajima et al. 
2009). Indeed, many other natural and dietary sources have been shown to exert anti-
metastasis potential (Tsuda et al. 2004). It will be worthwhile to further investigating 
these in the context of VGSC-dependent MCBs. 
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 Identification of additional mechanisms involved in VGSC regulation would 
also give a better understanding of the role of VGSCs in cancer metastasis. The 
involvement of steroid hormones (e.g. estrogen), growth factors (e.g. EGF, NGF), 
and protein kinases (e.g PKA) in VGSC-dependent cancer progression have all help 
us to understand the regulation of VGSC (Ding et al. 2008; Brackenbury & Djamgoz 
2006; Brackenbury & Djamgoz 2007; Onganer & Djamgoz 2007; Chioni et al. 2010; 
Fraser et al. 2010). Another interesting aspect is regulation of VGSC by hypoxia. In 
this study, we applied mainly 24 h hypoxia and showed that it significantly increased 
nNav1.5 mRNA expression. Additional data are required on nNav1.5 protein 
expression and signaling under hypoxic conditions. Furthermore, since β1-subunit 
has been shown to play a role in cancer cell adhesion, it also would be interesting to 
further investigate its behavior under hypoxia. 
Cancer hypoxia is closely related to acidosis. High-level expression of 
surface membrane tumour associated CAs, such as CA9 and CA12, have been 
suggested to correlate with tumour hypoxia and acidosis. In BCa, in vivo data have 
reported that the expressions of these CAs are very much depending on the tumour 
subtype and phenotypic heterogeneity (Gruvberger et al. 2001; Wykoff et al. 2001; 
van‘t Veer et al. 2002; Watson et al. 2003; Cooper et al. 2004; Tozlu et al. 2006; 
Creighton et al. 2006; Barnett et al. 2008; Rakha et al. 2009). Several in vitro studies 
have demonstrated the involvement CA9 in cancer acidosis by pH measurements. 
Acidic pH culture medium would facilitate cancer cell invasion by increase the 
expression / activity of degradative proteolytic enzymes. A probe for measuring pHe 
is the membrane-permeable pH-fluorophore, acetoxymethyl ester of carboxy-
SNARF-1 (SNARF) whilst pHi can be measured using the membrane-impermeant 
pH-fluorophore, fluorescein-5-(and-6)-sulfonic acid (FS) (Swietach et al. 2009).  
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Accumulating data that we (and others) have provided may be considered to 
be sufficient to bring VGSCs forward for BCa therapy. However, extending the 
research using in vivo system would be a necessary, intermediary step. Effects of 
VGSC blockers on BCa animal models thus would give support for clinical 
applications. The pharmacological agents tested in this study are already in clinical 
application and may be developed in the future for use in therapy of metastatic BCa. 
 
6.6 Data limitations 
In this study, we have identified a few limitations on the data analysis and data 
presented here. In confocal microscopy analysis, quantitative image analysis is 
necessary to compensate for human eye deficiency. Therefore, we have chosen to 
quantitatively analyse the expression of nNav1.5 at the plasma membrane and in the 
cytoplasm using the ‗cross-sectional‘ analysis with a straight line drawn across the 
cytoplasm avoiding the nucleus (Okuse et al. 2002; Shah et al. 2004; Brackenbury & 
Djamgoz 2006). Although we have standardized the measurement for plasma 
membrane to cover 1.5 µm inward from the edge of ConA staining and cytoplasmic 
signal intensity within the central 30 % of the line profile, the method is subject to 
lack of precision and subjectivity. There are few other methods for confocal 
microscopy image analysis that include, ‗free-hand‘ drawn for plasma membrane and 
and ‗box-area‘ analysis for cytoplasma protein. A better analysis of the data would 
be obtained if all methods are conducted and compared. 
There are a few data presented in this thesis are not deemed to be statistically 
significant although the effects are of high magnitude. There are two main reasons 
for this type of observation: For example in Figure 3.8C and Figure 5.2B where 
Matrigel invasion was not affected by 50 µM procaine and 100 µM of 
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acetazolamide, respectively, in both cases, student t-test was used to normalize the 
treatment group with the control group. However, (1) due to a small sample size 
which was barely acceptable for statistical analysis (n = 3) and (2) error/variability in 
the control group was so high, it lead to non-statistically significant for the treated 
group. A better analysis of the data would be obtained if experiments were repeated a 
few more times. 
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7.0 APPENDIXES 
 
 
Appendix 1 Partial nucleotide and amino acid sequence of VGSC-β1 from 
MDA-MB-231 and MCF-7 
 
The sequences were compared using online sequence alignment (ClustalW). (A) 
Nucleotide sequences of VGSC-β1 from MDA-MB-231 cells (B1) and VGSC-β1 
from MCF-7 cells (B1_1 & B1_2). The nucleotides were translated to amino acid 
using online ExPASy Translate Tool. (B) Amino acid sequences of VGSC-β1 from 
MDA-MB-231 cells (B1) and VGSC-β1 from MCF-7 cells (B1_1 & B1_2). 
Nucleotide and amino acid alignment showed that VGSC-β1 from MDA-MB-231 
and MCF-7 are almost identical.  
 
 
 
A
B1_1_   -GAGATGAGGTGTTGCAGCTGGAGGAGGATGAGCGCTTCGAGGGCCGCGTGGTGTGGAAT 59
B1_2_   -GAGATGAGGTGTTGCAGCTGGAGGAGGATGAGCGCTTCGAGGGCCGCGTGGTGTGGAAT 59
B1      AGAGATGAGGTGTTGCAGCTGGAGGAGGATGAGCGCTTCGAGGGCCGCGTGGTGTGGAAT 60
***********************************************************
B1_1_   GGCAGCCGGGGCACCAAAGACCTGCAGGATCTGTCTATCTTCATCACCAATGTCACCTAC 119
B1_2_   GGCAGCCGGGGCACCAAAGACCTGCAGGATCTGTCTATCTTCATCACCAATGTCACCTAC 119
B1      GGCAGCCGGGGCACCAAAGACCTGCAGGATCTGTCTATCTTCATCACCAATGTCACCTAC 120
************************************************************
B1_1_   AACCACTCGGGCGACTACGAGTGCCACGTCTACCGCCTGCTCTTCTTCGAAAACTACGAG 179
B1_2_   AACCACTCGGGCGACTACGAGTGCCACGTCTACCGCCTGCTCTTCTTCGAAAACTACGAG 179
B1      AACCACTCGGGCGACTACGAGTGCCACGTCTACCGCCTGCTCTTCTTCGAAAACTACGAG 180
************************************************************
B1_1_   CACAACACCAGCGTCGTCAAGAAGATCCACATTGAGGTAGTGGACAAAGCCAACAGAGAC 239
B1_2_   CACAACACCAGCGTCGTCAAGAAGATCCACATTGAGGTAGTGGACAAAGCCAACAGAGAC 239
B1      CACAACACCAGCGTCGTCAAGAAGATCCACATTGAGGTAGTGGACAAAGCCAACAGAGAC 240
************************************************************
B1_1_   ATGGCATCCATCGTGTCTGAGATCATGATGTATGTGCTCATTGTGGTGTTGACCATATGG 299
B1_2_   ATGGCATCCATCGTGTCTGAGATCATGATGTATGTGCTCATTGTGGTGTTGACCATATGG 299
B1      ATGGCATCCATCGTGTCTGAGATCATGATGTATGTGCTCATTGTGGTGTTGACCATATGG 300
************************************************************
B1_1_   CTCGTGGCAGAGATGATTTACTGCTACAAGAAGATCGCTGCCAAATG- 346
B1_2_   CTCGTGGCAGAGATGATTTACTGCTACAAGA-GATCGCTGCCATACTG 346
B1      CTCGTGGCAGAGATGATTTACTGCTACAAGAAGATCGCTGACATTC-- 346
******************************* ******** **     
B
B1       RDEVLQLEEDERFEGRVVWNGSRGTKDLQDLSIFITNVTYNHSGDYECHVYRLLFFENYE 60
B1_1_    -DEVLQLEEDERFEGRVVWNGSRGTKDLQDLSIFITNVTYNHSGDYECHVYRLLFFENYE 59
B1_2_    -DEVLQLEEDERFEGRVVWNGSRGTKDLQDLSIFITNVTYNHSGDYECHVYRLLFFENYE 59
***********************************************************
B1       HNTSVVKKIHIEVVDKANRDMASIVSEIMMYVLIVVLTIWLVAEMIYCYKKIADI 115
B1_1_    HNTSVVKKIHIEVVDKANRDMASIVSEIMMYVLIVVLTIWLVAEMIYCYKKIAAK 114
B1_2_    HNTSVVKKIHIEVVDKANRDMASIVSEIMMYVLIVVLTIWLVAEMIYCYKRSLPY 114
**************************************************:
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